The O O
authors O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
report O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
patients O B_PERSON/B_BIO
with O O
delayed O O
reactions O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
whom O O
intradermoreactions O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
IDR O B_LOCATION/B_ORGANIZATION
) O O
and O O
patch O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
tests O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O O
a O O
series O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
ionic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
non O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ionic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PRC O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
studied O O
. O O

The O O
skin O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
tests O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
revealed O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
delayed O O
reactions O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
24 O B_MEASURE/B_SPORT[ENT]
hours O I_MEASURE/I_SPORT[ENT]
and O O
48 O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
hours O B_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
by O O
IDR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
patch O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tests O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
only O O
some O O
PRC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
common O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chains O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
their O O
structures O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
25 O B_MEASURE
out O O
of O O
32 O B_MEASURE
episodes O I_MEASURE
( O O
78 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
, O O
plasma O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
ammonium O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
levels O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
mental O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
status O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
returned O O
to O O
normal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
within O O
2 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
after O O
adequate O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
management O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

The O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
quinine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
4 O B_MEASURE
- O O
aminopyridine O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
conditioned O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
place O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preference O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
changes O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
motor O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
induced O O
by O O
morphine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
the O O
counterbalanced O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
quinine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
attenuated O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
morphine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
induced O O
place O B_DISEASE
preference O I_DISEASE
, O O
whereas O O
4 O B_MEASURE
- O O
aminopyridine O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
ineffective O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
the O O
involvement O B_PERSON/B_DISEASE
of O O
quinine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
sensitive O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
but O O
not O O
4 O B_MEASURE
- O O
aminopyridine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
sensitive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
K O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
+ O B_PROTEIN[GENE]/B_DISEASE
) O O
- O O
channels O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
morphine O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reward O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Nociceptin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
also O O
known O O
as O O
orphanin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
FQ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
is O O
an O O
endogenous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
ligand O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
for O O
the O O
orphan O B_GENE
opioid O I_GENE
receptor O I_GENE
- O O
like O B_PROTEIN[GENE]
receptor O I_PROTEIN[GENE]
1 O I_PROTEIN[GENE]
( O O
ORL1 O B_GENE/B_DISEASE
) O O
and O O
involves O O
in O O
various O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
functions O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
central O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nervous O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CNS O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
) O O
. O O

Although O O
ORL1 O B_GENE
receptors O I_GENE
which O O
display O O
a O O
high O B_MEASURE/B_LOCATION
degree O I_MEASURE/I_LOCATION
of O O
sequence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
homology O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
with O O
classical O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
opioid O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
abundant O B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
hippocampus O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
little O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
is O O
known O O
regarding O O
their O O
role O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
learning O B_DISEASE
and O O
memory O B_DISEASE
. O O

Administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
nocistatin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
1 O B_MEASURE
. O O
5 O B_MEASURE
and O O
/ O O
or O O
5 O B_MEASURE
. O O
0 O B_MEASURE/B_PERSON
nmol O I_MEASURE/I_PERSON
mouse O I_MEASURE/I_PERSON
- O O
1 O B_MEASURE
, O O
i O O
. O O
c O O
. O O
v O B_PROTEIN[GENE]/B_LOCATION
. O O
) O O
30 O B_TIME[MEASURE]/B_LOCATION
min O I_TIME[MEASURE]/I_LOCATION
before O O
spontaneous O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
alternation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
performance O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
or O O
the O O
training O B_TIME[MEASURE]/B_LOCATION
session O I_TIME[MEASURE]/I_LOCATION
of O O
the O O
passive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
avoidance O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
task O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
attenuated O O
the O O
scopolamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
impairment O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
spontaneous O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alternation O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
passive O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
avoidance O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
behaviours O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O O
that O O
nocistatin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
a O O
new O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
biologically O O
active O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
peptide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
ameliorates O O
impairments O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
spontaneous O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
alternation O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
passive O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
avoidance O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
induced O O
by O O
scopolamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
and O O
suggested O O
that O O
these O O
peptides O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
play O O
opposite O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
roles O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
learning O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
memory O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
have O O
examined O O
the O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
remoxipride O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
three O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pyrrolidine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ring O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
metabolites O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
five O B_MEASURE/B_LOCATION
aromatic O B_MEASURE/I_LOCATION
ring O B_MEASURE/I_LOCATION
metabolites O B_MEASURE/I_LOCATION
of O O
the O O
parent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
compound O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
induce O O
apoptosis O B_DISEASE/B_GENE
in O O
HL60 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_SPECIES[BIO]
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_SPECIES[BIO]
and O O
human O B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
bone O I_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
marrow O I_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
progenitor O I_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
( O O
HBMP O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Apoptosis O B_DISEASE/B_GENE
was O O
assessed O O
by O O
fluorescence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
microscopy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
Hoechst O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
33342 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
and O O
propidium O B_TIME[MEASURE]/B_COLOR
iodide O I_TIME[MEASURE]/I_COLOR
stained O O
cell O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
samples O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O O
that O O
the O O
catechol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
hydroquinone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
metabolites O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
remoxipride O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
direct O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toxic O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
HL60 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O O
HBMP O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
leading O O
to O O
apoptosis O B_DISEASE/B_GENE
, O O
while O O
the O O
phenol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
metabolites O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
inactive O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Similarly O O
, O O
benzene O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
derived O O
catechol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
hydroquinone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
but O O
not O O
phenol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
induce O O
apoptosis O B_DISEASE/B_GENE
in O O
HBMP O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
[ O O
Moran O B_PERSON/B_LOCATION
et O I_PERSON/I_LOCATION
al O O
. O O
, O O
Mol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O
Pharmacol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O
, O O
50 O B_MEASURE
( O O
1996 O B_MEASURE
) O O
610 O B_MEASURE
- O O
615 O B_MEASURE
] O I_MEASURE
. O O

In O O
research O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
towards O O
the O O
development O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
new O B_DISEASE
atypical O I_DISEASE
antipsychotic O I_DISEASE
agents O I_DISEASE
, O O
one O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
strategy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
is O O
that O O
the O O
dopaminergic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
system O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
can O O
be O O
modulated O O
through O O
manipulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
serotonergic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
system O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

This O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
undergoes O O
rapid O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
tolerance O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
showing O O
a O O
significant O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
decrease O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
after O O
2 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days O B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
sub O B_DISEASE/B_MEASURE
- O O
chronic O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
L O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
- O O
NOARG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Reduced O O
nicotinamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
adenine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
dinucleotide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
phosphate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
diaphorase O B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
NADPH O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
d O B_PROTEIN[GENE]/B_DISEASE
) O O
histochemistry O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
also O O
employed O O
to O O
visualize O O
NOS O B_DISEASE/B_GENE
as O O
an O O
index O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
enzyme O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
mice O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
brain O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regions O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
related O O
to O O
motor O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
give O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
support O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O O
the O O
hypothesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
NO O O
plays O O
a O O
role O B_MEASURE/B_PERSON
in O O
motor O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
suggest O O
that O O
it O O
may O O
take O O
part O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
synaptic O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O O
by O O
antipsychotic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Both O O
forms O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
stress O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
led O O
to O O
prolonged O O
but O O
reversible O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
systolic O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
diastolic O B_DISEASE
dysfunction O I_DISEASE
. O O

The O O
isovolumic O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
relaxation O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
period O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
was O O
prolonged O O
45 O B_TIME[MEASURE]/B_ENT
minutes O I_TIME[MEASURE]/I_ENT
after O O
each O O
form O B_TIME[MEASURE]/B_LOCATION
of O O
stress O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
p O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

Recently O O
, O O
fenfluramine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
appetite O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
suppressants O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
became O O
widely O O
used O O
in O O
the O O
United O B_LOCATION/B_ORGANIZATION
States O I_LOCATION/I_ORGANIZATION
but O O
were O O
withdrawn O O
in O O
September O B_TIME[MEASURE]/B_LOCATION
1997 O I_TIME[MEASURE]/I_LOCATION
because O O
of O O
concerns O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
over O O
adverse O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
history O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
drug O B_DISEASE
exposure O I_DISEASE
also O O
was O O
taken O O
with O O
special O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
attention O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O O
the O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
antidepressants O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
anorexigens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
and O O
amphetamines O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

An O O
unexpectedly O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
( O O
11 O B_MEASURE
. O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
number O B_MEASURE/B_PERSON
of O O
patients O B_PERSON
with O O
SPH O B_DISEASE/B_GENE
had O O
used O O
anorexigens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

Although O O
reasonable O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
incidences O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
many O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
side O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
can O O
be O O
" O O
softly O O
" O O
deduced O O
from O O
current O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
reports O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
dealing O O
with O O
unfractionated O B_DISEASE
heparin O I_DISEASE
, O O
at O O
present O B_TIME[MEASURE]
the O O
incidences O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
side O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
with O O
newer O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
low O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecular O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weight O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heparins O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appear O O
to O O
be O O
much O O
less O O
common O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

Recent O O
findings O O
in O O
a O O
bipolar B B_DISEASE/B_PERSON
patient O O
receiving O O
maintenance O O
lithium O O
therapy O O
who O O
developed O O
hypercalcemia B B_DISEASE
and O O
severe O O
bradyarrhythmia B B_DISEASE
prompted O O
the O O
authors O O
to O O
conduct O O
a O O
retrospective O O
study O O
of O O
bipolar B B_NUMBER[MEASURE]
patients O O
with O O
lithium O O
- O O
associated O O
hypercalcemia B B_DISEASE
. O O

It O O
was O O
found O O
that O O
these O O
groups O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O O
not O O
differ O O
in O O
their O O
overall O B_MEASURE
frequency O I_MEASURE
of O O
ECG O B_DISEASE_ADJECTIVE[DISEASE]
abnormalities O I_DISEASE_ADJECTIVE[DISEASE]
; O O
however O O
, O O
there O O
were O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
differences O I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
frequency O B_MEASURE
of O O
conduction O B_DISEASE/B_LOCATION
defects O I_DISEASE/I_LOCATION
. O O

Patients O B_PERSON
in O O
group O B_NUMBER[MEASURE]/B_LOCATION
A O I_NUMBER[MEASURE]/I_LOCATION
had O O
significant O B_DISEASE/B_MEASURE
mortality O I_DISEASE/I_MEASURE
at O O
2 O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]/B_LOCATION
follow O I_TIME[MEASURE]/I_LOCATION
- O O
up O B_TIME[MEASURE]/B_LOCATION
( O O
28 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
, O O
in O O
contrast O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
zero O B_PERSON/B_DISEASE
mortality O I_PERSON/I_DISEASE
in O O
the O O
other O B_MEASURE/B_LOCATION
three O B_MEASURE/I_LOCATION
groups O B_MEASURE/I_LOCATION
. O O

Serum O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
blood O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
urea O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
creatinine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentrations O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
increased O O
significantly O O
in O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
given O O
an O O
iv O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
infusion O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
D O B_OTHER/B_PROTEIN[GENE]
- O O
AmB O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
kg O B_TIME[MEASURE]
but O O
not O O
in O O
those O O
given O O
the O O
same O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
dose O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
NS O B_DISEASE/B_PROTEIN[GENE]
- O O
718 O B_NUMBER[MEASURE]
. O O

None O B_PERSON/B_NUMBER[MEASURE]
of O O
them O O
needed O O
dialysis O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
a O O
renal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
biopsy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
because O O
of O O
a O O
typical O B_DISEASE
benign O I_DISEASE
course O I_DISEASE
. O O

Treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
sulfadiazine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
requires O O
exquisite O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
renal O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
water O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ingestion O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
possibly O O
the O O
alcalinization O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
urine O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Although O O
there O O
have O O
been O O
case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
reports O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
epidural O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
morphine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O O
these O O
symptoms O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
signs O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
this O O
has O O
not O O
been O O
previously O O
documented O O
with O O
IV O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
patient O B_PERSON/B_LOCATION
- O O
controlled O O
analgesia O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
morphine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Heart O B_MEASURE/B_DISEASE
rate O I_MEASURE/I_DISEASE
( O O
HR O B_LOCATION
) O O
, O O
mean O B_MEASURE/B_DISEASE
arterial O I_MEASURE/I_DISEASE
pressure O I_MEASURE/I_DISEASE
( O O
MBP O B_LOCATION/B_ORGANIZATION
) O O
, O O
positive O B_MEASURE
rate O I_MEASURE
of O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
left O B_DISEASE/B_GENE
ventricular O B_DISEASE/I_GENE
pressure O B_DISEASE/I_GENE
( O O
+ O B_PROTEIN[GENE]
LVdP O I_PROTEIN[GENE]
/ O O
dt O B_MEASURE/B_PROTEIN[GENE]
) O O
, O O
echocardiographically O O
assessed O O
left O O
ventricular O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
ejection O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
fraction O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
LVEF O B_LOCATION/B_MEASURE
) O O
, O O
and O O
fractional O B_MEASURE/B_DISEASE
shortening O I_MEASURE/I_DISEASE
( O O
FS O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
as O O
well O O
as O O
chronotropic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O O
isoproterenol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
exercise O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
sympathetic O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stimulation O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
evaluated O O
under O O
baseline O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
posttreatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
conditions O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

Thus O O
, O O
dronedarone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
amiodarone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
displayed O O
a O O
similar O B_MEASURE
level O I_MEASURE
of O O
antiadrenergic O B_DISEASE/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O B_DISEASE/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
did O O
not O O
impair O O
the O O
resting O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
left O O
ventricular O B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_BODY_PART_OR_ORGAN_COMPONENT/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
wished O O
to O O
develop O O
a O O
more O O
tolerable O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
liposomal O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doxorubicin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regimen O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
document O O
its O O
level O B_MEASURE/B_LOCATION
of O O
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
a O O
well O O
- O O
defined O O
patient O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
population O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O O
platinum O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
paclitaxel O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
refractory O B_DISEASE
disease O I_DISEASE
. O O

The O O
primary O O
efficacy O O
measure O O
was O O
the O O
Young O O
- O O
Mania B B_PERSON
Rating O O
Scale O O
( O O
Y O O
- O O
MRS O O
) O O
total O O
score O O
. O O

Response O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
euthymia O B_DISEASE_ADJECTIVE[DISEASE]
were O O
defined O O
, O O
a O O
priori O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
as O O
at O O
least O O
a O O
50 O B_MEASURE
% O I_MEASURE
improvement O I_MEASURE
from O O
baseline O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
end O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
point O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
as O O
a O O
score O B_MEASURE
of O O
no O O
less O B_MEASURE
than O O
12 O B_NUMBER[MEASURE]
at O O
end O B_LOCATION/B_MEASURE
point O I_LOCATION/I_MEASURE
in O O
the O O
Y O B_OTHER/B_LOCATION
- O O
MRS O B_MEASURE/B_LOCATION
total O I_MEASURE/I_LOCATION
score O I_MEASURE/I_LOCATION
, O O
respectively O O
. O O

Safety O O
was O O
assessed O O
using O O
adverse O O
events O O
, O O
Extrapyramidal B B_DISEASE
Symptom I I_DISEASE
( O O
EPS B B_LOCATION
) O O
rating O O
scales O O
, O O
laboratory O O
values O O
, O O
electrocardiograms O O
, O O
vital O O
signs O O
, O O
and O O
weight O O
change O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Olanzapine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
patients O B_PERSON/B_BIO
demonstrated O O
a O O
statistically O O
significant O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
greater O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
mean O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
+ O B_MEASURE/B_DISEASE
/ O O
- O O
SD O B_DISEASE/B_PROTEIN[GENE]
) O O
improvement O B_DISEASE_ADJECTIVE[DISEASE]
in O O
Y O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
MRS O B_MEASURE
total O I_MEASURE
score O I_MEASURE
than O O
placebo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
patients O B_PERSON/B_BIO
( O O
- O O
14 O B_MEASURE
. O O
8 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
12 O B_MEASURE
. O O
5 O B_MEASURE
and O O
- O O
8 O B_MEASURE
. O O
1 O B_MEASURE/B_LOCATION
+ O I_MEASURE/I_LOCATION
/ O O
- O O
12 O B_MEASURE
. O O
7 O B_MEASURE
, O O
respectively O O
; O O
P O B_MEASURE/B_LOCATION
< O I_MEASURE/I_LOCATION
. O O
001 O B_MEASURE
) O O
, O O
which O O
was O O
evident O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
the O O
first O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
postbaseline O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observation O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
week O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
randomization O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
and O O
was O O
maintained O O
throughout O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
last O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
observation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
carried O O
forward O O
) O O
. O O

Olanzapine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
treated O O
patients O B_PERSON/B_BIO
demonstrated O O
a O O
higher O B_MEASURE
rate O I_MEASURE
of O O
response O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
65 O B_MEASURE
% O I_MEASURE
vs O I_MEASURE
43 O I_MEASURE
% O I_MEASURE
, O O
respectively O O
; O O
P O B_OTHER/B_LOCATION
= O O
. O O
02 O B_MEASURE
) O O
and O O
euthymia O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
61 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
vs O O
36 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
respectively O O
; O O
P O B_OTHER/B_LOCATION
= O O
. O O
01 O B_MEASURE
) O O
than O O
placebo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
patients O B_PERSON/B_BIO
. O O

Useful O B_LOCATION/B_PERSON
Field O I_LOCATION/I_PERSON
of O O
View O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
UFOV O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
- O O
a O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
visual O B_DISEASE/B_ORGANISM_FUNCTION
attention O I_DISEASE/I_ORGANISM_FUNCTION
) O O
was O O
also O O
undertaken O O
. O O

Little O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
emerged O O
for O O
deterioration O B_DISEASE_ADJECTIVE[DISEASE]
in O O
FIELDS O B_DISEASE/B_PROTEIN[GENE]
and O O
UFOV O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Also O O
, O O
7 O B_NUMBER[MEASURE]/B_ORGANIZATION
of O O
12 O B_MEASURE/B_PERSON
drivers O B_MEASURE/I_PERSON
appeared O O
to O O
adjust O O
their O O
driving O O
behaviour O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
by O O
reducing O O
their O O
speed O B_MEASURE/B_SPORT[ENT]
on O O
the O O
driving O O
simulator O B_LOCATION/B_PERSON
, O O
leading O O
to O O
improved O B_DISEASE/B_LOCATION
steering O I_DISEASE/I_LOCATION
accuracy O I_DISEASE/I_LOCATION
. O O

The O O
Assessment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
Treatment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O O
Lisinopril O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Survival O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

BACKGROUND O O
: O O
Treatment O O
with O O
angiotensin O O
- O O
converting O O
enzyme O O
( O O
ACE O O
) O O
inhibitors O O
reduces O O
mortality O O
and O O
morbidity O O
in O O
patients O O
with O O
chronic O O
heart B B_DISEASE
failure I I_DISEASE
( O O
CHF B B_LOCATION/B_ORGANIZATION
) O O
, O O
but O O
most O O
affected O O
patients O O
are O O
not O O
receiving O O
these O O
agents O O
or O O
are O O
being O O
treated O O
with O O
doses O O
lower O O
than O O
those O O
found O O
to O O
be O O
efficacious O O
in O O
trials O O
, O O
primarily O O
because O O
of O O
concerns O O
about O O
the O O
safety O O
and O O
tolerability O O
of O O
these O O
agents O O
, O O
especially O O
at O O
the O O
recommended O O
doses O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
The O O
Assessment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
Lisinopril O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
Survival O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
study O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
a O O
multicenter O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
randomized O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
double O B_MEASURE/B_COLOR
- O O
blind O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trial O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
which O O
patients O B_PERSON/B_BIO
with O O
or O O
without O O
previous O B_DISEASE/B_GENE
ACE O I_DISEASE/I_GENE
inhibitor O I_DISEASE/I_GENE
treatment O I_DISEASE/I_GENE
were O O
stabilized O O
receiving O O
medium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
dose O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
lisinopril O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
12 O B_MEASURE
. O O
5 O B_MEASURE
or O O
15 O B_MEASURE
. O O
0 O B_MEASURE
mg O I_MEASURE
once O O
daily O O
[ O O
OD O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
for O O
2 O B_NUMBER[MEASURE]/B_LOCATION
to O O
4 O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
and O O
then O O
randomized O O
to O O
high O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
( O O
35 O B_MEASURE
. O O
0 O B_MEASURE
or O O
32 O B_MEASURE
. O O
5 O B_MEASURE
mg O I_MEASURE
OD O I_MEASURE
) O O
or O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
dose O B_MEASURE
( O O
5 O B_MEASURE
. O O
0 O B_MEASURE
or O O
2 O B_MEASURE
. O O
5 O B_MEASURE
mg O I_MEASURE
OD O I_MEASURE
) O O
groups O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Withdrawals O B_DISEASE
occurred O O
in O O
27 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
of O O
the O O
high O B_MEASURE/B_LOCATION
- O O
and O O
30 O B_MEASURE
. O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
the O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
dose O B_MEASURE/B_LOCATION
groups O B_MEASURE/I_LOCATION
. O O

We O O
emphasize O O
the O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
dopaminergic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
veralipride O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
symptoms O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ceased O O
after O O
switching O O
to O O
another O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
combination O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
appearance O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O O
MPO O B_LOCATION
- O O
ANCA O B_DISEASE/B_LOCATION
in O O
these O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
suspected O O
of O O
being O O
related O O
to O O
PTU O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
because O O
the O O
titres O B_MEASURE/B_GENE
of O O
MPO O B_LOCATION
- O O
ANCA O B_LOCATION/B_DISEASE
decreased O O
when O O
PTU O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
stopped O O
. O O

Cardioprotective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Picrorrhiza O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
kurroa O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O O
isoproterenol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
myocardial O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stress O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

BACKGROUND O O
: O O
This O O
study O O
examined O O
the O O
role O O
of O O
phase O O
2 O O
early O O
afterdepolarization O O
( O O
EAD O O
) O O
in O O
producing O O
a O O
trigger O O
to O O
initiate O O
torsade B B_DISEASE
de I I_DISEASE
pointes I I_DISEASE
( O O
TdP B B_LOCATION/B_ORGANIZATION
) O O
with O O
QT B B_DISEASE
prolongation I I_DISEASE
induced O O
by O O
dl O O
- O O
sotalol O O
and O O
azimilide O O
. O O

Azimilide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
however O O
, O O
significantly O O
prolonged O O
APD O B_DISEASE/B_PROTEIN[GENE]
and O O
QT O B_PROTEIN[GENE]/B_LOCATION
interval O I_PROTEIN[GENE]/I_LOCATION
at O O
concentrations O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
from O O
0 O B_MEASURE
. O O
1 O B_MEASURE
to O O
10 O B_MEASURE
micromol O I_MEASURE
/ O O
L O B_OTHER/B_MEASURE
but O O
shortened O O
them O O
at O O
30 O B_MEASURE/B_LOCATION
micromol O I_MEASURE/I_LOCATION
/ O O
L O B_OTHER/B_MEASURE
. O O

Unlike O O
dl O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
sotalol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
azimilide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
> O O
3 O B_MEASURE/B_LOCATION
micromol O I_MEASURE/I_LOCATION
/ O O
L O B_OTHER/B_MEASURE
) O O
increased O O
epicardial O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
APD O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
markedly O O
, O O
causing O O
a O O
diminished O B_DISEASE
TDR O I_DISEASE
. O O

Of O O
note O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
although O O
azimilide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
3 O B_MEASURE/B_LOCATION
to O O
10 O B_MEASURE
micromol O I_MEASURE
/ O O
L O B_OTHER/B_MEASURE
) O O
increased O O
APD O B_DISEASE
more O I_DISEASE
than O O
dl O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
sotalol O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
its O O
EADs O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
often O O
failed O O
to O O
propagate O O
transmurally O O
, O O
probably O O
because O O
of O O
a O O
diminished O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
TDR O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Further O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
suggesting O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
lack O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
exaggerated O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adrenergic O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
13 O B_NUMBER[MEASURE]
( O O
65 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
of O O
20 O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
required O O
supplemental O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
atropine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O O
reach O O
their O O
target O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
heart O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
rates O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Prenatal O O
cocaine O O
exposure O O
and O O
cranial O O
sonographic O O
findings O O
in O O
preterm B B_PERSON/B_BIO
infants I I_PERSON/I_BIO
. O O

We O O
sought O O
to O O
determine O O
if O O
prenatal O O
cocaine O O
exposure O O
increases O O
the O O
incidence O O
of O O
subependymal B B_DISEASE
cysts I I_DISEASE
in O O
preterm B B_PERSON/B_BIO
infants I I_PERSON/I_BIO
. O O

METHODS O O
: O O
We O O
retrospectively O O
reviewed O O
the O O
medical O O
records O O
and O O
cranial O O
sonograms O O
obtained O O
during O O
a O O
1 O O
- O O
year O O
period O O
on O O
122 O O
premature B B_TIME[MEASURE]/B_PERSON
( I I_TIME[MEASURE]/I_PERSON
< I I_TIME[MEASURE]/I_PERSON
36 I I_TIME[MEASURE]/I_PERSON
weeks I I_TIME[MEASURE]/I_PERSON
of I I_TIME[MEASURE]/I_PERSON
gestation I I_TIME[MEASURE]/I_PERSON
) I I_TIME[MEASURE]/I_PERSON
infants I I_TIME[MEASURE]/I_PERSON
. O O

CONCLUSIONS O O
: O O
We O O
found O O
an O O
increased O O
incidence O O
of O O
subependymal B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cyst I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
formation O O
in O O
preterm B B_PERSON
infants I I_PERSON
who O O
were O O
exposed O O
to O O
cocaine O O
prenatally O O
. O O

NCS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
included O O
recording O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
sensory O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nerve O B_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
action O B_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potentials O B_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
SNAPs O B_DISEASE
) O O
from O O
median O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
, O O
radial O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
ulnar O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
sural O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nerves O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
40 O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
decline O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
the O O
SNAP O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
index O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
considered O O
clinically O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Clinical O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
symptoms O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
a O O
decline O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
the O O
SNAP O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
index O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
occurred O O
concurrently O O
. O O

In O O
nontransgenic O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
animals O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
threshold O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
kanamycin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- O O
treated O O
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
was O O
45 O B_MEASURE
- O O
50 O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
dB O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
higher O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
in O O
saline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
injected O O
controls O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
also O O
suggest O O
transgenic O B_SPECIES[BIO]/B_PERSON
animals O I_SPECIES[BIO]/I_PERSON
as O O
suitable O B_PERSON/B_LOCATION
models O I_PERSON/I_LOCATION
to O O
investigate O O
the O O
underlying O O
mechanisms O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
possible O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
strategies O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
for O O
prevention O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Depressed O O
hepatic O O
secretion O O
of O O
triglyceride O O
accounted O O
only O O
for O O
30 O O
to O O
50 O O
% O O
of O O
accumulated O O
hepatic O O
triglyceride O O
, O O
indicating O O
that O O
additional O O
mechanisms O O
must O O
be O O
involved O O
in O O
the O O
production O O
of O O
the O O
triglyceride O O
- O O
rich O O
fatty B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
liver I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
response O O
to O O
tetracycline O O
. O O

The O O
magnitude O B_MEASURE
of O O
transformation O B_DISEASE
of O O
the O O
microglia O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assessed O O
by O O
the O O
number O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
intersections O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
significantly O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
PDN O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
than O O
in O O
controls O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
prefrontal O B_BODY_PART_OR_ORGAN_COMPONENT
cortex O I_BODY_PART_OR_ORGAN_COMPONENT
( O O
moderate O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
dose O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O O
24 O B_MEASURE
. O O
1 O B_MEASURE
; O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O O
dose O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O O
23 O B_MEASURE
. O O
6 O B_MEASURE
; O O
controls O B_MEASURE/B_PERSON
18 O I_MEASURE/I_PERSON
. O O
7 O B_NUMBER[MEASURE]
; O O
p O O
< O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
and O O
striatum O B_BODY_PART_OR_ORGAN_COMPONENT
( O O
moderate O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
dose O B_MEASURE
25 O I_MEASURE
. O O
6 O B_MEASURE
; O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O O
dose O B_MEASURE
26 O I_MEASURE
. O O
3 O B_MEASURE
; O O
controls O B_MEASURE/B_PERSON
18 O I_MEASURE/I_PERSON
. O O
9 O B_MEASURE
; O O
p O O
< O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
, O O
but O O
not O O
in O O
hippocampus O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O O

Four O B_PERSON
patients O I_PERSON
had O O
five O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
infusion O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
- O O
related O O
reactions O B_DISEASE
during O O
the O O
infusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
liposomal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doxorubicin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
leading O O
to O O
treatment O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
discontinuation O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
three O B_TIME[MEASURE]/B_PERSON
patients O I_TIME[MEASURE]/I_PERSON
. O O

Although O O
this O O
is O O
not O O
a O O
statistically O O
significant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
risk O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
physicians O B_PERSON
must O O
be O O
aware O B_PERSON
of O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
reversibility O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
authors O O
elected O O
to O O
name O O
this O O
syndrome O O
" O O
antibiomania B B_BACTERIUM[BIO]/B_GENE
. O O
" O O

The O O
participants O B_PERSON
recorded O O
menstrual O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
symptoms O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
possible O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
side O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
effects O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
at O O
different O B_MEASURE/B_ENT
times O I_MEASURE/I_ENT
( O O
0 O B_MEASURE
, O O
30 O B_MEASURE
, O O
60 O B_MEASURE
, O O
120 O B_MEASURE/B_ENT
minutes O I_MEASURE/I_ENT
) O O
after O O
the O O
first O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
dose O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
medication O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
the O O
first O B_SEQUENCE[MEASURE]/B_LOCATION
day O I_SEQUENCE[MEASURE]/I_LOCATION
of O O
the O O
cycle O B_TIME[MEASURE]
, O O
with O O
both O O
drugs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Both O O
treatments O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
significantly O O
reduced O O
DPI O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
the O O
30th O B_TIME[MEASURE]/B_PERSON
minute O B_TIME[MEASURE]/I_PERSON
( O O
GTN O B_LOCATION
, O O
- O O
12 O B_MEASURE
. O O
8 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
17 O B_MEASURE
. O O
9 O B_MEASURE
; O O
DCF O B_LOCATION/B_ORGANIZATION
, O O
- O O
18 O B_MEASURE
. O O
9 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
16 O B_MEASURE
. O O
6 O B_MEASURE
) O O
. O O

At O O
each O O
time O B_MEASURE/B_LOCATION
point O B_MEASURE/I_LOCATION
, O O
systolic O B_DISEASE/B_GENE
blood O I_DISEASE/I_GENE
pressure O I_DISEASE/I_GENE
( O O
BP O B_DISEASE/B_GENE
) O O
, O O
urinary O B_BODY_PART_OR_ORGAN_COMPONENT
protein O I_BODY_PART_OR_ORGAN_COMPONENT
excretion O I_BODY_PART_OR_ORGAN_COMPONENT
and O O
renal O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
histopathological O B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings O B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
evaluated O O
, O O
and O O
morphometric O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
image O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
done O O
. O O

Systolic O B_DISEASE/B_GENE
BP O I_DISEASE/I_GENE
in O O
the O O
PAN O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O O
significantly O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
at O O
4 O B_MEASURE
, O O
14 O B_NUMBER[MEASURE]
and O O
20 O B_MEASURE/B_ENT
weeks O I_MEASURE/I_ENT
, O O
but O O
was O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
PAN O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O O
temocapril O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
. O O

Urinary O B_DISEASE/B_PERSON
protein O I_DISEASE/I_PERSON
excretion O I_DISEASE/I_PERSON
in O O
the O O
PAN O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
increased O O
significantly O O
, O O
peaking O O
at O O
8 O B_MEASURE/B_ENT
days O I_MEASURE/I_ENT
, O O
then O O
decreased O O
at O O
4 O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
, O O
but O O
rose O O
again O O
significantly O O
at O O
14 O B_MEASURE
and O O
20 O B_MEASURE/B_ENT
weeks O I_MEASURE/I_ENT
. O O

There O O
was O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlation O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
urinary O B_LOCATION/B_ORGANIZATION
protein O I_LOCATION/I_ORGANIZATION
excretion O I_LOCATION/I_ORGANIZATION
and O O
GSI O B_DISEASE/B_GENE
( O O
r O B_OTHER/B_MEASURE
= O O
0 O B_MEASURE/B_LOCATION
. O O
808 O B_MEASURE
, O O
p O O
< O O
0 O B_MEASURE
. O O
0001 O B_MEASURE
) O O
. O O

The O O
ratio O B_MEASURE/B_PERSON
of O O
glomerular O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tuft O B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
area O B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
area O B_LOCATION/B_MEASURE
of O O
Bowman O B_DISEASE/B_LOCATION
' O B_DISEASE/I_LOCATION
s O B_DISEASE/I_LOCATION
capsules O B_DISEASE/I_LOCATION
( O O
GT O B_ORGANIZATION/B_LOCATION
/ O O
BC O B_LOCATION/B_ORGANIZATION
) O O
in O O
the O O
PAN O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
was O O
significantly O O
increased O O
, O O
but O O
it O O
was O O
significantly O O
lower O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
the O O
PAN O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O O
temocapril O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Hypoxaemia B B_PERSON
resolved O O
quickly O O
on O O
inhaled O O
nitric O O
oxide O O
therapy O O
. O O

The O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
describes O O
the O O
delayed O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
development O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
severe O B_DISEASE
bladder O I_DISEASE
pathology O I_DISEASE
in O O
a O O
susceptible O B_MEASURE/B_BIO
strain O I_MEASURE/I_BIO
of O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
DBA O B_LOCATION/B_ORGANIZATION
/ O O
2 O B_MEASURE
) O O
but O O
not O O
in O O
a O O
resistant O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
strain O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O O
C57BL O B_PROTEIN[GENE]/B_BIO
/ O O
6 O B_NUMBER[MEASURE]
) O O
when O O
both O O
were O O
treated O O
with O O
a O O
single O B_MEASURE
300 O I_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
dose O I_MEASURE
of O O
cyclophosphamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CY O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
. O O

Early O O
CY O O
toxicity B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
caused O O
a O O
typical O O
haemorrhagic B B_DISEASE_ADJECTIVE[DISEASE]
cystitis B I_DISEASE_ADJECTIVE[DISEASE]
in O O
both O O
strains O O
that O O
was O O
completely O O
repaired O O
in O O
about O O
7 O O
- O O
10 O O
days O O
. O O

Electron O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
microscopy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
disclosed O O
the O O
absence O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
typical O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
discoidal O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
vesicles O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
normally O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
cytoplasm O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
of O O
surface O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Median O B_TIME[MEASURE]/B_PERSON
overall O I_TIME[MEASURE]/I_PERSON
survival O I_TIME[MEASURE]/I_PERSON
time O I_TIME[MEASURE]/I_PERSON
was O O
10 O B_MEASURE
. O O
2 O B_MEASURE
months O I_MEASURE
[ O I_MEASURE
95 O I_MEASURE
% O I_MEASURE
confidence O I_MEASURE
interval O I_MEASURE
( O O
CI O B_LOCATION
) O O
: O O
8 O B_MEASURE
. O O
7 O B_MEASURE
- O O
11 O B_MEASURE
. O O
6 O B_MEASURE
] O I_MEASURE
, O O
and O O
median O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
progression O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
free O B_TIME[MEASURE]/B_LOCATION
survival O I_TIME[MEASURE]/I_LOCATION
time O I_TIME[MEASURE]/I_LOCATION
was O O
7 O B_MEASURE
. O O
6 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
( O O
95 O B_TIME[MEASURE]/B_LOCATION
% O I_TIME[MEASURE]/I_LOCATION
CI O I_TIME[MEASURE]/I_LOCATION
: O O
4 O B_MEASURE
. O O
4 O B_MEASURE
- O O
10 O B_MEASURE
. O O
9 O B_MEASURE
) O O
. O O

Younger O B_PERSON/B_ENT
children O I_PERSON/I_ENT
have O O
an O O
additional O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
risk O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
for O O
renal O B_DISEASE
complications O I_DISEASE
. O O

Baseline O O
electrocardiogram O O
abnormalities O O
and O O
market O O
elevations O O
not O O
associated O O
with O O
myocardial B B_DISEASE
necrosis I I_DISEASE
make O O
accurate O O
diagnosis O O
of O O
myocardial B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
infarction I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
MI B B_LOCATION/B_ORGANIZATION
) O O
difficult O O
in O O
patients O O
with O O
cocaine O O
- O O
associated O O
chest B B_DISEASE/B_LOCATION
pain I I_DISEASE/I_LOCATION
. O O

Angiography O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
performed O O
in O O
29 O B_NUMBER[MEASURE]
of O O
38 O B_TIME[MEASURE]/B_PERSON
patients O B_TIME[MEASURE]/I_PERSON
who O O
were O O
cTnI O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
with O O
significant O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
disease O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
present O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O O
25 O B_NUMBER[MEASURE]/B_PERSON
( O O
86 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
. O O

We O O
report O O
a O O
case O O
of O O
acute O O
interstitial B B_DISEASE
nephritis I I_DISEASE
( O O
AIN B B_TIME[MEASURE]/B_LOCATION
) O O
due O O
to O O
nicergoline O O
( O O
Sermion O O
) O O
. O O

Treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
was O O
consisted O O
of O O
withdrawal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
nicergoline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
intravenous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
methylprednisolone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
his O O
renal O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
completely O O
recovered O O
. O O

A O O
patient O O
with O O
chronic B B_DISEASE
renal I I_DISEASE
failure I I_DISEASE
( O O
CRF B B_LOCATION
) O O
developed O O
neuroleptic B B_DISEASE
malignant I I_DISEASE
syndrome I I_DISEASE
( O O
NMS B B_LOCATION/B_ORGANIZATION
) O O
after O O
administration O O
of O O
risperidone O O
and O O
levomepromazine O O
. O O

Coadministration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
carvedilol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreased O O
the O O
extent O B_MEASURE
of O O
cellular O B_DISEASE
vacuolization O I_DISEASE
in O O
cardiac O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
myocytes O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
prevented O O
the O O
inhibitory O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
doxorubicin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
mitochondrial O B_DISEASE
respiration O I_DISEASE
in O O
both O O
heart O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
liver O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

Moreover O O
, O O
all O O
adenosine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
receptor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
agonists O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O O
2 O B_NUMBER[MEASURE]
- O O
p O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
( O O
2 O B_MEASURE
- O O
carboxyethyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
phenethylamino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
5 O B_NUMBER[MEASURE]
' O O
- O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
ethylcarboxamidoadenosine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CGS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
21680 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
) O O
, O O
A2A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
receptor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
agonist O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
N6 O B_PROTEIN[GENE]/B_MEASURE
- O O
cyclopentyladenosine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CPA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
) O O
, O O
A1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
agonist O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
and O O
5 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
N O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
ethylcarboxamidoadenosine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
NECA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
A2 O B_PROTEIN[GENE]
/ O O
A1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agonist O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significantly O O
and O O
dose O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
dependently O O
decreased O O
cocaine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
locomotor O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CPA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
reduced O O
cocaine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
action O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
at O O
the O O
doses O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
which O O
, O O
given O O
alone O O
, O O
did O O
not O O
influence O O
motility O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
while O O
CGS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
21680 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
NECA O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreased O O
the O O
action O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
cocaine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
at O O
the O O
doses O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
, O O
given O O
alone O O
, O O
decreased O O
locomotor O B_DISEASE/B_ORGANISM_FUNCTION
activity O B_DISEASE/I_ORGANISM_FUNCTION
in O O
animals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
selective O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
blockade O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
A2 O B_GENE
adenosine O I_GENE
receptor O I_GENE
by O O
DMPX O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
3 O B_NUMBER[MEASURE]
, O O
7 O B_NUMBER[MEASURE]
- O O
dimethyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_MEASURE
- O O
propargylxanthine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
significantly O O
enhanced O O
cocaine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
locomotor O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
animals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
selective O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blockade O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
A2 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
adenosine O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
DMPX O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
non O B_DISEASE
- O O
selective O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blockade O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
adenosine O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
caffeine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
significantly O O
increased O O
the O O
action O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
amphetamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
the O O
locomotor O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

OBJECTIVES O O
: O O
The O O
aim O O
of O O
this O O
study O O
was O O
to O O
determine O O
whether O O
the O O
use O O
of O O
amiodarone O O
in O O
patients O O
with O O
atrial B B_DISEASE
fibrillation I I_DISEASE
( O O
AF B B_LOCATION/B_ORGANIZATION
) O O
increases O O
the O O
risk O O
of O O
bradyarrhythmia B B_DISEASE
requiring O O
a O O
permanent O O
pacemaker O O
. O O

METHODS O O
: O O
A O O
study O O
cohort O O
of O O
8 O O
, O O
770 O O
patients O O
age O O
> O O
or O O
= O O
65 O O
years O O
with O O
a O O
new O O
diagnosis O O
of O O
AF B B_DISEASE
was O O
identified O O
from O O
a O O
provincewide O O
database O O
of O O
Quebec O O
residents O O
with O O
a O O
myocardial B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
MI B B_LOCATION
) O O
between O O
1991 O O
and O O
1999 O O
. O O

Multivariable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
logistic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
regression O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
used O O
to O O
estimate O O
the O O
odds O B_MEASURE
ratio O I_MEASURE
( O O
OR O O
) O O
of O O
pacemaker O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
insertion O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
associated O O
with O O
amiodarone O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
controlling O O
for O O
baseline O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
risk O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
factors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
exposure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
sotalol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
Class O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O O
antiarrhythmic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
blockers O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
calcium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
channel O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blockers O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
digoxin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
amiodarone O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
associated O O
with O O
an O O
increased O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
pacemaker O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
insertion O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
OR O O
: O O
2 O B_MEASURE
. O O
14 O B_MEASURE
, O O
95 O B_LOCATION
% O I_LOCATION
confidence O I_LOCATION
interval O I_LOCATION
[ O O
CI O B_LOCATION/B_MEASURE
] O O
: O O
1 O B_MEASURE
. O O
30 O B_MEASURE
to O O
3 O B_MEASURE
. O O
54 O B_MEASURE
) O O
. O O

Digoxin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
the O O
only O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
other O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
medication O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
associated O O
with O O
an O O
increased O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
pacemaker O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
insertion O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
OR O O
: O O
1 O B_MEASURE
. O O
78 O B_MEASURE
, O O
95 O B_LOCATION
% O I_LOCATION
CI O I_LOCATION
: O O
1 O B_NUMBER[MEASURE]
. O O
37 O B_MEASURE
to O O
2 O B_NUMBER[MEASURE]
. O O
31 O B_MEASURE
) O O
. O O

The O O
finding O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
an O O
augmented O B_DISEASE_ADJECTIVE[DISEASE]
risk O I_DISEASE_ADJECTIVE[DISEASE]
of O O
pacemaker O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
insertion O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
elderly O B_PERSON/B_BIO
women O I_PERSON/I_BIO
receiving O O
amiodarone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
requires O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Indomethacin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
morphologic O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
rat O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
urinary O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
bladder O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
epithelium O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

OBJECTIVES O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
To O O
evaluate O O
the O O
morphologic O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
rat O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
urothelium O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
induced O O
by O O
indomethacin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
The O O
light O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
findings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
showed O O
some O O
focal O B_DISEASE
epithelial O I_DISEASE
degeneration O I_DISEASE
that O O
was O O
more O O
prominent O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
high O B_MEASURE/B_PERSON
- O O
dose O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Three O B_NUMBER[MEASURE]/B_PERSON
men O I_NUMBER[MEASURE]/I_PERSON
( O O
15 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
showed O O
a O O
decline O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
serum O B_DISEASE
PSA O I_DISEASE
of O O
at O O
least O O
50 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
, O O
sustained O O
throughout O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

The O O
authors O O
present O O
a O O
case O O
of O O
early O O
( O O
within O O
4 O O
days O O
) O O
development O O
of O O
torsade B B_DISEASE
de I I_DISEASE
pointes I I_DISEASE
( O O
TdP B B_PROTEIN[GENE]/B_LOCATION
) O O
associated O O
with O O
oral O O
amiodarone O O
therapy O O
. O O

Myotonia B B_DISEASE/B_LOCATION
congenita I I_DISEASE/I_LOCATION
( O O
MC B B_LOCATION
) O O
is O O
caused O O
by O O
a O O
defect O O
in O O
the O O
skeletal O O
muscle O O
chloride O O
channel O O
function O O
, O O
which O O
may O O
cause O O
sustained B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
membrane I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
depolarisation I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
diagnosis O O
MC B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
was O O
confirmed O O
genetically O O
. O O

Breathing O B_PERSON/B_LOCATION
movements O I_PERSON/I_LOCATION
caused O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
thoracic O B_MEASURE/B_LOCATION
volume O I_MEASURE/I_LOCATION
and O O
forced O O
air O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
to O O
flow O O
tidally O O
through O O
a O O
pneumotachograph O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Systemic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
application O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
KCN O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
to O O
evaluate O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
peripheral O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemoreception O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
ventilation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
, O O
led O O
to O O
a O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
VE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O O
both O O
groups O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
The O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
pilocarpine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
animals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
an O O
altered O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
react O O
to O O
( O O
or O O
compensate O O
for O O
) O O
blood O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
gas O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
changes O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
ventilation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
suggest O O
that O O
it O O
is O O
centrally O O
determined O O
. O O

Progesterone O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
potentiation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
bupivacaine O B_DISEASE
arrhythmogenicity O I_DISEASE
in O O
pentobarbital O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
anesthetized O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
beating O O
rat O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
heart O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
cell O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
cultures O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
progesterone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
bupivacaine O B_DISEASE
arrhythmogenicity O I_DISEASE
in O O
beating O O
rat O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
heart O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
myocyte O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
cultures O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
on O O
anesthetized O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
rats O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O O
determined O O
. O O

Neither O O
progesterone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nor O O
estradiol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
bupivacaine O B_DISEASE/B_GENE
arrhythmogenicity O B_DISEASE/I_GENE
were O O
potentiated O O
by O O
epinephrine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Chronic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
progesterone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
pretreatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
5 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
/ O O
day O B_TIME[MEASURE]
for O O
21 O B_TIME[MEASURE]
days O I_TIME[MEASURE]
) O O
caused O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
bupivacaine O B_DISEASE/B_GENE
arrhythmogenicity O I_DISEASE/I_GENE
in O O
intact O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pentobarbital O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
anesthetized O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
progesterone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
potentiate O O
bupivacaine O B_DISEASE/B_ORGANISM_FUNCTION
arrhythmogenicity O I_DISEASE/I_ORGANISM_FUNCTION
both O O
in O O
vivo O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
in O O
vitro O B_SPECIES[BIO]/B_LOCATION
. O O

There O O
was O O
no O O
relationship O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
sFas O B_GENE/B_DISEASE
to O O
eventual O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcome O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
patients O B_PERSON/B_LOCATION
. O O

Two O B_PERSON
patients O I_PERSON
developed O O
device O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
related O O
complications O B_DISEASE
and O O
two O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
experienced O O
abnormal O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weight O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
gain O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

It O O
reduces O O
the O O
severity O B_MEASURE
of O O
" O O
off O O
" O O
phase O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
symptoms O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
improves O O
the O O
axial O B_DISEASE
symptoms O I_DISEASE
and O O
reduces O O
levodopa O B_DISEASE
requirements O I_DISEASE
. O O

Eyes O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
subsequently O O
enucleated O O
because O O
of O O
treatment O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
failure O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
n O B_PROTEIN[GENE]/B_LOCATION
= O I_PROTEIN[GENE]/I_LOCATION
4 O I_PROTEIN[GENE]/I_LOCATION
) O O
were O O
examined O O
histologically O O
. O O

Seven O B_NUMBER[MEASURE]
( O O
54 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
) O O
of O O
the O O
13 O B_PERSON
patients O I_PERSON
experienced O O
visual O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recovery O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
stopping O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Thirteen O B_MEASURE/B_PERSON
patients O I_MEASURE/I_PERSON
have O O
been O O
treated O O
to O O
date O B_DISEASE
with O O
1 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
or O O
2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
% O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
topical O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
glycopyrrolate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Thus O O
, O O
three O B_NUMBER[MEASURE]/B_PERSON
of O O
six O B_NUMBER[MEASURE]/B_PERSON
patients O B_NUMBER[MEASURE]/I_PERSON
had O O
their O O
menstrual O B_DISEASE
irregularity O I_DISEASE
successfully O O
corrected O O
with O O
bromocriptine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Moreover O O
, O O
both O O
drugs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
the O O
dose O B_MEASURE/B_LOCATION
of O O
0 O B_MEASURE
. O O
5 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
antagonized O O
completely O O
the O O
convulsant O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
activity O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
the O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
35S O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
TBPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
binding O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
induced O O
by O O
isoniazide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
350 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE/B_LOCATION
s O I_MEASURE/I_LOCATION
. O O
c O O
. O O
) O O
as O O
well O O
as O O
the O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
35S O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
TBPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
binding O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
induced O O
by O O
foot O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
shock O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
stress O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Pharmacodynamics O O
of O O
the O O
hypotensive B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O O
of O O
levodopa O O
in O O
parkinsonian B B_DISEASE
patients O O
. O O

Blood O O
pressure O O
effects O O
of O O
i O O
. O O
v O O
. O O
levodopa O O
were O O
examined O O
in O O
parkinsonian B B_NUMBER[MEASURE]/B_PERSON
patients O O
with O O
stable O O
and O O
fluctuating O O
responses O O
to O O
levodopa O O
. O O

The O O
magnitude O O
of O O
the O O
hypotensive B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O O
of O O
levodopa O O
was O O
concentration O O
dependent O O
and O O
was O O
fit O O
to O O
an O O
Emax O O
model O O
in O O
fluctuating O O
responders O O
. O O

Baseline O O
blood O O
pressures O O
were O O
higher O O
in O O
fluctuating O O
patients O O
; O O
a O O
higher O O
baseline O O
blood O O
pressure O O
correlated O O
with O O
greater O O
hypotensive B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O O
. O O

We O O
conclude O O
that O O
levodopa O O
has O O
a O O
central O O
hypotensive B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
action O O
that O O
parallels O O
the O O
motor O O
effects O O
in O O
fluctuating O O
patients O O
. O O

After O O
normal O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serum O I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium O I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
returned O O
, O O
further O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
doxorubicin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemotherapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
without O O
vincristine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
did O O
not O O
produce O O
this O O
complication O B_DISEASE
. O O

There O O
is O O
a O O
paucity O B_DISEASE/B_MEASURE
of O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
from O O
well O O
- O O
designed O O
trials O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

More O O
convincing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
required O O
showing O O
that O O
digoxin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
improves O O
symptoms O B_DISEASE
or O O
exercise O B_DISEASE_ADJECTIVE[DISEASE]
capacity O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Angiotensin O B_GENE
- O O
converting O O
enzyme O B_ENZYME[GENE]
( O O
ACE O B_PERSON/B_PROTEIN[GENE]
) O O
inhibitors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O O
be O O
used O O
first O O
as O O
they O O
are O O
safer O B_DISEASE_ADJECTIVE[DISEASE]
, O O
do O O
not O O
require O O
blood O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
level O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
monitoring O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
modify O O
progression O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
disease O B_DISEASE
, O O
relieve O O
symptoms O B_DISEASE
, O O
improve O O
exercise O B_DISEASE_ADJECTIVE[DISEASE]
tolerance O I_DISEASE_ADJECTIVE[DISEASE]
and O O
reduce O O
mortality O B_DISEASE/B_MEASURE
. O O

Caution O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O O
be O O
exercised O O
in O O
using O O
digoxin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
until O O
large O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mortality O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trials O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
completed O O
showing O O
either O O
benefit O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
or O O
harm O B_DISEASE
. O O

Supine O B_DISEASE/B_GENE
blood O I_DISEASE/I_GENE
pressure O I_DISEASE/I_GENE
was O O
reduced O O
( O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
from O O
170 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
20 O B_MEASURE
/ O O
102 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
6 O B_MEASURE
mmHg O I_MEASURE
to O O
153 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
19 O B_MEASURE
/ O O
92 O B_MEASURE
+ O O
/ O O
- O O
8 O B_MEASURE
, O O
147 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
18 O B_MEASURE
/ O O
88 O B_MEASURE
+ O O
/ O O
- O O
7 O B_MEASURE
and O O
144 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
14 O B_MEASURE
/ O O
87 O B_MEASURE
+ O O
/ O O
- O O
6 O B_MEASURE
mmHg O I_MEASURE
at O O
2 O B_NUMBER[MEASURE]
, O O
4 O B_MEASURE
and O O
6 O B_MEASURE/B_ENT
weeks O I_MEASURE/I_ENT
respectively O O
in O O
evaluable O B_PERSON/B_TIME[MEASURE]
patients O I_PERSON/I_TIME[MEASURE]
. O O

Normalization O B_DISEASE/B_PERSON
and O O
responder O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rates O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
6 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
weeks O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
were O O
86 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
and O O
69 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
respectively O O
. O O

Anaesthesia O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
induction O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
and O O
emergence O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
times O B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
respiratory O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
cardiovascular O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
variables O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
showed O O
no O O
significant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

After O O
withdrawal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
pharmacon O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
all O O
symptoms O B_DISEASE
disappeared O O
spontaneously O O
. O O

Vinorelbine O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
- O O
related O O
cardiac O B_DISEASE_ADJECTIVE[DISEASE]
events O I_DISEASE_ADJECTIVE[DISEASE]
: O O
a O O
meta O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
randomized O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
clinical O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
trials O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Several O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cases O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cardiac O B_DISEASE
adverse O I_DISEASE
reactions O I_DISEASE
related O O
to O O
vinorelbine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
VNR O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
have O O
been O O
reported O O
in O O
the O O
literature O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Outcomes O B_PERSON/B_LOCATION
of O O
interest O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
severe O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cardiac O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
events O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
toxic O B_DISEASE
deaths O I_DISEASE
and O O
cardiac O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
event O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
related O O
deaths O B_DISEASE
reported O O
in O O
each O O
publication O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

The O O
incidence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
cardiac O B_DISEASE
events O I_DISEASE
with O O
VNR O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
1 O B_MEASURE
. O O
19 O B_MEASURE
% O I_MEASURE
[ O I_MEASURE
95 O I_MEASURE
% O I_MEASURE
confidence O I_MEASURE
interval O I_MEASURE
( O O
CI O B_MEASURE/B_LOCATION
) O O
( O O
0 O B_MEASURE
. O O
75 O B_MEASURE
; O O
1 O B_MEASURE
. O O
67 O B_MEASURE
) O O
] O O
. O O

There O O
was O O
no O O
difference O B_MEASURE
in O O
the O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
cardiac O B_DISEASE
events O I_DISEASE
between O O
VNR O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
other O B_MEASURE/B_LOCATION
drugs O B_MEASURE/I_LOCATION
[ O B_MEASURE/I_LOCATION
odds O B_MEASURE/I_LOCATION
ratio O B_MEASURE/I_LOCATION
: O O
0 O B_MEASURE
. O O
92 O B_MEASURE
, O O
95 O B_MEASURE
% O I_MEASURE
CI O I_MEASURE
( O O
0 O B_MEASURE
. O O
54 O B_MEASURE
; O O
1 O B_MEASURE
. O O
55 O B_MEASURE
) O O
] O O
. O O

Vinorelbine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
related O O
cardiac O B_DISEASE
events O I_DISEASE
concern O O
about O O
1 O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
treated O O
patients O B_PERSON/B_BIO
in O O
clinical O B_LOCATION/B_ORGANIZATION
trials O I_LOCATION/I_ORGANIZATION
. O O

However O O
, O O
the O O
risk O B_DISEASE
associated O O
with O O
VNR O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
seems O O
to O O
be O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
that O O
of O O
other O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
chemotherapeutic O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
agents O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
same O B_LOCATION/B_PERSON
indications O I_LOCATION/I_PERSON
. O O

In O O
all O O
, O O
16 O B_PERSON
patients O I_PERSON
with O O
unequivocal O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
defects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
continued O O
the O O
medication O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Mean O O
right O B_DISEASE/B_MEASURE
eye O I_DISEASE/I_MEASURE
MRD O I_DISEASE/I_MEASURE
at O O
presentation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O O
36 O B_MEASURE
. O O
98 O B_MEASURE
degrees O I_MEASURE
( O O
range O B_MEASURE/B_LOCATION
22 O I_MEASURE/I_LOCATION
. O O
25 O B_MEASURE
- O O
51 O B_MEASURE
. O O
0 O B_MEASURE
) O O
, O O
compared O O
to O O
38 O B_MEASURE
. O O
40 O B_MEASURE
degrees O I_MEASURE
( O O
range O B_MEASURE/B_LOCATION
22 O I_MEASURE/I_LOCATION
. O O
5 O B_MEASURE
- O O
49 O B_MEASURE
. O O
75 O B_MEASURE
) O O
after O O
follow O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
up O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
; O O
P O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
338 O B_MEASURE
unpaired O I_MEASURE
t O I_MEASURE
- O O
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Biopsy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O O
an O O
abundance O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
Demodex O B_DISEASE
mites O I_DISEASE
in O O
2 O B_NUMBER[MEASURE]
of O O
these O O
patients O B_PERSON/B_LOCATION
. O O

A O O
variety O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
factors O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
as O O
vasoactive O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
properties O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
tacrolimus O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
proliferation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
Demodex O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
due O O
to O O
local O B_DISEASE
immunosuppression O I_DISEASE
, O O
and O O
the O O
occlusive O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
properties O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
ointment O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
may O O
be O O
involved O O
in O O
the O O
observed O O
phenomena O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Cortical O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
maps O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
revealed O O
severe O B_COLOR/B_PERSON
gray O I_COLOR/I_PERSON
- O O
matter O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
deficits O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
the O O
cingulate O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
limbic O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
paralimbic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cortices O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
MA O B_DISEASE/B_PERSON
abusers O I_DISEASE/I_PERSON
( O O
averaging O O
11 O B_MEASURE
. O O
3 O B_MEASURE
% O I_MEASURE
below O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
; O O
p O O
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

MA O B_LOCATION/B_DISEASE
may O O
selectively O O
damage O O
the O O
medial O B_BODY_PART_OR_ORGAN_COMPONENT
temporal O I_BODY_PART_OR_ORGAN_COMPONENT
lobe O I_BODY_PART_OR_ORGAN_COMPONENT
and O O
, O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
metabolic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
cingulate O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
limbic O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
cortex O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
, O O
inducing O O
neuroadaptation O B_DISEASE
, O O
neuropil O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduction O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
or O O
cell O B_DISEASE
death O I_DISEASE
. O O

Disruption O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
hepatic O B_DISEASE/B_GENE
lipid O I_DISEASE/I_GENE
homeostasis O I_DISEASE/I_GENE
in O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
amiodarone O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
is O O
associated O O
with O O
peroxisome O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proliferator O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
activated O O
receptor O B_GENE
- O O
alpha O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
target O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
gene O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activation O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Niacin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
extended O O
- O O
release O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
/ O O
lovastatin O B_MEASURE
1 O I_MEASURE
, O O
000 O B_MEASURE
/ O O
40 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
dosed O O
as O O
initial O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
was O O
associated O O
with O O
good O B_DISEASE_ADJECTIVE[DISEASE]
compliance O I_DISEASE_ADJECTIVE[DISEASE]
and O O
safety O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
had O O
very O O
low O B_DISEASE_ADJECTIVE[DISEASE]
incidences O I_DISEASE_ADJECTIVE[DISEASE]
of O O
increased O O
liver O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
muscle O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
enzymes O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

After O O
she O O
had O O
received O O
a O O
total O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
only O O
0 O B_MEASURE
. O O
9 O B_MEASURE
mg O I_MEASURE
droperidol O I_MEASURE
, O O
a O O
syringe O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
containing O O
diamorphine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
only O O
was O O
substituted O O
and O O
her O O
unease O B_DISEASE
resolved O O
completely O O
. O O

However O O
, O O
one O B_TIME[MEASURE]/B_LOCATION
month O I_TIME[MEASURE]/I_LOCATION
after O O
switching O O
over O O
nifekalant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
sotalol O O
, O O
a O O
short O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
duration O B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
ST O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
elevation O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
documented O O
in O O
ECG O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
monitoring O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
at O O
almost O O
the O O
same O B_TIME[MEASURE]/B_LOCATION
time O B_TIME[MEASURE]/I_LOCATION
for O O
three O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
consecutive O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
days O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

ST O B_DISEASE/B_LOCATION
elevation O I_DISEASE/I_LOCATION
with O O
chest O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
discomfort O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disappeared O O
since O O
he O O
began O O
taking O O
long O O
- O O
acting O O
diltiazem O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Our O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
trazodone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
2 O B_MEASURE
. O O
5 O B_MEASURE
- O O
20 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
does O O
not O O
block O O
pre O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
and O O
postsynaptic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
striatal O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
D2 O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
DA O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
receptors O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
while O O
at O O
30 O B_MEASURE
, O O
40 O B_MEASURE
and O O
50 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
it O O
blocks O O
postsynaptic O B_DISEASE/B_BIO
striatal O I_DISEASE/I_BIO
D2 O I_DISEASE/I_BIO
DA O I_DISEASE/I_BIO
receptors O I_DISEASE/I_BIO
. O O

Fifteen O O
dyskinetic B B_PERSON
, O O
12 O O
nondyskinetic O O
patients O O
, O O
and O O
a O O
control O O
group O O
were O O
included O O
. O O

Deglutition O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
assessed O O
using O O
modified O O
barium O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
swallow O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O O
videofluoroscopy O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Dyskinetic B B_MEASURE/B_PERSON
patients O O
tended O O
to O O
have O O
a O O
greater O O
OPSE O O
than O O
nondyskinetic O O
( O O
Dunnett O O
, O O
P O O
= O O
0 O O
. O O
06 O O
) O O
. O O

In O O
the O O
current O O
study O O
, O O
dyskinetic B B_NUMBER[MEASURE]/B_PERSON
patients O O
performed O O
better O O
in O O
swallowing O O
function O O
, O O
which O O
could O O
be O O
explained O O
on O O
the O O
basis O O
of O O
a O O
greater O O
levodopa O O
dose O O
. O O

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
investigated O O
the O O
expression O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
nuclear O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
kappaB O B_PROTEIN[GENE]/B_MEASURE
( O O
NF O B_DISEASE/B_PROTEIN[GENE]
- O O
kappaB O B_GENE
) O O
, O O
mitogen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
activated O O
protein O B_GENE/B_BACTERIUM[BIO]
( O O
MAP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
kinases O B_GENE/B_LOCATION
and O O
macrophages O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
renal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cortex O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
structural O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
functional O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
renal O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treated O O
with O O
gentamicin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
gentamicin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pyrrolidine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dithiocarbamate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PDTC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
an O O
NF O B_DISEASE/B_PROTEIN[GENE]
- O O
kappaB O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Gentamicin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
treated O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presented O O
a O O
transitory O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
plasma O B_DISEASE/B_MEASURE
creatinine O I_DISEASE/I_MEASURE
levels O I_DISEASE/I_MEASURE
. O O

Increased O O
ED O B_GENE/B_DISEASE
- O O
1 O B_MEASURE/B_LOCATION
, O O
MAP O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinases O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
NF O B_DISEASE/B_GENE
- O O
kappaB O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
staining O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
also O O
observed O O
in O O
the O O
renal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cortex O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
from O O
all O O
gentamicin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
treated O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O O
to O O
control O O
( O O
p O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

Treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
PDTC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reduced O O
the O O
functional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
structural O B_DISEASE
changes O I_DISEASE
induced O O
by O O
gentamicin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

A O O
high O B_MEASURE/B_DISEASE
index O I_MEASURE/I_DISEASE
of O O
suspicion O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
lead O O
to O O
a O O
quick O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnostic O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
procedure O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
successful O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decompressive O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
surgery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

BACKGROUND O O
: O O
Patients O O
with O O
primary B B_DISEASE
systemic I I_DISEASE
amyloidosis I I_DISEASE
( O O
AL B B_LOCATION/B_PERSON
) O O
have O O
a O O
poor O O
prognosis O O
. O O

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
undertaken O O
to O O
further O O
examine O O
its O O
risk O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
impact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
posttransplant O B_DISEASE
mortality O I_DISEASE
. O O

Acute B B_DISEASE_ADJECTIVE[DISEASE]
renal I I_DISEASE_ADJECTIVE[DISEASE]
insufficiency I I_DISEASE_ADJECTIVE[DISEASE]
( O O
ARI B B_PERSON/B_LOCATION
) O O
after O O
high O O
- O O
dose O O
melphalan O O
was O O
defined O O
by O O
a O O
minimum O O
increase O O
of O O
0 O O
. O O
5 O O
mg O O
/ O O
dL O O
( O O
44 O O
micromol O O
/ O O
L O O
) O O
in O O
the O O
serum O O
creatinine O O
level O O
that O O
is O O
greater O O
than O O
50 O O
% O O
of O O
baseline O O
immediately O O
after O O
conditioning O O
. O O

Age O B_DISEASE/B_GENE
and O O
urine O B_DISEASE/B_MEASURE
sediment O I_DISEASE/I_MEASURE
score O I_DISEASE/I_MEASURE
remained O O
independently O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
risk O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
factors O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
the O O
multivariate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Blood O O
pressure O O
was O O
manipulated O O
by O O
one O O
of O O
the O O
following O O
schedules O O
during O O
120 O O
min O O
of O O
reperfusion O O
: O O
Control O O
, O O
normotensive O O
reperfusion O O
; O O
90 O O
/ O O
hypertension B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
90 O O
/ O O
HTN B B_LOCATION
) O O
, O O
blood O O
pressure O O
was O O
increased O O
by O O
35 O O
mm O O
Hg O O
during O O
the O O
initial O O
90 O O
min O O
of O O
reperfusion O O
only O O
; O O
15 O O
/ O O
hypertension B B_DISEASE/B_MEASURE
( O O
15 O O
/ O O
HTN B B_DISEASE/B_LOCATION
) O O
, O O
normotensive O O
reperfusion O O
for O O
30 O O
min O O
followed O O
by O O
15 O O
min O O
of O O
hypertension B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
75 O O
min O O
of O O
normotension O O
. O O

Part O B_MEASURE/B_LOCATION
B O I_MEASURE/I_LOCATION
, O O
for O O
eight O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
different O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
rats O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
each O O
group O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
brain O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
barrier O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
permeability O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
evaluated O O
by O O
measuring O O
the O O
amount O B_MEASURE/B_LOCATION
and O O
extent O B_MEASURE/B_LOCATION
of O O
extravasation O B_DISEASE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O O
Evans O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Blue O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dye O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Specific O O
gravity O O
was O O
greater O O
in O O
the O O
15 O O
/ O O
HTN B B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
group O O
( O O
1 O O
. O O
043 O O
+ O O
/ O O
- O O
0 O O
. O O
002 O O
) O O
versus O O
the O O
90 O O
/ O O
HTN B B_MEASURE
( O O
1 O O
. O O
036 O O
+ O O
/ O O
- O O
0 O O
. O O
003 O O
) O O
and O O
control O O
( O O
1 O O
. O O
037 O O
+ O O
/ O O
- O O
0 O O
. O O
003 O O
) O O
groups O O
. O O

BACKGROUND O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Acetaminophen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
paracetamol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
- O O
P O B_OTHER/B_PROTEIN[GENE]
) O O
and O O
Nimesulide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
N O B_OTHER/B_LOCATION
) O O
are O O
widely O O
used O O
analgesic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
antipyretic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
inflammatory O B_DISEASE
drugs O I_DISEASE
. O O

On O O
the O O
contrary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
non O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
- O O
steroidal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
anti O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
- O O
inflammatory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
NSAIDs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
are O O
commonly O O
involved O O
in O O
such O B_DISEASE/B_LOCATION
reactions O I_DISEASE/I_LOCATION
. O O

All O O
patients O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
observed O O
for O O
6 O B_TIME[MEASURE]/B_SPORT[ENT]
hours O I_TIME[MEASURE]/I_SPORT[ENT]
after O O
each O O
challenge O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O O
and O O
controlled O O
again O O
after O O
24 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
hours O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
to O O
exclude O O
delayed O O
reactions O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
: O O
No O O
reaction O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
observed O O
with O O
placebo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O O
eight O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
patients O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
88 O B_MEASURE
. O O
8 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
tolerated O O
CE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Odds O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ratios O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
calculated O O
using O O
a O O
conditional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
logistic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
including O O
potential O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
confounding O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
both O O
for O O
the O O
whole O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
population O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
for O O
the O O
various O B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
underlying O O
diseases O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
the O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
width O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
GAP43 O B_GENE/B_LOCATION
- O O
ir O B_LOCATION/B_PROTEIN[GENE]
band O B_LOCATION/I_PROTEIN[GENE]
in O O
the O O
IML O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
showed O O
that O O
CHX O B_DISEASE
+ O O
Pilo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
animals O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
had O O
a O O
significantly O O
larger O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
band O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
p O B_MEASURE/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
03 O B_MEASURE
) O O
as O O
compared O O
with O O
that O O
in O O
the O O
Pilo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Nicotine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antagonizes O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
caffeine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
but O O
not O O
pentylenetetrazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
anxiogenic O B_DISEASE
effect O I_DISEASE
in O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
: O O
Adult O B_PERSON
male O I_PERSON
Swiss O I_PERSON
Webster O I_PERSON
mice O I_PERSON
( O O
25 O B_MEASURE
- O O
32 O B_MEASURE
g O I_MEASURE
) O O
were O O
given O O
nicotine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
0 O B_MEASURE/B_LOCATION
. O O
05 O B_MEASURE
- O O
0 O B_MEASURE
. O O
25 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE/B_LOCATION
s O I_MEASURE/I_LOCATION
. O O
c O B_DISEASE/B_LOCATION
. O O
) O O
or O O
saline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
min O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O O
caffeine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
70 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE/B_PERSON
i O O
. O O
p O B_MEASURE/B_LOCATION
. O O
) O O
or O O
pentylenetetrazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
15 O B_MEASURE
and O O
30 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
i O O
. O O
p O B_MEASURE/B_LOCATION
. O O
) O O
injections O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
each O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
their O O
combinations O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
did O O
not O O
produce O O
any O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
locomotor O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Clinical O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
heterogeneity O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
precluded O O
meta O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
most O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
hepatocellular O B_DISEASE/B_MEASURE
pattern O B_DISEASE/I_MEASURE
of O O
damage O B_DISEASE
was O O
the O O
most O O
common O B_DISEASE_ADJECTIVE[DISEASE]
( O O
58 O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
) O O
, O O
was O O
inversely O O
correlated O O
with O O
age O B_DISEASE/B_MEASURE
( O O
P O B_MEASURE/B_LOCATION
< O I_MEASURE/I_LOCATION
. O O
0001 O B_MEASURE
) O O
, O O
and O O
had O O
the O O
worst O B_MEASURE/B_LOCATION
outcome O I_MEASURE/I_LOCATION
( O O
Cox O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regression O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
P O B_MEASURE/B_LOCATION
< O I_MEASURE/I_LOCATION
. O O
034 O B_MEASURE
) O O
. O O

VCM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O O
administrated O O
intraperitoneally O O
( O O
i O B_DISEASE/B_TIME[MEASURE]
. O O
p O B_MEASURE/B_LOCATION
. O O
) O O
with O O
200mgkg O B_MEASURE
( O O
- O O
1 O B_MEASURE/B_LOCATION
) O O
twice O O
daily O O
for O O
7 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days O B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Erdosteine O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
caused O O
a O O
marked O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reduction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
extent O B_DISEASE/B_MEASURE
of O O
tubular O B_DISEASE
damage O I_DISEASE
. O O

The O O
patient O B_PERSON/B_BIO
achieved O O
a O O
partial O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
response O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
6 O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
months O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O O
the O O
initiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
S O B_DISEASE/B_GENE
- O O
1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Hepatocellular B B_DISEASE
carcinoma I I_DISEASE
in O O
Fanconi B B_PERSON/B_BIO
' I I_PERSON/I_BIO
s I I_PERSON/I_BIO
anemia I I_PERSON/I_BIO
treated O O
with O O
androgen O O
and O O
corticosteroid O O
. O O

Reactive O B_DISEASE/B_PERSON
oxygen O I_DISEASE/I_PERSON
species O I_DISEASE/I_PERSON
particularly O O
affect O O
the O O
cardiac O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
myocytes O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
because O O
these O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
seem O O
to O O
have O O
a O O
relatively O O
poor O B_DISEASE/B_MEASURE
antioxidant O I_DISEASE/I_MEASURE
defense O I_DISEASE/I_MEASURE
system O I_DISEASE/I_MEASURE
. O O

The O O
ratio O B_MEASURE
of O O
aberrant O B_DISEASE/B_GENE
cardiomyocytes O I_DISEASE/I_GENE
in O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treated O O
with O O
DOX O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
preceded O O
by O O
monoHER O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
those O O
in O O
mice O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treated O O
with O O
saline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ranged O O
from O O
1 O B_NUMBER[MEASURE]
. O O
6 O B_MEASURE
to O O
2 O B_MEASURE
. O O
8 O B_MEASURE
( O O
mean O O
2 O B_MEASURE
. O O
2 O B_MEASURE
, O O
95 O B_MEASURE
% O I_MEASURE
CI O I_MEASURE
1 O I_MEASURE
. O O
2 O B_MEASURE
- O O
4 O B_MEASURE
. O O
1 O B_MEASURE
, O O
P O B_OTHER/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
019 O B_MEASURE
) O O
. O O

The O O
mean O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
protective O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
by O O
adding O O
monoHER O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
before O O
DOX O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
led O O
to O O
a O O
significant O B_MEASURE
4 O I_MEASURE
. O O
4 O B_MEASURE
- O O
fold O B_MEASURE
reduction O I_MEASURE
( O O
P O B_OTHER/B_MEASURE
< O O
0 O B_MEASURE
. O O
001 O B_MEASURE
, O O
95 O B_MEASURE
% O I_MEASURE
CI O I_MEASURE
2 O I_MEASURE
. O O
3 O B_MEASURE
- O O
8 O B_MEASURE
. O O
2 O B_MEASURE
) O O
of O O
abnormal O B_DISEASE/B_GENE
cardiomyocytes O I_DISEASE/I_GENE
. O O

BACKGROUND O O
: O O
Bepridil O O
hydrochloride O O
( O O
Bpd O O
) O O
has O O
attracted O O
attention O O
as O O
an O O
effective O O
drug O O
for O O
atrial B B_DISEASE_ADJECTIVE[DISEASE]
fibrillation I I_DISEASE_ADJECTIVE[DISEASE]
( O O
AF B B_LOCATION/B_ORGANIZATION
) O O
and O O
atrial B B_DISEASE
flutter I I_DISEASE
( O O
AFL B B_ORGANIZATION/B_LOCATION
) O O
. O O

However O O
, O O
serious O O
adverse O O
effects O O
, O O
including O O
torsade B B_DISEASE
de I I_DISEASE
pointes I I_DISEASE
( O O
Tdp B B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
have O O
been O O
reported O O
. O O

Adverse O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
observed O O
in O O
19 O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
( O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
during O O
an O O
average O B_MEASURE/B_LOCATION
follow O B_MEASURE/I_LOCATION
- O O
up O B_LOCATION/B_LANGUAGE
of O O
20 O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
months O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
have O O
previously O O
shown O O
that O O
a O O
permanent O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
deficiency O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
brain O B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
renin O B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
- O O
angiotensin O B_DISEASE_ADJECTIVE[DISEASE]/B_ENZYME[GENE]
system O B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
( O O
RAS O B_LOCATION/B_DISEASE
) O O
may O O
increase O O
the O O
sensitivity O B_MEASURE
of O O
the O O
baroreflex O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
heart O B_DISEASE
rate O I_DISEASE
. O O

Transgenic O B_PERSON/B_BIO
rats O I_PERSON/I_BIO
with O O
low O B_DISEASE
brain O I_DISEASE
angiotensinogen O I_DISEASE
( O O
TGR O B_LOCATION/B_ORGANIZATION
) O O
were O O
used O O
. O O

In O O
isolated O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
hearts O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O O
Iso O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
induced O O
a O O
significantly O O
greater O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
left O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ventricular O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
LV O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
) O O
pressure O B_DISEASE/B_MEASURE
and O O
maximal O B_MEASURE/B_DISEASE
contraction O I_MEASURE/I_DISEASE
( O O
+ O B_LOCATION/B_PROTEIN[GENE]
dP O I_LOCATION/I_PROTEIN[GENE]
/ O O
dt O B_PROTEIN[GENE]/B_MEASURE
( O O
max O B_PERSON/B_MEASURE
) O O
) O O
in O O
the O O
TGR O B_BODY_PART_OR_ORGAN_COMPONENT/B_PROTEIN[GENE]
than O O
in O O
the O O
Sprague O B_PERSON
- O O
Dawley O B_PERSON
( O O
SD O B_MEASURE/B_DISEASE
) O O
rats O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
decrease O B_DISEASE
in O O
the O O
heart O B_MEASURE/B_LOCATION
rate O B_MEASURE/I_LOCATION
( O O
HR O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
) O O
induced O O
by O O
the O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
AR O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antagonist O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
metoprolol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
conscious O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
rats O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
was O O
significantly O O
attenuated O O
in O O
TGR O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
compared O O
with O O
SD O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
rats O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
( O O
- O O
9 O B_MEASURE
. O O
9 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
1 O B_MEASURE
. O O
7 O B_MEASURE
% O I_MEASURE
vs O I_MEASURE
. O O
- O O
18 O B_MEASURE
. O O
1 O B_MEASURE/B_LOCATION
+ O I_MEASURE/I_LOCATION
/ O O
- O O
1 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
) O O
, O O
whereas O O
the O O
effect O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
parasympathetic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
blockade O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
atropine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
HR O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
was O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
both O O
strains O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Methadone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
prolongs O O
the O O
QT O B_DISEASE
interval O I_DISEASE
in O O
vitro O B_SPECIES[BIO]/B_LOCATION
in O O
a O O
dose O B_MEASURE
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
manner O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

QTc O B_DISEASE/B_GENE
length O I_DISEASE/I_GENE
was O O
weakly O O
but O O
significantly O O
associated O O
with O O
methadone O B_MEASURE/B_LOCATION
daily O I_MEASURE/I_LOCATION
dose O I_MEASURE/I_LOCATION
( O O
Spearman O B_LOCATION/B_MEASURE
rank O I_LOCATION/I_MEASURE
correlation O I_LOCATION/I_MEASURE
coefficient O I_LOCATION/I_MEASURE
, O O
0 O B_MEASURE/B_LOCATION
. O O
20 O B_MEASURE
; O O
P O B_MEASURE
< O I_MEASURE
. O O
01 O B_MEASURE
) O O
. O O

These O O
include O O
augmented O O
endothelin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
1 O B_TIME[MEASURE]
( O O
ET O B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
1 O B_NUMBER[MEASURE]
) O O
release O B_ENT/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
increased O O
sympathetic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nervous O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
elevated O O
tissue O B_DISEASE
oxidative O I_DISEASE
stress O I_DISEASE
. O O

Mean O B_DISEASE/B_GENE
arterial O B_DISEASE/I_GENE
pressure O B_DISEASE/I_GENE
of O O
conscious O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
rats O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
119 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
2 O B_MEASURE
mm O I_MEASURE
Hg O I_MEASURE
in O O
control O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O O
194 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
5 O B_MEASURE
mm O I_MEASURE
Hg O I_MEASURE
in O O
LNNA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
rats O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

Maximal O B_TIME[MEASURE]/B_PERSON
contraction O I_TIME[MEASURE]/I_PERSON
to O O
norepinephrine O B_LOCATION
was O O
modestly O O
reduced O O
in O O
arteries O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
from O O
LNNA O B_DISEASE/B_GENE
compared O O
with O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
rats O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
whereas O O
the O O
maximum O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
contraction O I_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
ET O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
1 O B_NUMBER[MEASURE]
was O O
significantly O O
reduced O O
( O O
54 O B_PERSON/B_MEASURE
% O B_PERSON/I_MEASURE
control O B_PERSON/I_MEASURE
) O O
. O O

Mean O O
circulatory O O
filling O O
pressure O O
, O O
an O O
in O O
vivo O O
measure O O
of O O
venomotor O O
tone O O
, O O
was O O
not O O
elevated O O
in O O
LNNA O O
hypertension B B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
1 O O
or O O
2 O O
weeks O O
after O O
LNNA O O
. O O

The O O
superoxide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
scavenger O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
tempol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
30 O B_MEASURE
, O O
100 O B_MEASURE
, O O
and O O
300 O B_MEASURE
micromol O I_MEASURE
kg O I_MEASURE
( O O
- O O
1 O B_MEASURE
) O O
, O O
IV O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
did O O
not O O
change O O
arterial O B_DISEASE/B_GENE
pressure O B_DISEASE/I_GENE
in O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
rats O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
but O O
caused O O
a O O
dose O B_MEASURE
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]
decrease O I_DISEASE_ADJECTIVE[DISEASE]
in O O
LNNA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
rats O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
- O O
18 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
8 O B_MEASURE
, O O
- O O
26 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
15 O B_MEASURE
, O O
and O O
- O O
54 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
11 O B_MEASURE
mm O I_MEASURE
Hg O I_MEASURE
) O O
. O O

Carotid O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
arteries O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
vena O B_BODY_PART_OR_ORGAN_COMPONENT
cava O I_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
sympathetic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ganglia O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
from O O
LNNA O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
higher O B_DISEASE_ADJECTIVE[DISEASE]
basal O I_DISEASE_ADJECTIVE[DISEASE]
levels O I_DISEASE_ADJECTIVE[DISEASE]
of O O
superoxide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
compared O O
with O O
those O O
from O O
control O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

METHODS O O
: O O
We O O
identified O O
seven O O
SNP O O
( O O
single O O
nucleotide O O
polymorphism O O
) O O
( O O
- O O
141Cins O O
> O O
del O O
, O O
TaqIB O O
, O O
TaqID O O
, O O
Ser311Cys O O
, O O
rs6275 O O
, O O
rs6277 O O
and O O
TaqIA O O
) O O
in O O
the O O
DRD2 O O
gene O O
in O O
146 O O
schizophrenic B B_DISEASE/B_PERSON
inpatients O O
( O O
59 O O
with O O
EPS B B_DISEASE
and O O
87 O O
without O O
EPS B B_LOCATION
according O O
to O O
the O O
Simpson O O
- O O
Angus O O
Scale O O
) O O
treated O O
with O O
chlorpromazine O O
after O O
8 O O
weeks O O
. O O

Tonic O O
dopaminergic O O
stimulation O O
impairs B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
associative I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
learning I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
healthy O O
subjects O O
. O O

Because O O
levodopa O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
increases O O
both O O
phasic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
tonic O B_DISEASE_ADJECTIVE[DISEASE]
dopaminergic O I_DISEASE_ADJECTIVE[DISEASE]
neurotransmission O I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
critical O B_LOCATION
mechanism O I_LOCATION
mediating O O
the O O
enhancement O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
learning O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
unresolved O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Stopping O O
minocycline O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
led O O
to O O
amelioration O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
symptoms O B_DISEASE
and O O
normalization O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
CRP O B_DISEASE
level O I_DISEASE
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
At O O
a O O
median O B_MEASURE/B_LOCATION
follow O B_MEASURE/I_LOCATION
- O O
up O B_LOCATION/B_LANGUAGE
of O O
14 O B_MEASURE
. O O
1 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
, O O
the O O
overall O B_DISEASE
recurrence O I_DISEASE
rate O I_DISEASE
in O O
the O O
51 O B_PERSON/B_DISEASE
patients O I_PERSON/I_DISEASE
was O O
3 O B_MEASURE
. O O
9 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
( O O
2 O B_MEASURE
/ O O
51 O B_MEASURE
) O O
. O O

The O O
overall O B_DISEASE
patient O I_DISEASE
survival O I_DISEASE
was O O
88 O B_MEASURE
. O O
3 O B_MEASURE
% O I_MEASURE
, O O
and O O
82 O B_MEASURE
. O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
after O O
1 O B_SEQUENCE[MEASURE]
and O O
2 O B_NUMBER[MEASURE]/B_ENT
years O I_NUMBER[MEASURE]/I_ENT
, O O
respectively O O
. O O

A O O
daily O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oral O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
100 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
lamivudine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O O
2 O B_TIME[MEASURE]
weeks O I_TIME[MEASURE]
before O O
transplantation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
for O O
10 O B_PERSON/B_DISEASE
patients O B_PERSON/I_DISEASE
enabled O O
57 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
( O O
4 O B_MEASURE
/ O O
7 O B_MEASURE
) O O
and O O
62 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
( O O
5 O B_MEASURE
/ O O
8 O B_MEASURE
) O O
of O O
HBV O B_DISEASE/B_GENE
- O O
DNA O B_GENE/B_DISEASE
and O O
HBeAg O B_DISEASE/B_GENE
positive O B_DISEASE/I_GENE
patients O B_DISEASE/I_GENE
respectively O O
to O O
convert O O
to O O
be O O
negative O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Lamivudine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
combined O O
with O O
intramuscular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
HBIg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
can O O
effectively O O
prevent O O
allograft O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
from O O
the O O
recurrence O B_DISEASE_ADJECTIVE[DISEASE]
of O O
HBV O B_DISEASE
after O O
liver O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplantation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

No O O
adverse O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
eslicarbazepine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acetate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
observed O O
in O O
the O O
behavioral O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O O
EEG O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
patterns O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
studied O O
, O O
including O O
sleep O B_DISEASE
/ O O
wakefulness O B_DISEASE
cycle O I_DISEASE
, O O
at O O
the O O
doses O B_MEASURE/B_LOCATION
studied O O
. O O

Caspase O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
activation O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O O
cisplatin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
inhibited O O
by O O
CAA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Thus O O
, O O
CAA O O
directly O O
reacts O O
with O O
cellular O O
protein O O
and O O
non O O
- O O
protein O O
thiols O O
, O O
mediating O O
its O O
toxicity B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
hRPTEC O O
. O O

Similarly O O
, O O
clinician O B_PERSON
ratings O I_PERSON
showed O O
reductions O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
anger O B_MEASURE/B_ENT
subscale O I_MEASURE/I_ENT
of O O
the O O
Children O B_DISEASE
' O I_DISEASE
s O I_DISEASE
Psychiatric O I_DISEASE
Rating O I_DISEASE
Scale O I_DISEASE
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Response O B_DISEASE
rates O I_DISEASE
did O O
not O O
significantly O O
differ O O
between O O
olanzapine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
43 O B_MEASURE
. O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
95 O B_LOCATION
% O I_LOCATION
CI O I_LOCATION
= O O
28 O B_MEASURE
. O O
8 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
- O O
58 O B_MEASURE
. O O
6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
and O O
risperidone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
54 O B_MEASURE
. O O
3 O B_MEASURE
% O I_MEASURE
, O O
95 O B_LOCATION
% O I_LOCATION
CI O I_LOCATION
= O O
39 O B_MEASURE
. O O
9 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
- O O
68 O B_MEASURE
. O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
. O O

Body O B_DISEASE/B_LOCATION
mass O I_DISEASE/I_LOCATION
index O I_DISEASE/I_LOCATION
at O O
baseline O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
at O O
4 O B_MEASURE/B_LOCATION
months O I_MEASURE/I_LOCATION
was O O
24 O B_MEASURE
. O O
3 O B_MEASURE
( O O
95 O B_LOCATION
% O I_LOCATION
CI O I_LOCATION
= O O
22 O B_MEASURE
. O O
8 O B_MEASURE
- O O
25 O B_MEASURE
. O O
7 O B_MEASURE
) O O
versus O B_MEASURE
28 O I_MEASURE
. O O
2 O B_MEASURE
( O O
95 O B_LOCATION
% O I_LOCATION
CI O I_LOCATION
= O O
26 O B_MEASURE
. O O
7 O B_MEASURE
- O O
29 O B_MEASURE
. O O
7 O B_MEASURE
) O O
with O O
olanzapine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
23 O B_MEASURE
. O O
9 O B_MEASURE
( O O
95 O B_LOCATION
% O I_LOCATION
CI O I_LOCATION
= O O
22 O B_MEASURE
. O O
5 O B_MEASURE
- O O
25 O B_MEASURE
. O O
3 O B_MEASURE
) O O
versus O B_MEASURE
26 O I_MEASURE
. O O
7 O B_MEASURE
( O O
95 O B_LOCATION
% O I_LOCATION
CI O I_LOCATION
= O O
25 O B_MEASURE
. O O
2 O B_MEASURE
- O O
28 O B_MEASURE
. O O
2 O B_MEASURE
) O O
with O O
risperidone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Olanzapine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
may O O
have O O
an O O
advantage O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
motor O B_DISEASE/B_PERSON
side O I_DISEASE/I_PERSON
effects O I_DISEASE/I_PERSON
. O O

OBJECTIVE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
To O O
review O O
the O O
natural O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
history O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
ocular O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
systemic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adverse O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
patients O B_PERSON
taking O O
hydroxychloroquine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sulfate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
who O O
attended O O
an O O
ophthalmic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
screening O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
program O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

RESULTS O B_MEASURE
: O O
Records O B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
262 O B_PERSON
patients O I_PERSON
who O O
were O O
taking O O
hydroxychloroquine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
screened O O
in O O
the O O
Department O B_ORGANIZATION/B_LOCATION
of O O
Ophthalmology O B_DISEASE/B_ORGANIZATION
were O O
reviewed O O
. O O

Of O O
the O O
262 O B_PERSON/B_DISEASE
patients O I_PERSON/I_DISEASE
, O O
14 O B_MEASURE
( O O
18 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
of O O
76 O B_NUMBER[MEASURE]/B_PERSON
who O O
had O O
stopped O O
treatment O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
the O O
time O B_TIME[MEASURE]/B_LOCATION
of O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
experienced O O
documented O O
adverse O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Systemic O B_DISEASE
adverse O I_DISEASE
effects O I_DISEASE
occurred O O
in O O
8 O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
( O O
10 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
) O O
and O O
ocular O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
adverse O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
effects O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
in O O
5 O B_NUMBER[MEASURE]
( O O
6 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
) O O
. O O

Patients O B_PERSON/B_BIO
taking O O
hydroxychloroquine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
can O O
demonstrate O O
a O O
toxic O B_DISEASE_ADJECTIVE[DISEASE]
reaction O I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
retina O B_BODY_PART_OR_ORGAN_COMPONENT
despite O O
the O O
absence O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
known O O
risk O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
the O O
preceding O O
months O B_TIME[MEASURE]
she O O
had O O
received O O
neo O B_DISEASE
- O O
adjuvant O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
chemotherapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
epirubicin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
paclitaxel O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Taxol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
cyclophosphamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

OBJECTIVES O O
: O O
The O O
risk O O
of O O
acute B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
myocardial I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
infarction I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
AMI B B_LOCATION/B_ORGANIZATION
) O O
with O O
COX O O
- O O
2 O O
inhibitors O O
may O O
offset O O
their O O
gastrointestinal O O
( O O
GI O O
) O O
benefit O O
compared O O
with O O
non O O
- O O
selective O O
( O O
NS O O
) O O
non O O
- O O
steroidal O O
anti O O
- O O
inflammatory O O
drugs O O
( O O
NSAIDs O O
) O O
. O O

RESULTS O B_MEASURE/B_PERSON
: O O
Person O B_PERSON/B_NUMBER[MEASURE]
- O O
years O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
exposure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
among O O
non O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
- O O
users O B_PERSON
of O O
aspirin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O O
: O O
75 O B_MEASURE
, O O
761 O B_MEASURE
to O O
acetaminophen O O
, O O
42 O B_MEASURE
, O O
671 O B_MEASURE
to O O
rofecoxib O O
65 O B_NUMBER[MEASURE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
860 O B_MEASURE
to O O
celecoxib O O
, O O
and O O
37 O B_MEASURE
, O O
495 O B_MEASURE
to O O
NS O B_DISEASE
- O O
NSAIDs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Among O O
users O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
aspirin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
they O O
were O O
: O O
14 O B_MEASURE
, O O
671 O B_MEASURE
to O O
rofecoxib O O
, O O
22 O B_MEASURE
, O O
875 O B_MEASURE
to O O
celecoxib O O
, O O
9 O B_MEASURE
, O O
832 O B_MEASURE
to O O
NS O B_DISEASE/B_PROTEIN[GENE]
- O O
NSAIDs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
38 O B_MEASURE
, O O
048 O B_MEASURE
to O O
acetaminophen O O
. O O

Among O O
non O O
- O O
users O O
of O O
aspirin O O
, O O
the O O
adjusted O O
hazard O O
ratios O O
( O O
95 O O
% O O
confidence O O
interval O O
) O O
of O O
hospitalization O O
for O O
AMI B B_LOCATION/B_ORGANIZATION
/ O O
GI O O
vs O O
the O O
acetaminophen O O
( O O
with O O
no O O
aspirin O O
) O O
group O O
were O O
: O O
rofecoxib O O
1 O O
. O O
27 O O
( O O
1 O O
. O O
13 O O
, O O
1 O O
. O O
42 O O
) O O
, O O
celecoxib O O
0 O O
. O O
93 O O
( O O
0 O O
. O O
83 O O
, O O
1 O O
. O O
03 O O
) O O
, O O
naproxen O O
1 O O
. O O
59 O O
( O O
1 O O
. O O
31 O O
, O O
1 O O
. O O
93 O O
) O O
, O O
diclofenac O O
1 O O
. O O
17 O O
( O O
0 O O
. O O
99 O O
, O O
1 O O
. O O
38 O O
) O O
and O O
ibuprofen O O
1 O O
. O O
05 O O
( O O
0 O O
. O O
74 O O
, O O
1 O O
. O O
51 O O
) O O
. O O

It O O
was O O
reported O O
that O O
there O O
was O O
a O O
case O O
of O O
severe B B_PERSON
malaria I I_PERSON
patient O O
with O O
jaundice B B_DISEASE
who O O
presented O O
with O O
arrhythmia B B_DISEASE
( O O
premature B B_DISEASE/B_PROTEIN[GENE]
ventricular I B_DISEASE/I_PROTEIN[GENE]
contraction I B_DISEASE/I_PROTEIN[GENE]
) O O
while O O
getting O O
quinine O O
infusion O O
was O O
reported O O
. O O

Administration O O
of O O
parenteral O O
quinine O O
must O O
be O O
done O O
carefully O O
and O O
with O O
good O O
observation O O
because O O
of O O
its O O
pro O O
- O O
arrhythmic B B_DISEASE_ADJECTIVE[DISEASE]
effect O O
, O O
especially O O
in O O
older O O
patients O O
who O O
have O O
heart B B_DISEASE
diseases I I_DISEASE
or O O
patients O O
with O O
electrolyte B B_DISEASE
disorder I I_DISEASE
( O O
hypokalemia B B_LOCATION/B_ORGANIZATION
) O O
which O O
frequently O O
occurs O O
due O O
to O O
vomiting B B_DISEASE
and O O
or O O
diarrhea B B_DISEASE
in O O
malaria B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
cases O O
. O O

Wilson B B_DISEASE/B_GENE
' I I_DISEASE/I_GENE
s I I_DISEASE/I_GENE
disease I I_DISEASE/I_GENE
is O O
an O O
autosomal O O
recessive O O
disorder O O
of O O
hepatic O O
copper O O
metabolism O O
with O O
consequent O O
copper O O
accumulation O O
and O O
toxicity B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
in O O
many O O
tissues O O
and O O
consequent O O
hepatic B B_DISEASE
, I I_DISEASE
neurologic I I_DISEASE
and I I_DISEASE
psychiatric I I_DISEASE
disorders I I_DISEASE
. O O

We O O
report O O
a O O
case O O
of O O
Wilson B B_PERSON
' I I_PERSON
s I I_PERSON
disease I I_PERSON
with O O
chronic B B_DISEASE
liver I I_DISEASE
disease I I_DISEASE
; O O
moreover O O
, O O
in O O
our O O
patient O O
, O O
presenting O O
also O O
with O O
high O O
levels O O
of O O
state O O
anxiety B B_DISEASE
without O O
depression B B_DISEASE
, O O
99mTc O O
- O O
ECD O O
- O O
SPECT O O
showed O O
cortical O O
hypoperfusion O O
in O O
frontal O O
lobes O O
, O O
more O O
marked O O
on O O
the O O
left O O
frontal O O
lobe O O
. O O

Since O O
most O O
of O O
Wilson B B_PERSON
' I I_PERSON
s I I_PERSON
disease I I_PERSON
penicillamine O O
- O O
treated O O
patients O O
do O O
not O O
seem O O
to O O
develop O O
this O O
skin B B_DISEASE_ADJECTIVE[DISEASE]
lesion I I_DISEASE_ADJECTIVE[DISEASE]
, O O
it O O
could O O
be O O
conceivable O O
that O O
a O O
specific O O
genetic O O
factor O O
is O O
involved O O
in O O
drug O O
response O O
. O O

The O O
patient O B_PERSON
' O O
s O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
observations O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
were O O
within O O
normal O B_TIME[MEASURE]/B_LOCATION
limits O I_TIME[MEASURE]/I_LOCATION
, O O
he O O
was O O
administered O O
oxygen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
via O O
a O O
face O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEDICAL_DEVICE[OBJECT]
mask O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEDICAL_DEVICE[OBJECT]
and O O
glyceryl O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
trinitrate O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
GTN O B_DISEASE/B_LOCATION
) O O
. O O

The O O
cause O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appears O O
to O O
be O O
the O O
Bezold O B_PERSON/B_LOCATION
- O O
Jarish O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reflex O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
stimulation O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
ventricular O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
walls O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
which O O
in O O
turn O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreases O O
sympathetic O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outflow O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
the O O
vasomotor O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
centre O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
restimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
this O O
area O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
N O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
methyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
D O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
aspartic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
15 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
postlesion O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
failed O O
to O O
produce O O
a O O
pressor O B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O I_DISEASE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

One O B_MEASURE/B_ENT
day O I_MEASURE/I_ENT
postlesion O I_MEASURE/I_ENT
, O O
the O O
resting O B_DISEASE/B_GENE
mean O B_DISEASE/I_GENE
arterial O B_DISEASE/I_GENE
pressure O B_DISEASE/I_GENE
was O O
significantly O O
decreased O O
in O O
lesioned O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
rats O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
when O O
compared O O
with O O
sham O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
rats O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
( O O
100 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
7 O B_MEASURE
versus O I_MEASURE
173 O I_MEASURE
+ O I_MEASURE
/ O O
- O O
4 O B_MEASURE
mm O I_MEASURE
Hg O I_MEASURE
, O O
p O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

The O O
ganglionic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
blocker O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
trimethaphan O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
5 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_TIME[MEASURE]
i O O
. O O
v O B_PROTEIN[GENE]/B_MEASURE
. O O
) O O
caused O O
similar O B_DISEASE_ADJECTIVE[DISEASE]
reductions O I_DISEASE_ADJECTIVE[DISEASE]
in O O
mean O B_DISEASE/B_GENE
arterial O I_DISEASE/I_GENE
pressure O I_DISEASE/I_GENE
in O O
both O O
lesioned O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
sham O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Mean O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
MSDBP O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O O
mean O O
sitting O O
systolic O B_MEASURE/B_LOCATION
BP O I_MEASURE/I_LOCATION
( O O
MSSBP O B_DISEASE/B_LOCATION
) O O
were O O
analyzed O O
at O O
the O O
8 O B_NUMBER[MEASURE]
- O O
week O B_TIME[MEASURE]/B_LOCATION
core O I_TIME[MEASURE]/I_LOCATION
study O I_TIME[MEASURE]/I_LOCATION
end O I_TIME[MEASURE]/I_LOCATION
point O I_TIME[MEASURE]/I_LOCATION
. O O

Response O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
defined O O
as O O
MSDBP O B_DISEASE/B_LOCATION
< O O
90 O B_MEASURE/B_LOCATION
mm O I_MEASURE/I_LOCATION
Hg O I_MEASURE/I_LOCATION
or O O
a O O
> O B_MEASURE
or O O
= O O
10 O B_MEASURE
mm O I_MEASURE
Hg O I_MEASURE
decrease O I_MEASURE
compared O O
to O O
baseline O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
defined O O
as O O
MSDBP O B_DISEASE/B_MEASURE
< O O
90 O B_MEASURE
mm O I_MEASURE
Hg O I_MEASURE
compared O O
with O O
baseline O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

All O O
active O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatments O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
associated O O
with O O
significantly O O
reduced O O
MSSBP O B_DISEASE
and O O
MSDBP O B_DISEASE/B_GENE
during O O
the O O
core O B_NUMBER[MEASURE]
8 O I_NUMBER[MEASURE]
- O O
week O B_TIME[MEASURE]/B_LOCATION
study O I_TIME[MEASURE]/I_LOCATION
, O O
with O O
each O O
monotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
significantly O O
contributing O O
to O O
the O O
overall O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
combination O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
VAL O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
HCTZ O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
. O O

Each O O
combination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
was O O
associated O O
with O O
significantly O O
greater O B_DISEASE_ADJECTIVE[DISEASE]
reductions O I_DISEASE_ADJECTIVE[DISEASE]
in O O
MSSBP O B_DISEASE/B_GENE
and O O
MSDBP O B_DISEASE/B_GENE
compared O O
with O O
the O O
monotherapies O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
placebo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
all O O
, O O
P O B_MEASURE/B_PROTEIN[GENE]
< O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
. O O

The O O
mean O B_MEASURE
reduction O I_MEASURE
in O O
MSSBP O B_DISEASE/B_GENE
/ O O
MSDBP O B_DISEASE
with O O
VAL O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
/ O O
HCTZ O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
320 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
25 O B_MEASURE
mg O I_MEASURE
was O O
24 O B_MEASURE
. O O
7 O B_MEASURE
/ O O
16 O B_MEASURE
. O O
6 O B_MEASURE
mm O I_MEASURE
Hg O I_MEASURE
, O O
compared O O
with O O
5 O B_MEASURE
. O O
9 O B_MEASURE
/ O O
7 O B_MEASURE
. O O
0 O B_MEASURE
mm O I_MEASURE
Hg O I_MEASURE
with O O
placebo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
reduction O B_DISEASE_ADJECTIVE[DISEASE]
in O O
MSSBP O B_DISEASE/B_GENE
was O O
significantly O O
greater O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
with O O
VAL O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
HCTZ O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
320 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
25 O B_MEASURE
mg O I_MEASURE
compared O O
with O O
VAL O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
HCTZ O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
160 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
12 O B_MEASURE
. O O
5 O B_MEASURE
mg O I_MEASURE
( O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
002 O B_MEASURE
) O O
. O O

Rates O B_MEASURE
of O O
response O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
BP O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
significantly O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
groups O B_ORGANIZATION/B_PERSON
that O O
received O O
combination O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
compared O O
with O O
those O O
that O O
received O O
monotherapy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

The O O
efficacy O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
tolerability O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
VAL O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
/ O O
HCTZ O B_DISEASE/B_LOCATION
combinations O B_DISEASE/I_LOCATION
were O O
maintained O O
during O O
the O O
extension O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
797 O B_TIME[MEASURE]
patients O I_TIME[MEASURE]
) O O
. O O

However O O
, O O
very O O
few O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O O
evaluated O O
whether O O
chelation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
improves O O
cognitive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
outcomes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
Pb O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
exposed O O
children O B_PERSON/B_BIO
, O O
or O O
whether O O
these O O
agents O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
have O O
adverse O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
that O O
may O O
affect O O
brain O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
development O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
absence O B_DISEASE/B_LOCATION
of O O
Pb O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
exposure O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Succimer O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
Pb O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
exposed O O
rats O B_BIO/B_PERSON
significantly O O
improved O O
learning O B_DISEASE
, O O
attention O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
and O O
arousal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
regulation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
although O O
the O O
efficacy O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
varied O O
as O O
a O O
function O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
Pb O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
functional O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
deficit O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Caffeine O O
challenge O O
test O O
in O O
panic B B_DISEASE/B_PERSON
disorder I I_DISEASE/I_PERSON
and O O
depression B B_TIME[MEASURE]/B_PERSON
with O O
panic B B_DISEASE
attacks I I_DISEASE
. O O

Our O O
aim O O
was O O
to O O
observe O O
if O O
patients O O
with O O
panic B B_DISEASE
disorder I I_DISEASE
( O O
PD B B_LOCATION
) O O
and O O
patients O O
with O O
major B B_DISEASE/B_PERSON
depression I I_DISEASE/I_PERSON
with O O
panic B B_DISEASE
attacks I I_DISEASE
( O O
MDP B B_DISEASE/B_PROTEIN[GENE]
) O O
( O O
Diagnostic O O
and O O
Statistical O O
Manual O O
of O O
Mental B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Disorders I I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Fourth O O
Edition O O
criteria O O
) O O
respond O O
in O O
a O O
similar O O
way O O
to O O
the O O
induction O O
of O O
panic B B_DISEASE
attacks I I_DISEASE
by O O
an O O
oral O O
caffeine O O
challenge O O
test O O
. O O

The O O
patients O O
with O O
PD B B_LOCATION
and O O
MDP B B_DISEASE/B_PROTEIN[GENE]
were O O
more O O
sensitive O O
to O O
caffeine O O
than O O
were O O
patients O O
with O O
MD B B_DISEASE
and O O
healthy O O
volunteers O O
. O O

BACKGROUND O O
AND O O
AIM O O
OF O O
THE O O
STUDY O O
: O O
Undersized O O
mitral O O
annuloplasty O O
( O O
MAP O O
) O O
is O O
effective O O
in O O
patients O O
with O O
dilated B B_DISEASE_ADJECTIVE[DISEASE]
cardiomyopathy I I_DISEASE_ADJECTIVE[DISEASE]
and O O
functional O O
mitral B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
regurgitation I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
MR B B_LOCATION
) O O
since O O
, O O
as O O
well O O
as O O
addressing O O
the O O
MR B B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
the O O
MAP O O
may O O
also O O
reshape O O
the O O
dilated O O
left O O
ventricular O O
( O O
LV O O
) O O
base O O
. O O

Concomitantly O O
, O O
the O O
diastolic O B_MEASURE/B_LOCATION
diameter O I_MEASURE/I_LOCATION
of O O
the O O
LV O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
base O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
and O O
LV O B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sphericity O I_BODY_PART_OR_ORGAN_COMPONENT/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreased O O
( O O
i O O
. O O
e O B_DISEASE/B_PROTEIN[GENE]
. O O
, O O
improved O O
) O O
from O O
37 O B_MEASURE
. O O
4 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
9 O B_MEASURE
. O O
3 O B_MEASURE
to O O
35 O B_MEASURE
. O O
9 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
10 O B_MEASURE
mm O I_MEASURE
( O O
p O B_MEASURE/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
063 O B_MEASURE
) O O
, O O
and O O
from O O
67 O B_MEASURE
. O O
9 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
18 O B_MEASURE
. O O
6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
to O O
65 O B_MEASURE
. O O
3 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
18 O B_MEASURE
. O O
9 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
( O O
p O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
016 O B_MEASURE
) O O
, O O
respectively O O
. O O

Decreases O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O O
evident O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
both O O
LV O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
diastolic O B_MEASURE/B_LOCATION
pressure O B_MEASURE/I_LOCATION
( O O
from O O
17 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
7 O B_MEASURE
to O O
15 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
6 O B_MEASURE
mmHg O I_MEASURE
, O O
p O O
= O O
0 O B_NUMBER[MEASURE]
. O O
0480 O B_MEASURE
and O O
Tau O B_PROTEIN[GENE]/B_DISEASE
( O O
from O O
48 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
8 O B_MEASURE
to O O
45 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
8 O B_MEASURE
ms O I_MEASURE
, O O
p O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
, O O
while O O
fractional O B_MEASURE/B_GENE
shortening O B_MEASURE/I_GENE
at O O
the O O
LV O B_MEASURE/B_PROTEIN[GENE]
base O B_MEASURE/I_PROTEIN[GENE]
increased O O
from O O
7 O B_MEASURE
. O O
7 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
4 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
to O O
9 O B_MEASURE
. O O
4 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
4 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
( O O
p O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_NUMBER[MEASURE]
. O O
045 O B_MEASURE
) O O
. O O

After O O
MAP O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
increases O B_DISEASE_ADJECTIVE[DISEASE]
were O O
identified O O
in O O
both O O
cardiac O B_MEASURE/B_ORGANIZATION
output O B_MEASURE/I_ORGANIZATION
( O O
from O O
1 O B_MEASURE
. O O
54 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_NUMBER[MEASURE]
. O O
57 O B_MEASURE
to O O
1 O B_MEASURE
. O O
65 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
57 O B_MEASURE/B_PERSON
1 O I_MEASURE/I_PERSON
/ O O
min O B_MEASURE/B_PERSON
) O O
and O O
Emax O B_DISEASE/B_GENE
( O O
from O O
1 O B_MEASURE
. O O
86 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
9 O B_MEASURE
to O O
2 O B_MEASURE
. O O
41 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
1 O B_MEASURE
. O O
31 O B_MEASURE
mmHg O I_MEASURE
/ O O
ml O B_MEASURE/B_PERSON
) O O
. O O

We O O
report O O
a O O
57 O O
- O O
year O O
- O O
old O O
woman O O
with O O
end B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
stage I I_DISEASE/I_GENE
renal I I_DISEASE/I_GENE
disease I I_DISEASE/I_GENE
receiving O O
continuous O O
ambulatory O O
peritoneal O O
dialysis O O
( O O
CAPD O O
) O O
, O O
who O O
developed O O
slurred O O
speech O O
, O O
tremor B B_DISEASE
, O O
bizarre O O
behavior O O
, O O
progressive O O
mental O O
confusion B B_DISEASE
, O O
and O O
2 O O
episodes O O
of O O
generalized O O
tonic B B_DISEASE
- I I_DISEASE
clonic I I_DISEASE
seizure I I_DISEASE
( O O
GTCS B B_LOCATION
) O O
after O O
5 O O
doses O O
of O O
piperacillin O O
/ O O
tazobactam O O
( O O
2 O O
g O O
/ O O
250 O O
mg O O
) O O
were O O
given O O
for O O
bronchiectasis B B_PERSON
with O O
secondary B B_DISEASE
infection I I_DISEASE
. O O

Initiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
flux O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
hemodialysis O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
rapidly O O
reversed O O
the O O
neurologic O B_DISEASE
symptoms O I_DISEASE
within O O
4 O B_TIME[MEASURE]
hours O I_TIME[MEASURE]
. O O

We O O
therefore O O
examined O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
local O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anesthesia O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
vocal O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cord O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
better O O
understand O O
its O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consequences O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
All O O
patients O B_PERSON/B_BIO
had O O
normal O B_DISEASE
vocal O I_DISEASE
cord O I_DISEASE
function O I_DISEASE
preoperatively O O
. O O

The O O
aim O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O O
to O O
conduct O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
facial O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recognition O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
performance O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
recreational O B_LOCATION/B_PERSON
cocaine O I_LOCATION/I_PERSON
users O I_LOCATION/I_PERSON
. O O

An O O
emotional O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
facial O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
EFE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
task O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
consisting O O
of O O
a O O
male O B_PERSON/B_COLOR
and O O
female O B_PERSON
face O I_PERSON
expressing O O
six O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
basic O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
emotions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
happiness O B_DISEASE/B_PERSON
, O O
surprise O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
sadness O B_DISEASE/B_PERSON
, O O
anger O B_DISEASE/B_PERSON
, O O
fear O B_DISEASE/B_PERSON
, O O
and O O
disgust O B_DISEASE/B_PERSON
) O O
was O O
administered O O
. O O

Participants O B_PERSON/B_BIO
were O O
also O O
assessed O O
with O O
the O O
" O O
Eyes O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
task O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
" O O
to O O
investigate O O
their O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
recognize O O
more O O
complex O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
emotional O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
states O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
Symptom O B_MEASURE/B_PROTEIN[GENE]
CheckList O B_MEASURE/I_PROTEIN[GENE]
- O O
90 O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Revised O O
to O O
measure O O
psychopathology O B_DISEASE
. O O

The O O
RC O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
also O O
correctly O O
identified O O
anger O B_DISEASE/B_PERSON
, O O
fear O B_DISEASE/B_PERSON
, O O
happiness O B_DISEASE/B_PERSON
, O O
and O O
surprise O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
more O O
slowly O O
than O O
CN O B_DISEASE/B_LOCATION
, O O
but O O
not O O
OC O B_PERSON/B_LOCATION
participants O B_PERSON/I_LOCATION
. O O

The O O
OC O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
was O O
slower O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O O
CN O B_DISEASE/B_MEASURE
when O O
correctly O O
identifying O O
disgust O B_DISEASE/B_PERSON
. O O

The O O
neuropathology O B_DISEASE_ADJECTIVE[DISEASE]
of O O
SNR O B_DISEASE
was O O
investigated O O
using O O
immunohistochemical O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
techniques O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
the O O
major O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
emphasis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
time O B_TIME[MEASURE]/B_LOCATION
- O O
course O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
astrocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

By O O
6 O O
h O O
, O O
vasogenic B B_PERSON
edema I I_PERSON
covered O O
the O O
lesioned B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
SNR I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

By O O
24 O B_TIME[MEASURE]/B_LOCATION
h O O
, O O
glial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
neuronal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
markers O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O O
a O O
massive O B_DISEASE/B_MEASURE
lesion O I_DISEASE/I_MEASURE
in O O
the O O
center O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
SNR O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

By O O
48 O B_MEASURE
- O O
72 O B_TIME[MEASURE]
h O I_TIME[MEASURE]
, O O
astrocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
surrounding O O
the O O
lesion O B_DISEASE
increased O O
in O O
size O B_MEASURE
, O O
and O O
polymorphic O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
phagocytotic O B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
cells O B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
invaded O O
the O O
damaged O O
area O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O O

Additional O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
pathology O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
similar O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
quality O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
found O O
in O O
the O O
globus O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
pallidus O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O O

Since O O
astrocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
were O O
always O O
damaged O O
in O O
parallel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
in O O
SNR O B_DISEASE/B_PROTEIN[GENE]
it O O
is O O
proposed O O
that O O
the O O
anatomical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
functional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
interrelationship O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
between O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
astrocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O O
particularly O O
tight O B_DISEASE_ADJECTIVE[DISEASE]
in O O
SNR O B_DISEASE/B_PROTEIN[GENE]
. O O

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
exposure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
animals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
BCNU O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
during O O
pregnancy O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
leads O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
to O O
delayed O O
maturation O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
offspring O O
cerebellum O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
and O O
melatonin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
protects O O
the O O
cerebellum O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
against O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
BCNU O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Over O O
the O O
first O B_TIME[MEASURE]/B_ENT
3 O I_TIME[MEASURE]/I_ENT
weeks O I_TIME[MEASURE]/I_ENT
after O O
the O O
i O O
. O O
v O B_PROTEIN[GENE]/B_LOCATION
. O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
free O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
polymer O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
bound O O
DOX O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
all O O
animals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
a O O
transient O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
reduction O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
body O B_DISEASE
weight O I_DISEASE
. O O

However O O
, O O
the O O
maximal O B_MEASURE
reduction O I_MEASURE
in O O
body O B_DISEASE
weight O I_DISEASE
seen O O
in O O
animals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
received O O
polymer O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
bound O O
DOX O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
4 O B_MEASURE/B_LOCATION
mg O I_MEASURE/I_LOCATION
/ O O
kg O B_MEASURE
) O O
was O O
significantly O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
that O O
observed O O
in O O
those O O
that O O
received O O
free O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
DOX O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
4 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE/B_PERSON
) O O
or O O
a O O
mixture O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
unmodified O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parent O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
HPMA O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
copolymer O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
free O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
DOX O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
4 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
; O O
P O B_MEASURE/B_LOCATION
less O I_MEASURE/I_LOCATION
than O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
. O O

Sequential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurements O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cardiac O B_DISEASE
output O I_DISEASE
in O O
surviving O O
animals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
received O O
either O O
free O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
DOX O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
or O O
the O O
mixture O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
HPMA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
copolymer O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
free O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
DOX O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
showed O O
a O O
reduction O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
approximately O O
30 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
in O O
function O B_DISEASE/B_MEASURE
beginning O O
at O O
the O O
4th O B_TIME[MEASURE]/B_LOCATION
week O I_TIME[MEASURE]/I_LOCATION
after O O
drug O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
administration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
no O O
significant O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
histological O I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
change O I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
observed O O
in O O
the O O
heart O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
of O O
animals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
received O O
DOX O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
the O O
form O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
HPMA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
copolymer O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
conjugates O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
were O O
killed O O
at O O
the O O
end O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O O
the O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
these O O
animals O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
shown O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
heart O B_DISEASE
rate O I_DISEASE
beginning O O
at O O
8 O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
after O O
drug O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
administration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
. O O
( O O
ABSTRACT O B_TIME[MEASURE]/B_LOCATION
TRUNCATED O I_TIME[MEASURE]/I_LOCATION
AT O O
400 O B_LOCATION/B_PERSON
WORDS O I_LOCATION/I_PERSON
) O O

Each O O
patient O O
received O O
comprehensive O O
health O O
care O O
, O O
including O O
medical O O
and O O
substance B B_PERSON/B_ORGANIZATION
abuse I I_PERSON/I_ORGANIZATION
consultations O O
. O O

Treatment O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
not O O
correlated O O
with O O
the O O
incidence O B_MEASURE/B_LOCATION
, O O
time O B_MEASURE/B_LOCATION
- O O
course O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
or O O
severity O B_MEASURE
of O O
capsaicin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
burning O B_DISEASE
. O O

This O O
lack O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
effects O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
may O O
stem O O
from O O
the O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
contribution O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
de O B_DISEASE
- O O
novo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
synthesis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
to O O
cellular O B_DISEASE
inositol O I_DISEASE
supply O I_DISEASE
or O O
to O O
the O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
de O B_DISEASE
- O O
novo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
synthesis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
by O O
lithium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
itself O O
. O O

He O O
then O O
presented O O
to O O
the O O
emergency O B_PERSON/B_LOCATION
department O I_PERSON/I_LOCATION
feeling O I_PERSON/I_LOCATION
quite O O
ill O B_DISEASE
and O O
was O O
found O O
to O O
have O O
a O O
blood O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
urea O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
nitrogen O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
BUN O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
) O O
concentration O B_MEASURE
of O O
of O O
147 O B_MEASURE
mg O I_MEASURE
/ O O
dl O B_PROTEIN[GENE]/B_TIME[MEASURE]
, O O
creatinine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
15 O B_MEASURE
. O O
3 O B_MEASURE
mg O I_MEASURE
/ O O
dl O B_TIME[MEASURE]/B_PROTEIN[GENE]
and O O
serum O O
potassium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
8 O B_MEASURE
. O O
7 O B_MEASURE
mEq O I_MEASURE
/ O O
l O B_MEASURE/B_DISEASE
. O O

However O O
, O O
in O O
the O O
tubular O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
basement O I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
membrane O I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TBM O B_DISEASE/B_PROTEIN[GENE]
) O O
, O O
very O O
intense O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
granular O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
deposits O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
polyclonal O B_PROTEIN[GENE]
IgG O I_PROTEIN[GENE]
and O O
C3 O B_GENE
were O O
noted O O
. O O

He O O
needed O O
dialysis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
2 O B_TIME[MEASURE]/B_DISEASE
weeks O B_TIME[MEASURE]/I_DISEASE
and O O
was O O
treated O O
successfully O O
with O O
steroids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
6 O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
months O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Serum O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
patients O B_PERSON/B_LOCATION
were O O
tested O O
by O O
polymerase O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
chain O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
reaction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
restriction O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fragment O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
length O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymorphism O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PCR O B_LOCATION
- O O
RFLP O B_PROTEIN[GENE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
for O O
detection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
YMDD O B_DISEASE/B_GENE
motif O B_DISEASE/I_GENE
mutants O B_DISEASE/I_GENE
. O O

All O O
patients O B_PERSON
were O O
also O O
tested O O
for O O
liver O B_DISEASE/B_GENE
enzymes O I_DISEASE/I_GENE
, O O
anti O O
- O O
HCV O B_DISEASE/B_GENE
, O O
HBeAg O B_DISEASE/B_GENE
, O O
and O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
HBe O B_GENE/B_DISEASE
. O O

HBeAg O B_DISEASE/B_GENE
was O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
40 O B_MEASURE
% O I_MEASURE
and O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
HBe O B_GENE/B_DISEASE
in O O
60 O B_NUMBER[MEASURE]/B_LOCATION
% O I_NUMBER[MEASURE]/I_LOCATION
of O O
the O O
patients O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
HCV O B_DISEASE
was O O
negative O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
all O O
of O O
them O O
. O O

YMDD O B_DISEASE/B_PERSON
motif O I_DISEASE/I_PERSON
mutants O I_DISEASE/I_PERSON
were O O
not O O
detected O O
in O O
any O O
of O O
the O O
patients O B_PERSON/B_BIO
despite O O
the O O
liver O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
enzyme O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
levels O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
the O O
presence O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
HBeAg O B_DISEASE/B_GENE
or O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
HBe O B_GENE/B_DISEASE
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
Subjects O B_PERSON/B_LOCATION
( O O
n O B_OTHER/B_MEASURE
= O O
114 O B_MEASURE
) O O
undergoing O O
extraction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
impacted O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
third O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
molars O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
received O O
either O O
2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lidocaine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
0 O B_MEASURE
. O O
5 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bupivacaine O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O O
surgery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
either O O
rofecoxib O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
50 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
placebo O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
orally O O
90 O B_TIME[MEASURE]
min O I_TIME[MEASURE]
before O O
surgery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
for O O
the O O
following O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
48 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
h O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
role O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
nerve O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
NGF O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
in O O
contributing O O
to O O
increased O O
voiding O B_MEASURE/B_DISEASE
frequency O B_MEASURE/I_DISEASE
and O O
altered O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
sensation O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O O
the O O
urinary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
bladder O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
has O O
been O O
suggested O O
. O O

The O O
functional O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
significance O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
p75 O B_GENE
( O O
NTR O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
expression O B_GENE
in O O
micturition O B_DISEASE
reflexes O I_DISEASE
remains O O
to O O
be O O
determined O O
. O O

Azathioprine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
suicidal O B_DISEASE
erythrocyte O I_DISEASE
death O I_DISEASE
. O O

Clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
comparison O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
cardiorespiratory O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
during O O
unilateral O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
conventional O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
spinal O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
anaesthesia O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Efforts O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
must O O
therefore O O
continue O O
to O O
be O O
made O O
to O O
obviate O O
this O O
setback O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
OBJECTIVE O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
To O O
evaluate O O
the O O
cardiovascular O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
respiratory O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
changes O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
during O O
unilateral O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
conventional O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
spinal O I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
anaesthesia O I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Patients O B_PERSON
in O O
the O O
conventional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
had O O
statistically O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
greater O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
fall O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
the O O
systolic O B_DISEASE/B_GENE
blood O I_DISEASE/I_GENE
pressures O I_DISEASE/I_GENE
at O O
15 O B_MEASURE
, O O
30 O B_MEASURE
and O O
45 O B_MEASURE/B_ENT
minutes O I_MEASURE/I_ENT
when O O
compared O O
to O O
the O O
baseline O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
P O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
003 O B_MEASURE
, O O
0 O B_MEASURE/B_LOCATION
. O O
001 O B_MEASURE
and O O
0 O B_MEASURE
. O O
004 O B_MEASURE
) O O
. O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Compared O O
to O O
conventional O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
spinal O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
anaesthesia O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
unilateral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
spinal O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
anaesthesia O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O O
associated O O
with O O
fewer O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiovascular O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
perturbations O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
study O O
' O O
s O O
aims O O
were O O
to O O
measure O O
variations O O
in O O
sural O O
nerve O O
sensory O O
action O O
potential O O
( O O
SAP O O
) O O
amplitude O O
in O O
patients O O
with O O
refractory O O
cutaneous B B_DISEASE/B_LOCATION
lupus I I_DISEASE/I_LOCATION
erythematosus I I_DISEASE/I_LOCATION
( O O
CLE B B_DISEASE
) O O
treated O O
with O O
thalidomide O O
and O O
use O O
these O O
findings O O
to O O
identify O O
the O O
neurotoxic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potential O O
of O O
thalidomide O O
and O O
the O O
recovery O O
capacity O O
of O O
sensory O O
fibres O O
after O O
discontinuation O O
of O O
treatment O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
During O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
11 O B_MEASURE/B_PERSON
patients O I_MEASURE/I_PERSON
showed O O
a O O
reduction O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
sural O B_DISEASE/B_GENE
nerve O I_DISEASE/I_GENE
SAP O I_DISEASE/I_GENE
amplitude O I_DISEASE/I_GENE
compared O O
to O O
baseline O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
9 O B_NUMBER[MEASURE]/B_PERSON
with O O
a O O
reduction O B_MEASURE
> O I_MEASURE
or O O
= O O
50 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
and O O
2 O B_MEASURE
< O I_MEASURE
50 O I_MEASURE
% O I_MEASURE
) O O
. O O

After O O
thalidomide O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
sural O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
SAP O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
amplitude O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
recovered O O
in O O
3 O B_TIME[MEASURE]/B_PERSON
patients O I_TIME[MEASURE]/I_PERSON
. O O

At O O
detection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
reduction O B_DISEASE_ADJECTIVE[DISEASE]
in O O
sural O B_DISEASE/B_MEASURE
nerve O I_DISEASE/I_MEASURE
SAP O I_DISEASE/I_MEASURE
amplitude O I_DISEASE/I_MEASURE
, O O
the O O
median O B_MEASURE
thalidomide O I_MEASURE
cumulative O I_MEASURE
dose O I_MEASURE
was O O
21 O B_MEASURE
. O O
4 O B_MEASURE
g O I_MEASURE
. O O

The O O
threshold O O
neurotoxic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dosage O O
is O O
lower O O
than O O
previously O O
reported O O
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Sural O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
nerve O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
SAP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
amplitude O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
reduction O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O O
a O O
reliable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
sensitive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
marker O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
degeneration O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
recovery O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
sensory O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
fibres O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O O

This O O
electrophysiological O O
parameter O O
provides O O
information O O
about O O
subclinical O O
neurotoxic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potential O O
of O O
thalidomide O O
but O O
is O O
not O O
helpful O O
in O O
predicting O O
the O O
appearance O O
of O O
sensory O O
symptoms O O
. O O

Two O B_NUMBER[MEASURE]/B_PERSON
cases O I_NUMBER[MEASURE]/I_PERSON
had O O
a O O
fatal O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
outcome O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
one O B_NUMBER[MEASURE]/B_PERSON
resulted O O
in O O
severe O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
sequelae O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
notable O B_PERSON/B_MEASURE
fact O I_PERSON/I_MEASURE
was O O
that O O
this O O
complication O B_DISEASE
occurred O O
in O O
three O B_PERSON
patients O I_PERSON
hospitalized O O
before O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
began O O
, O O
with O O
whom O O
particularly O O
strict O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
therapeutic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
precautions O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
taken O O
, O O
i O O
. O O
e O O
. O O
, O O
initial O B_MEASURE
dose O I_MEASURE
less O I_MEASURE
than O O
10 O B_SEQUENCE[MEASURE]/B_LOCATION
mg O I_SEQUENCE[MEASURE]/I_LOCATION
of O O
DEC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
very O O
gradual O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increases O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
associated O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
allergic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

This O O
type O B_MEASURE/B_DISEASE
of O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
complication O B_DISEASE
may O O
not O O
be O O
that O O
uncommon O B_DISEASE_ADJECTIVE[DISEASE]
in O O
highly O O
endemic O B_PERSON/B_NUMBER[MEASURE]
regions O I_PERSON/I_NUMBER[MEASURE]
. O O

It O O
occurs O O
primarily O O
, O O
but O O
not O O
exclusively O O
, O O
in O O
subjects O B_PERSON/B_BIO
presenting O O
with O O
a O O
high O B_DISEASE/B_PERSON
microfilarial O I_DISEASE/I_PERSON
load O I_DISEASE/I_PERSON
. O O

In O O
the O O
kidneys O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
glomeruli O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
had O O
membrane O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
spikes O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
prominent O B_DISEASE/B_LOCATION
swelling O B_DISEASE/I_LOCATION
of O O
podocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
subepithelial O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
deposits O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
which O O
were O O
sometimes O O
large O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
and O O
hump O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
like O B_LOCATION/B_BIO
. O O

AIMS O O
: O O
This O O
study O O
sought O O
to O O
assess O O
the O O
risk O O
of O O
developing O O
coronary B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
artery I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disease I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
CAD B B_DISEASE/B_LOCATION
) O O
associated O O
with O O
initial O O
treatment O O
of O O
type B B_PERSON
2 I I_PERSON
diabetes I I_PERSON
with O O
different O O
sulphonylureas O O
. O O

The O O
hazard O B_DISEASE
decreased O O
0 O B_MEASURE
. O O
3 O B_MEASURE
- O O
fold O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
0 O B_MEASURE/B_LOCATION
. O O
7 O B_MEASURE
- O O
1 O B_NUMBER[MEASURE]
. O O
7 O B_MEASURE
, O O
P O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
385 O B_MEASURE
) O O
with O O
glimepiride O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
0 O B_NUMBER[MEASURE]
. O O
4 O B_MEASURE
- O O
fold O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
0 O B_MEASURE/B_LOCATION
. O O
7 O B_MEASURE
- O O
1 O B_NUMBER[MEASURE]
. O O
3 O B_MEASURE
, O O
P O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_NUMBER[MEASURE]
. O O
192 O B_MEASURE
) O O
with O O
gliclazide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
0 O B_NUMBER[MEASURE]
. O O
4 O B_MEASURE
- O O
fold O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
0 O B_MEASURE/B_LOCATION
. O O
7 O B_MEASURE
- O O
1 O B_NUMBER[MEASURE]
. O O
1 O B_MEASURE
, O O
P O B_LOCATION/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
09 O B_MEASURE
) O O
with O O
either O O
. O O

Groups O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ADR O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
6 O B_MEASURE
) O O
, O O
ADR O B_LOCATION/B_ORGANIZATION
+ O I_LOCATION
LOS O I_LOCATION
( O O
6 O B_NUMBER[MEASURE]
) O O
and O O
ADR O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
12 O B_NUMBER[MEASURE]
) O O
, O O
and O O
ADR O B_LOCATION/B_ORGANIZATION
+ O I_LOCATION
LOS O I_LOCATION
( O O
12 O B_MEASURE
) O O
received O O
ADR O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
2 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
/ O O
b O B_TIME[MEASURE]/B_DISEASE
. O O
w O O
. O O
i O O
. O O
v O B_TIME[MEASURE]/B_GENE
. O O
) O O
twice O O
in O O
a O O
3 O B_NUMBER[MEASURE]
- O O
week O B_TIME[MEASURE]/B_LOCATION
interval O I_TIME[MEASURE]/I_LOCATION
. O O

Group O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ADR O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O O
LOS O B_DISEASE/B_LOCATION
( O O
6 O B_MEASURE
) O O
received O O
losartan O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
10 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
/ O O
b O B_OTHER/B_TIME[MEASURE]
. O O
w O O
. O O
/ O O
day O B_TIME[MEASURE]
by O O
gavages O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
) O O
for O O
6 O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
and O O
group O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ADR O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ O I_MEASURE
LOS O I_MEASURE
( O O
12 O B_NUMBER[MEASURE]
) O O
for O O
12 O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
after O O
second O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injection O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
ADR O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

BACKGROUND O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
: O O
Our O O
aim O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
to O O
investigate O O
postoperative O B_DISEASE_ADJECTIVE[DISEASE]
complications O I_DISEASE_ADJECTIVE[DISEASE]
and O O
mortality O B_DISEASE
after O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
aprotinin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
compared O O
to O O
tranexamic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
an O O
unselected O B_LOCATION/B_TIME[MEASURE]
, O O
consecutive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cohort O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
The O O
pre O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
and O O
intraoperative O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
variables O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
comparable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
treatment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Both O O
antifibrinolytic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
drugs O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
bear O O
the O O
risk O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
adverse O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcome O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
depending O O
on O O
the O O
type O B_DISEASE/B_MEASURE
of O O
cardiac O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
surgery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

The O O
patient O B_PERSON
' O O
s O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
change O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
mental O B_DISEASE
status O I_DISEASE
was O O
first O O
reported O O
nine O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
after O O
the O O
initiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

( O O
+ O O
) O O
- O O
Propranolol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
no O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
fatty O B_DISEASE/B_GENE
acid O B_DISEASE/I_GENE
mobilization O B_DISEASE/I_GENE
but O O
significantly O O
reduced O O
the O O
increments O B_DISEASE
in O O
both O O
lactate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
glucose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O O
4 O B_MEASURE/B_LOCATION
. O O

Improving O O
glioblastoma B B_DISEASE
multiforme I I_DISEASE
( O O
GBM B B_LOCATION/B_ORGANIZATION
) O O
treatment O O
with O O
radio O O
- O O
chemotherapy O O
remains O O
a O O
challenge O O
. O O

Partial O B_DISEASE_ADJECTIVE[DISEASE]
response O I_DISEASE_ADJECTIVE[DISEASE]
and O O
stabilization O B_DISEASE
rates O I_DISEASE
were O O
2 O B_MEASURE
% O I_MEASURE
and O O
32 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
respectively O O
, O O
with O O
an O O
overall O B_TIME[MEASURE]
time O I_TIME[MEASURE]
to O O
progression O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
12 O B_TIME[MEASURE]
weeks O I_TIME[MEASURE]
. O O

One O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]/B_PERSON
overall O I_TIME[MEASURE]/I_PERSON
survival O I_TIME[MEASURE]/I_PERSON
( O O
OS O B_DISEASE
) O O
rate O B_MEASURE
was O O
42 O B_DISEASE_ADJECTIVE[DISEASE]
% O I_DISEASE_ADJECTIVE[DISEASE]
, O O
with O O
a O O
median O B_MEASURE/B_LOCATION
OS O I_MEASURE/I_LOCATION
of O O
40 O B_NUMBER[MEASURE]/B_ENT
weeks O I_NUMBER[MEASURE]/I_ENT
. O O

PURPOSE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
This O O
paper O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
reviews O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
chronic O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lithium O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
on O O
serum O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
calcium O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
level O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
and O O
parathyroid O B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glands O B_DISEASE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
its O O
pathogenesis O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
options O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Careful O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
patient O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
selection O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
long O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
term O B_TIME[MEASURE]
follow O I_TIME[MEASURE]
- O O
up O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
can O O
reduce O O
morbidity O B_DISEASE/B_MEASURE
. O O

By O O
routinely O O
monitoring O O
serum O B_DISEASE
calcium O I_DISEASE
levels O I_DISEASE
, O O
healthcare O B_PERSON
providers O I_PERSON
can O O
improve O O
the O O
quality O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
life O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
this O O
patient O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Carbimazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
methimazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
have O O
a O O
lower O B_MEASURE/B_PERSON
incidence O I_MEASURE/I_PERSON
of O O
reported O O
ANCA O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
positive O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
side O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
PUT O B_PERSON
. O O

Aspirin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
primary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prevention O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cardiovascular O B_DISEASE/B_LOCATION
events O I_DISEASE/I_LOCATION
: O O
an O O
update O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
for O O
the O O
U O B_OTHER/B_LOCATION
. O O
S O B_OTHER/B_DISEASE
. O O

Argatroban O B_MEASURE/B_LOCATION
0 O I_MEASURE/I_LOCATION
. O O
5 O B_MEASURE
- O O
1 O B_MEASURE
. O O
2 O B_MEASURE
microg O I_MEASURE
/ O O
kg O B_MEASURE/B_LOCATION
/ O O
min O B_TIME[MEASURE]/B_PERSON
typically O O
supports O O
therapeutic O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aPTTs O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Argatroban O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
has O O
no O O
specific O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
antidote O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
and O O
if O O
excessive O B_DISEASE
anticoagulation O I_DISEASE
occurs O O
, O O
argatroban O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O O
be O O
stopped O O
or O O
reduced O O
. O O

Methadone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
may O O
aggravate O O
this O O
problem O B_DISEASE
. O O

He O O
had O O
used O O
heroin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
since O O
age O B_TIME[MEASURE]
20 O I_TIME[MEASURE]
, O O
and O O
had O O
used O O
150 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methadone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
daily O O
for O O
6 O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
months O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

A O O
lesion O B_DISEASE/B_GENE
induced O O
by O O
6 O B_MEASURE/B_LOCATION
- O O
OHDA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
produced O O
more O O
severe O B_DISEASE_ADJECTIVE[DISEASE]
motor O I_DISEASE_ADJECTIVE[DISEASE]
deterioration O I_DISEASE_ADJECTIVE[DISEASE]
in O O
CB1 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
KO O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mice O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
accompanied O O
by O O
more O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
loss O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
DA O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
neurons O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
increased O O
PENK O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gene O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
expression O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
CPu O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Oxidative O B_DISEASE_ADJECTIVE[DISEASE]
/ O O
nitrosative O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
and O O
neuroinflammatory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
parameters O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O O
estimated O O
in O O
the O O
CPu O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
cingulate O B_PERSON/B_LOCATION
cortex O I_PERSON/I_LOCATION
( O O
Cg O B_DISEASE/B_LOCATION
) O O
. O O

CB1 O B_PERSON/B_PROTEIN[GENE]
KO O I_PERSON/I_PROTEIN[GENE]
mice O I_PERSON/I_PROTEIN[GENE]
exhibited O O
higher O B_DISEASE/B_GENE
MDA O B_DISEASE/I_GENE
levels O B_DISEASE/I_GENE
and O O
iNOS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
protein O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
expression O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
the O O
CPu O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Cg O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
compared O O
to O O
WT O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mice O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

An O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
GSSG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
within O O
hepatic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
tissue O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
during O O
intestinal O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reperfusion O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
suggests O O
exposure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
hepatocytes O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
to O O
an O O
oxidant O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stress O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
lack O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
increase O I_DISEASE_ADJECTIVE[DISEASE]
in O O
products O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
lipid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
peroxidation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
suggests O O
that O O
the O O
oxidant O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stress O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
of O O
insufficient O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
magnitude O I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
result O O
in O O
irreversible O B_DISEASE
injury O I_DISEASE
to O O
hepatocyte O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
membranes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
suggest O O
that O O
the O O
measurement O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
tissue O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
GSSG O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
may O O
be O O
a O O
more O O
sensitive O B_MEASURE/B_PERSON
indicator O B_MEASURE/I_PERSON
of O O
oxidant O B_DISEASE
stress O I_DISEASE
than O O
measurement O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
products O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
lipid O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peroxidation O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

To O O
achieve O O
this O O
aim O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
the O O
effects O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
ouabain O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
injection O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
immediately O O
after O O
and O O
7 O B_TIME[MEASURE]
days O I_TIME[MEASURE]
following O O
a O O
single O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ICV O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
at O O
concentrations O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
10 O B_MEASURE
( O O
- O O
2 O B_MEASURE
) O O
and O O
10 O B_MEASURE
( O O
- O O
3 O B_MEASURE
) O O
M O B_MEASURE/B_OTHER
) O O
on O O
locomotion O B_DISEASE
was O O
measured O O
using O O
the O O
open O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
field O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Additionally O O
, O O
thiobarbituric O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reactive O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
substances O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
TBARSs O B_DISEASE
) O O
and O O
superoxide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
production O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
measured O O
in O O
submitochondrial O B_LOCATION/B_BIO
particles O I_LOCATION/I_BIO
of O O
the O O
prefrontal O B_BODY_PART_OR_ORGAN_COMPONENT
cortex O I_BODY_PART_OR_ORGAN_COMPONENT
, O O
hippocampus O B_BODY_PART_OR_ORGAN_COMPONENT
, O O
striatum O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
amygdala O B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Primary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
objective O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
overall O B_DISEASE
response O I_DISEASE
rate O I_DISEASE
( O O
ORR O B_DISEASE/B_LOCATION
) O O
. O O

ORR O B_DISEASE/B_PERSON
was O O
4 O B_MEASURE
. O O
7 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
( O O
7 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
stratum O I_MEASURE
1 O I_MEASURE
; O O
2 O B_MEASURE
. O O
3 O B_MEASURE
% O I_MEASURE
stratum O I_MEASURE
2 O I_MEASURE
) O O
. O O

Median O B_TIME[MEASURE]/B_PERSON
progression O I_TIME[MEASURE]/I_PERSON
- O O
free O B_TIME[MEASURE]/B_ORGANIZATION
survivals O I_TIME[MEASURE]/I_ORGANIZATION
( O O
PFSs O B_DISEASE
) O O
were O O
2 O B_MEASURE
. O O
6 O B_MEASURE
( O O
stratum O B_TIME[MEASURE]/B_PERSON
1 O I_TIME[MEASURE]/I_PERSON
) O O
and O O
2 O B_MEASURE
. O O
7 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
( O O
stratum O B_PERSON
2 O I_PERSON
) O O
. O O

Cox O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regression O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
IHC O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
scores O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
found O O
that O O
only O O
phospho O B_GENE
AKT O I_GENE
( O O
pAKT O B_PROTEIN[GENE]/B_LOCATION
) O O
was O O
a O O
significant O B_MEASURE
independent O I_MEASURE
predictor O I_MEASURE
of O O
worse O B_DISEASE
PFS O I_DISEASE
. O O

In O O
patients O B_PERSON/B_LOCATION
without O O
cocaine O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
coronary O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
computerized O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
tomography O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
angiography O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CTA O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
has O O
been O O
shown O O
to O O
be O O
useful O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
identifying O O
a O O
group O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
patients O B_PERSON
at O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
risk O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
for O O
cardiac O B_DISEASE/B_LOCATION
events O I_DISEASE/I_LOCATION
who O O
can O O
be O O
safely O O
discharged O O
. O O

Consecutive O B_PERSON
patients O I_PERSON
received O O
either O O
immediate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
coronary O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
CTA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
the O O
ED O B_DISEASE/B_TIME[MEASURE]
( O O
without O O
serial O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
markers O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
or O O
underwent O O
coronary O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
CTA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
after O O
a O O
brief O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
observation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
period O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
with O O
serial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cardiac O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
marker O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
measurements O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

The O O
pathophysiologic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
that O O
disorder O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remain O O
unknown O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
. O O

After O O
an O O
initially O O
uneventful O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
course O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
after O O
the O O
transplant O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
the O O
patient O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
rapidly O O
fell O O
into O O
deep O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
coma O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
Cerebral O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
MRI O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
scan O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O O
typical O B_DISEASE/B_LOCATION
signs O B_DISEASE/I_LOCATION
of O O
enhancement O B_DISEASE
in O O
the O O
pontine O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
posterior O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
regions O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
termination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
treatment O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O O
any O O
calcineurin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulted O O
in O O
a O O
complete O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
resolution O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
that O O
complication O B_DISEASE
. O O

BACKGROUND O O
: O O
To O O
review O O
evidence O O
- O O
based O O
treatment O O
options O O
in O O
patients O O
with O O
cerebral B B_DISEASE/B_GENE
edema I I_DISEASE/I_GENE
complicating O O
fulminant B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hepatic I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
failure I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
FHF B B_LOCATION/B_PROTEIN[GENE]
) O O
and O O
discuss O O
the O O
potential O O
applications O O
of O O
hypothermia B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

The O O
patient O B_PERSON
had O O
depressed O O
of O O
mental O B_DISEASE
status O I_DISEASE
lasting O O
at O O
least O O
24 O B_TIME[MEASURE]/B_PERSON
h O I_TIME[MEASURE]/I_PERSON
prior O I_TIME[MEASURE]/I_PERSON
to O O
admission O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

We O O
then O O
initiated O O
therapeutic O O
hypothermia B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
which O O
was O O
continued O O
for O O
5 O O
days O O
. O O

A O O
clinical O O
trial O O
of O O
hypothermia B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
patients O O
with O O
this O O
condition O O
is O O
warranted O O
. O O

All O O
patients O B_PERSON
underwent O O
objective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assessment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
electrophysiological O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
wide O B_NUMBER[MEASURE]/B_LOCATION
- O O
field O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
multifocal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
electroretinography O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
and O O
conventional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
visual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
field O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
testing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
static O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
perimetry O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) O O
. O O

Bilateral O B_DISEASE
visual O I_DISEASE
field O I_DISEASE
constriction O I_DISEASE
was O O
observed O O
in O O
59 O B_PERSON/B_MEASURE
% O B_PERSON/I_MEASURE
of O O
patients O B_PERSON
currently O O
taking O O
VGB O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
43 O B_PERSON/B_MEASURE
% O B_PERSON/I_MEASURE
of O O
patients O B_PERSON
who O O
previously O O
took O O
VGB O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
24 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
patients O B_PERSON
with O O
no O O
exposure O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
VGB O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Assessment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
retinal O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O O
abnormal O B_DISEASE
responses O I_DISEASE
in O O
48 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
of O O
current O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
VGB O B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
users O B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
and O O
22 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
of O O
prior O B_PERSON/B_ORGANIZATION
VGB O I_PERSON/I_ORGANIZATION
users O I_PERSON/I_ORGANIZATION
, O O
but O O
in O O
none O B_PERSON/B_MEASURE
of O O
the O O
patients O B_PERSON/B_LOCATION
without O O
previous O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exposure O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O O
VGB O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
We O O
included O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
from O O
people O B_PERSON
participating O O
in O O
the O O
Vancouver O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Injection O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Drug O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Users O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
who O O
reported O O
injecting O O
illicit O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
least O O
once O O
in O O
the O O
month O B_TIME[MEASURE]/B_LOCATION
before O O
enrolment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
lived O O
in O O
the O O
greater O B_LOCATION
Vancouver O I_LOCATION
area O I_LOCATION
, O O
were O O
HIV O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
negative O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
enrolment O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
completed O O
at O O
least O O
1 O B_NUMBER[MEASURE]/B_PERSON
follow O O
- O O
up O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
visit O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
widely O O
used O O
chemotherapeutic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agent O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
5 O B_MEASURE
- O O
fluorouracil O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
5 O B_MEASURE/B_PERSON
- O O
FU O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
, O O
readily O O
crosses O O
the O O
blood O B_BODY_PART_OR_ORGAN_COMPONENT
- O O
brain O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
barrier O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
so O O
could O O
have O O
a O O
direct O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
brain O B_DISEASE
function O I_DISEASE
. O O

In O O
particular O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
this O O
anti O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mitotic O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
drug O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
could O O
reduce O O
cell O B_DISEASE
proliferation O I_DISEASE
in O O
the O O
neurogenic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
regions O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
adult O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
brain O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
contrast O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
reports O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
indicate O O
that O O
hippocampal O B_DISEASE
dependent O I_DISEASE
neurogenesis O I_DISEASE
and O O
cognition O B_DISEASE/B_ORGANISM_FUNCTION
are O O
enhanced O O
by O O
the O O
SSRI O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
antidepressant O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
Fluoxetine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

A O O
separate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
animals O B_BIO/B_PERSON
was O O
tested O O
using O O
a O O
hippocampal O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
dependent O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
spatial O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
working O O
memory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
test O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
object O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
location O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
recognition O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
test O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
OLR O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

We O O
have O O
recently O O
demonstrated O O
that O O
disruption O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
extracellular O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
matrix O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
ECM O B_PROTEIN[GENE]/B_LOCATION
) O O
/ O O
integrin O B_GENE
signaling O O
via O O
elimination O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
integrin O B_GENE
- O O
linked O O
kinase O B_ENZYME[GENE]/B_LOCATION
( O O
ILK O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
in O O
hepatocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
interferes O O
with O O
signals O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
leading O O
to O O
termination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
liver O B_DISEASE/B_ORGANISM_FUNCTION
regeneration O B_DISEASE/I_ORGANISM_FUNCTION
. O O

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigates O O
the O O
role O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
ILK O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
liver O B_DISEASE
enlargement O I_DISEASE
induced O O
by O O
phenobarbital O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
PB O B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
. O O

Wild O B_PERSON/B_BIO
- O O
type O B_MEASURE/B_DISEASE
( O O
WT O B_PROTEIN[GENE]/B_LOCATION
) O O
and O O
ILK O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
: O O
liver O B_DISEASE/B_MEASURE
- O O
/ O B_PERSON/B_PROTEIN[GENE]
- O O
mice O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
given O O
PB O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
0 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
in O O
drinking O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
water O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O O
for O O
10 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days O B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

In O O
the O O
WT O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
mice O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
, O O
the O O
increase O B_DISEASE/B_MEASURE
was O O
as O O
expected O O
from O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
literature O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
1 O B_MEASURE
. O O
8 O B_TIME[MEASURE]
times O I_TIME[MEASURE]
) O O
and O O
seems O O
to O O
have O O
leveled O O
off O O
after O O
day O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
2 O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
. O O

Hepatocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
of O O
the O O
ILK O B_DISEASE/B_PROTEIN[GENE]
/ O O
liver O B_GENE/B_DISEASE
- O O
/ O B_PERSON/B_PROTEIN[GENE]
- O O
mice O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
continued O O
to O O
proliferate O O
up O O
until O O
day O B_DISEASE/B_ORGANISM_FUNCTION
10 O I_DISEASE/I_ORGANISM_FUNCTION
. O O

ILK O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
liver O B_GENE/B_DISEASE
- O O
/ O B_DISEASE/B_GENE
- O O
mice O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
showed O O
increased O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
key O B_GENE
genes O I_GENE
involved O O
in O O
hepatocyte O B_DISEASE
proliferation O I_DISEASE
at O O
different O B_TIME[MEASURE]/B_LOCATION
time O I_TIME[MEASURE]/I_LOCATION
points O I_TIME[MEASURE]/I_LOCATION
during O O
PB O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
administration O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Lack O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
ILK O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
hepatocytes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
imparts O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
prolonged O O
proliferative O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
not O O
only O O
to O O
stimuli O O
related O O
to O O
liver O B_DISEASE
regeneration O I_DISEASE
but O O
also O O
to O O
xenobiotic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemical O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mitogens O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
PB O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Gentamicin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
treated O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exhibited O O
significantly O O
decreased O O
creatinine O B_MEASURE/B_DISEASE
clearance O B_MEASURE/I_DISEASE
along O O
with O O
increased O O
plasma O B_DISEASE/B_GENE
creatinine O I_DISEASE/I_GENE
levels O I_DISEASE/I_GENE
. O O

During O O
induction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
he O O
suffered O O
ileal O B_DISEASE
perforation O I_DISEASE
and O O
ileostomy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
was O O
performed O O
. O O

After O O
recovery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
his O O
renal O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
could O O
safely O O
treat O O
the O O
patient O B_PERSON/B_DISEASE
with O O
HD O B_DISEASE/B_PROTEIN[GENE]
- O O
MTX O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
controlling O O
drainage O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O O
ileostoma O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
with O O
total O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
parenteral O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
nutrition O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

The O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
included O O
871 O B_PERSON
women O I_PERSON
with O O
HIV O B_DISEASE/B_LOCATION
who O O
were O O
recruited O O
from O O
1993 O B_MEASURE
- O O
1995 O B_MEASURE
in O O
four O B_LOCATION
US O I_LOCATION
cities O I_LOCATION
. O O

When O O
participants O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
stratified O O
by O O
antiretroviral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
ART O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O O
the O O
association O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
alcohol O B_DISEASE
and O O
CD4 O B_GENE
+ O I_GENE
T O I_GENE
- O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
did O O
not O O
reach O O
statistical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significance O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Our O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
implications O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O O
the O O
provision O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O O
alcohol O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_EDU[ORGANIZATION]
use O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_EDU[ORGANIZATION]
interventions O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_EDU[ORGANIZATION]
and O O
psychological O B_ORGANIZATION/B_DISEASE_ADJECTIVE[DISEASE]
resources O I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
to O O
improve O O
the O O
health O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
women O B_PERSON/B_LOCATION
with O O
HIV O B_DISEASE/B_LOCATION
. O O

Hippocampal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
integrity O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O O
essential O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
cognitive O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
functions O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

On O O
the O O
other O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
hand O I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
induction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
metallothionein O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
MT O B_LOCATION/B_PROTEIN[GENE]
) O O
by O O
ZnSO O B_LOCATION/B_ORGANIZATION
( O O
4 O B_MEASURE/B_LOCATION
) O O
and O O
its O O
role O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
neuroprotection O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
has O O
been O O
documented O O
. O O

Third O B_PERSON/B_ORGANIZATION
group O I_PERSON/I_ORGANIZATION
received O O
BCNU O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
20 O B_MEASURE/B_LOCATION
mg O I_MEASURE/I_LOCATION
/ O O
kg O B_TIME[MEASURE]
, O O
i O O
. O O
v O B_MEASURE/B_GENE
, O O
once O O
) O O
24 O B_MEASURE/B_LOCATION
h O O
after O O
injection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
normal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
saline O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
i O B_DISEASE/B_PROTEIN[GENE]
. O O
c O O
. O O
v O O
) O O
. O O

Histology O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
revealed O O
diffuse O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infiltration O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
myocardium O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
by O O
eosinophils O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
with O O
myocyte O B_DISEASE
damage O I_DISEASE
. O O

These O O
symptoms O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
due O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
' O O
sensitisation O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
' O O
following O O
repeated O O
levodopa O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
or O O
a O O
direct O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
effect O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
dopamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O O
the O O
disease O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
state O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O O

MATERIAL O B_LOCATION/B_TIME[MEASURE]
AND O O
METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
A O O
total O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
33 O B_MEASURE/B_PERSON
patients O B_MEASURE/I_PERSON
successfully O O
treated O O
with O O
PTRA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
PTRA O B_PERSON/B_ORGANIZATION
group O I_PERSON/I_ORGANIZATION
, O O
mean O B_TIME[MEASURE]
age O I_TIME[MEASURE]
70 O I_TIME[MEASURE]
+ O I_TIME[MEASURE]
/ O O
- O O
12 O B_TIME[MEASURE]
years O I_TIME[MEASURE]
, O O
23 O B_PERSON
female O I_PERSON
, O O
basal O B_MEASURE
creatinine O I_MEASURE
1 O I_MEASURE
. O O
46 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
79 O B_MEASURE
, O O
range O B_MEASURE/B_LOCATION
0 O I_MEASURE/I_LOCATION
. O O
7 O B_MEASURE
- O O
4 O B_MEASURE
. O O
9 O B_MEASURE
mg O I_MEASURE
/ O O
dl O B_TIME[MEASURE]/B_DISEASE
) O O
were O O
compared O O
with O O
33 O B_PERSON
patients O I_PERSON
undergoing O O
successful O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
PCI O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PCI O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
group O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
) O O
, O O
matched O O
for O O
basal O B_TIME[MEASURE]/B_PERSON
creatinine O I_TIME[MEASURE]/I_PERSON
( O O
1 O B_MEASURE
. O O
44 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
6 O B_MEASURE
, O O
range O B_MEASURE/B_LOCATION
0 O I_MEASURE/I_LOCATION
. O O
7 O B_MEASURE
- O O
3 O B_MEASURE
. O O
4 O B_MEASURE
mg O I_MEASURE
/ O O
dl O B_TIME[MEASURE]/B_DISEASE
) O O
, O O
gender O B_PERSON/B_MEASURE
, O O
and O O
age O B_DISEASE
. O O

In O O
both O O
groups O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
postprocedural O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
48 O B_MEASURE
h O O
) O O
serum O B_DISEASE
creatinine O I_DISEASE
was O O
measured O O
. O O

Changes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
serum O B_DISEASE/B_GENE
creatinine O I_DISEASE/I_GENE
after O O
intervention O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
after O O
- O O
before O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
were O O
significantly O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
PTRA O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
PCI O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
- O O
0 O B_MEASURE/B_LOCATION
. O O
12 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_NUMBER[MEASURE]
. O O
5 O B_MEASURE/B_SPORT[ENT]
vs O I_MEASURE/I_SPORT[ENT]
. O O
0 O B_MEASURE/B_LOCATION
. O O
13 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
3 O B_MEASURE
, O O
P O B_OTHER/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
014 O B_MEASURE
) O O
. O O

The O O
effectiveness O O
of O O
PTRA O O
on O O
renal O O
function O O
seems O O
to O O
be O O
barely O O
influenced O O
by O O
CM O O
toxicity B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
. O O

Cimetidine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
a O O
histamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
H2 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
antagonist O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
produces O O
a O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
arterial O B_DISEASE/B_GENE
pressure O I_DISEASE/I_GENE
due O O
to O O
vasodilatation O B_DISEASE
, O O
especially O O
in O O
critically O O
ill O B_PERSON/B_DISEASE
patients O I_PERSON/I_DISEASE
. O O

We O O
, O O
therefore O O
, O O
investigated O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
histamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
H1 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
receptor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antagonist O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
diphenhydramine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
on O O
the O O
haemodynamic O B_DISEASE
changes O I_DISEASE
observed O O
after O O
cimetidine O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
in O O
ICU O B_SPECIES[BIO]/B_PERSON
patients O I_SPECIES[BIO]/I_PERSON
. O O

In O O
the O O
non O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
pretreatment O B_PERSON/B_ORGANIZATION
group O I_PERSON/I_ORGANIZATION
, O O
mean O B_DISEASE
arterial O I_DISEASE
pressure O I_DISEASE
( O O
MAP O B_LOCATION/B_ORGANIZATION
) O O
decreased O O
from O O
107 O B_MEASURE
. O O
4 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
8 O B_MEASURE
. O O
4 O B_MEASURE
mmHg O I_MEASURE
to O O
86 O B_MEASURE
. O O
7 O B_MEASURE
+ O O
/ O O
- O O
11 O B_MEASURE
. O O
4 O B_MEASURE
mmHg O I_MEASURE
( O O
P O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
two O B_TIME[MEASURE]/B_ENT
minutes O I_TIME[MEASURE]/I_ENT
after O O
cimetidine O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Also O O
, O O
systemic O B_DISEASE
vascular O I_DISEASE
resistance O I_DISEASE
( O O
SVR O B_DISEASE/B_PROTEIN[GENE]
) O O
decreased O O
during O O
the O O
eight O B_NUMBER[MEASURE]
- O O
minute O B_TIME[MEASURE]/B_LOCATION
observation O I_TIME[MEASURE]/I_LOCATION
period O I_TIME[MEASURE]/I_LOCATION
( O O
P O B_MEASURE/B_PERSON
less O I_MEASURE/I_PERSON
than O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
. O O

In O O
contrast O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
in O O
the O O
pretreatment O B_TIME[MEASURE]/B_LOCATION
group O B_TIME[MEASURE]/I_LOCATION
, O O
little O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
haemodynamic O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
change O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
seen O O
. O O

Patients O B_PERSON
often O O
consume O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
suicidal O B_DISEASE
intent O I_DISEASE
or O O
with O O
a O O
background O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
substance O B_DISEASE
dependence O I_DISEASE
. O O

Twenty O O
( O O
56 O O
% O O
) O O
acetaminophen O O
- O O
induced O O
ALF B B_DISEASE
patients O O
had O O
a O O
formal O O
psychiatric O O
diagnosis O O
before O O
LT O O
( O O
non O O
- O O
acetaminophen O O
- O O
induced O O
ALF B B_LOCATION/B_DISEASE
= O O
0 O O
/ O O
35 O O
, O O
CLD B B_LOCATION
= O O
2 O O
/ O O
34 O O
; O O
P O O
< O O
0 O O
. O O
01 O O
for O O
all O O
) O O
and O O
nine O O
( O O
25 O O
% O O
) O O
had O O
a O O
previous O O
suicide O O
attempt O O
. O O

Multidisciplinary O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
approaches O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
with O O
long O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
term O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
psychiatric O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
follow O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
up O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
contribute O O
to O O
low O B_DISEASE/B_MEASURE
post O I_DISEASE/I_MEASURE
- O O
transplant O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
suicide O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
rates O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
seen O O
and O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
rates O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
graft O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
loss O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
because O O
of O O
non O B_DISEASE
- O O
compliance O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

BACKGROUND O O
AND O O
PURPOSE O O
: O O
Cerebral B B_DISEASE
microbleeds I I_DISEASE
( O O
MB B B_LOCATION/B_PERSON
) O O
are O O
potential O O
risk O O
factors O O
for O O
intracerebral B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
hemorrhage I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
ICH B B_DISEASE/B_LOCATION
) O O
, O O
but O O
it O O
is O O
unclear O O
if O O
they O O
are O O
a O O
contraindication O O
to O O
using O O
antithrombotic O O
drugs O O
. O O

Insights O O
could O O
be O O
gained O O
by O O
pooling O O
data O O
on O O
MB B B_DISEASE/B_GENE
frequency O O
stratified O O
by O O
antithrombotic O O
use O O
in O O
cohorts O O
with O O
ICH B B_DISEASE/B_LOCATION
and O O
ischemic B B_DISEASE_ADJECTIVE[DISEASE]
stroke I I_DISEASE_ADJECTIVE[DISEASE]
( O O
IS B B_LOCATION
) O O
/ O O
transient B B_DISEASE_ADJECTIVE[DISEASE]
ischemic I I_DISEASE_ADJECTIVE[DISEASE]
attack I I_DISEASE_ADJECTIVE[DISEASE]
( O O
TIA B B_LOCATION/B_ORGANIZATION
) O O
. O O

METHODS O O
: O O
We O O
performed O O
a O O
systematic O O
review O O
of O O
published O O
and O O
unpublished O O
data O O
from O O
cohorts O O
with O O
stroke B B_DISEASE/B_LOCATION
or O O
TIA B B_DISEASE/B_LOCATION
to O O
compare O O
the O O
presence O O
of O O
MB B B_DISEASE/B_GENE
in O O
: O O
( O O
1 O O
) O O
antithrombotic O O
users O O
vs O O
nonantithrombotic O O
users O O
with O O
ICH B B_DISEASE/B_LOCATION
; O O
( O O
2 O O
) O O
antithrombotic O O
users O O
vs O O
nonusers O O
with O O
IS B B_DISEASE/B_LOCATION
/ O O
TIA B B_LOCATION/B_ORGANIZATION
; O O
and O O
( O O
3 O O
) O O
ICH B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
vs O O
ischemic B B_DISEASE/B_LOCATION
events O O
stratified O O
by O O
antithrombotic O O
use O O
. O O

RESULTS O O
: O O
In O O
a O O
pooled O O
analysis O O
of O O
1460 O O
ICH B B_LOCATION/B_PERSON
and O O
3817 O O
IS B B_LOCATION/B_ORGANIZATION
/ O O
TIA B B_LOCATION/B_ORGANIZATION
, O O
MB B B_DISEASE/B_GENE
were O O
more O O
frequent O O
in O O
ICH B B_LOCATION/B_PERSON
vs O O
IS B B_LOCATION/B_ORGANIZATION
/ O O
TIA B B_LOCATION/B_ORGANIZATION
in O O
all O O
treatment O O
groups O O
, O O
but O O
the O O
excess O O
increased O O
from O O
2 O O
. O O
8 O O
( O O
odds O O
ratio O O
; O O
range O O
, O O
2 O O
. O O
3 O O
- O O
3 O O
. O O
5 O O
) O O
in O O
nonantithrombotic O O
users O O
to O O
5 O O
. O O
7 O O
( O O
range O O
, O O
3 O O
. O O
4 O O
- O O
9 O O
. O O
7 O O
) O O
in O O
antiplatelet O O
users O O
and O O
8 O O
. O O
0 O O
( O O
range O O
, O O
3 O O
. O O
5 O O
- O O
17 O O
. O O
8 O O
) O O
in O O
warfarin O O
users O O
( O O
P O O
difference O O
= O O
0 O O
. O O
01 O O
) O O
. O O

There O O
was O O
also O O
an O O
excess O O
of O O
MB B B_DISEASE/B_GENE
in O O
warfarin O O
users O O
vs O O
nonusers O O
with O O
ICH B B_LOCATION/B_PERSON
( O O
OR O O
, O O
2 O O
. O O
7 O O
; O O
95 O O
% O O
CI O O
, O O
1 O O
. O O
6 O O
- O O
4 O O
. O O
4 O O
; O O
P O O
< O O
0 O O
. O O
001 O O
) O O
but O O
none O O
in O O
warfarin O O
users O O
with O O
IS B B_LOCATION
/ O O
TIA B B_DISEASE/B_LOCATION
( O O
OR O O
, O O
1 O O
. O O
3 O O
; O O
95 O O
% O O
CI O O
, O O
0 O O
. O O
9 O O
- O O
1 O O
. O O
7 O O
; O O
P O O
= O O
0 O O
. O O
33 O O
; O O
P O O
difference O O
= O O
0 O O
. O O
01 O O
) O O
. O O

There O O
was O O
a O O
smaller O O
excess O O
of O O
MB B B_DISEASE/B_GENE
in O O
antiplatelet O O
users O O
vs O O
nonusers O O
with O O
ICH B B_LOCATION/B_PERSON
( O O
OR O O
, O O
1 O O
. O O
7 O O
; O O
95 O O
% O O
CI O O
, O O
1 O O
. O O
3 O O
- O O
2 O O
. O O
3 O O
; O O
P O O
< O O
0 O O
. O O
001 O O
) O O
, O O
but O O
findings O O
were O O
similar O O
for O O
antiplatelet O O
users O O
with O O
IS B B_LOCATION
/ O O
TIA B B_LOCATION/B_ORGANIZATION
( O O
OR O O
, O O
1 O O
. O O
4 O O
; O O
95 O O
% O O
CI O O
, O O
1 O O
. O O
2 O O
- O O
1 O O
. O O
7 O O
; O O
P O O
< O O
0 O O
. O O
001 O O
; O O
P O O
difference O O
= O O
0 O O
. O O
25 O O
) O O
. O O

CONCLUSIONS O O
: O O
The O O
excess O O
of O O
MB B B_PROTEIN[GENE]/B_LOCATION
in O O
warfarin O O
users O O
with O O
ICH B B_DISEASE
compared O O
to O O
other O O
groups O O
suggests O O
that O O
MB B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increase O O
the O O
risk O O
of O O
warfarin O O
- O O
associated O O
ICH B B_DISEASE
. O O

Early O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
recognition O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
incorporates O O
the O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
serologic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
clues O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
paramount O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
to O O
timely O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
institution O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
of O O
treatment O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
its O O
delay O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
may O O
result O O
in O O
catastrophic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
number O B_MEASURE
of O O
treatments O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
received O O
and O O
adverse O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
noted O O
. O O

The O O
patient O B_PERSON/B_DISEASE
recovered O O
after O O
discontinuing O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
with O O
no O O
recurrence O B_DISEASE
in O O
2 O B_TIME[MEASURE]/B_ENT
years O I_TIME[MEASURE]/I_ENT
. O O

RESEARCH O B_NUMBER[MEASURE]/B_ORGANIZATION
DESIGN O I_NUMBER[MEASURE]/I_ORGANIZATION
AND O O
METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
EndoMT O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
induced O O
in O O
a O O
mouse O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
pancreatic O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
microvascular O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
endothelial O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
line O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MMEC O B_DISEASE/B_TIME[MEASURE]
) O O
in O O
the O O
presence O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
advanced O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glycation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
end O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
products O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
AGEs O B_DISEASE/B_BACTERIUM[BIO]
) O O
and O O
in O O
the O O
endothelial O B_DISEASE/B_GENE
lineage O I_DISEASE/I_GENE
- O O
traceble O B_GENE/B_DISEASE
mouse O I_GENE/I_DISEASE
line O I_GENE/I_DISEASE
Tie2 O I_GENE/I_DISEASE
- O O
Cre O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
Loxp O B_GENE/B_MEASURE
- O O
EGFP O B_GENE/B_MEASURE
by O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
AGEs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
, O O
with O O
nonglycated O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mouse O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
albumin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
serving O O
as O O
a O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Patients O B_PERSON/B_DISEASE
become O O
progressively O O
refractory O B_DISEASE_ADJECTIVE[DISEASE]
to O O
conventional O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemotherapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
their O O
prognosis O B_DISEASE
is O O
poor O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
last O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
episode O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
of O O
acute O B_DISEASE/B_LOCATION
renal O I_DISEASE/I_LOCATION
failure O I_DISEASE/I_LOCATION
at O O
which O O
stage O B_TIME[MEASURE]/B_ENT
the O O
patient O B_PERSON/B_DISEASE
was O O
seen O O
by O O
the O O
authors O B_PERSON
of O O
this O O
report O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

The O O
concentration O B_MEASURE/B_LOCATION
of O O
serum O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
potassium O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
, O O
and O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sinus O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rhythm O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
restored O O
after O O
correction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
serum O B_DISEASE
potassium O I_DISEASE
level O I_DISEASE
. O O

This O O
case O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
good O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
example O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
electrolyte O B_DISEASE
imbalance O I_DISEASE
causing O O
acute O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
life O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
- O O
threatening O O
cardiac O B_DISEASE
events O I_DISEASE
. O O

Lumbar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
puncture O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
were O O
inconclusive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
no O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blood O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cultures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
positive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
MSSA O B_DISEASE/B_BACTERIUM[BIO]
. O O

At O O
a O O
dose O B_MEASURE/B_LOCATION
of O O
9 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
, O O
resultant O B_DISEASE_ADJECTIVE[DISEASE]
penetration O I_DISEASE_ADJECTIVE[DISEASE]
of O O
5 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
in O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
reports O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
more O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
inflamed O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
meninges O B_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

EEG O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analyses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
number O B_MEASURE
and O O
duration O B_MEASURE
of O O
ictal O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
periods O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
EEG O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receiving O O
l O B_PROTEIN[GENE]/B_DISEASE
- O O
arginine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
prior O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
lindane O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
this O O
number O B_MEASURE
in O O
rats O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pretreated O O
with O O
L O B_OTHER/B_LOCATION
- O O
NAME O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
i O O
. O O
v O B_PROTEIN[GENE]/B_LOCATION
. O O
bolus O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
administration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
cromakalim O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O B_NUMBER[MEASURE]
- O O
10 O B_MEASURE
micrograms O I_MEASURE
/ O O
kg O B_MEASURE/B_PERSON
) O O
and O O
pinacidil O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
3 O B_MEASURE
- O O
100 O B_MEASURE
micrograms O I_MEASURE
/ O O
kg O B_MEASURE/B_PERSON
) O O
on O O
large O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
( O O
circumflex O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
artery O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
) O O
and O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
coronary O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
arteries O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
on O O
systemic O B_DISEASE
hemodynamics O I_DISEASE
were O O
investigated O O
in O O
chronically O O
instrumented O O
conscious O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
dogs O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
compared O O
to O O
those O O
of O O
nitroglycerin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
0 O B_MEASURE
. O O
03 O B_MEASURE
- O O
10 O B_MEASURE
micrograms O I_MEASURE
/ O O
kg O B_MEASURE
) O O
. O O

Nitroglycerin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
up O O
to O O
0 O B_MEASURE
. O O
3 O B_MEASURE
micrograms O I_MEASURE
/ O O
kg O B_MEASURE
, O O
selectively O O
increased O O
circumflex O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
artery O B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diameter O B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CxAD O B_DISEASE/B_LOCATION
) O O
without O O
simultaneously O O
affecting O O
any O O
other O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
cardiac O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
or O O
systemic O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
hemodynamic O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
parameter O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

In O O
contrast O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
, O O
cromakalim O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
pinacidil O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
all O O
doses O B_MEASURE/B_LOCATION
and O O
nitroglycerin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
doses O B_MEASURE
higher O I_MEASURE
than O O
0 O B_MEASURE
. O O
3 O B_MEASURE
micrograms O I_MEASURE
/ O O
kg O B_MEASURE
simultaneously O O
and O O
dose O B_MEASURE
- O O
dependently O O
increased O O
CxAD O B_DISEASE/B_GENE
, O O
coronary O B_DISEASE/B_GENE
blood O B_DISEASE/I_GENE
flow O B_DISEASE/I_GENE
and O O
heart O B_MEASURE/B_DISEASE
rate O I_MEASURE/I_DISEASE
and O O
decreased O O
coronary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
vascular O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
resistance O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
aortic O B_MEASURE/B_DISEASE
pressure O B_MEASURE/I_DISEASE
. O O

Cromakalim O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
approximately O O
8 O B_NUMBER[MEASURE]
- O O
to O O
9 O B_MEASURE
. O O
5 O B_MEASURE
- O O
fold O B_LOCATION/B_MEASURE
more O O
potent O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
pinacidil O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
increasing O O
CxAD O B_DISEASE
. O O

When O O
circumflex O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
artery O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flow O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
maintained O O
constant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
the O O
increases O B_DISEASE_ADJECTIVE[DISEASE]
in O O
CxAD O B_DISEASE/B_GENE
induced O O
by O O
cromakalim O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
10 O B_MEASURE
micrograms O I_MEASURE
/ O O
kg O B_MEASURE/B_PERSON
) O O
, O O
pinacidil O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
30 O B_MEASURE
micrograms O I_MEASURE
/ O O
kg O B_MEASURE/B_PERSON
) O O
and O O
nitroglycerin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
10 O B_MEASURE
micrograms O I_MEASURE
/ O O
kg O B_MEASURE/B_PERSON
) O O
were O O
reduced O O
by O O
68 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
7 O B_MEASURE
, O O
54 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
9 O B_MEASURE
and O O
1 O B_MEASURE/B_LOCATION
+ O I_MEASURE/I_LOCATION
/ O O
- O O
1 O B_MEASURE
% O I_MEASURE
, O O
respectively O O
. O O

Thus O O
, O O
whereas O O
nitroglycerin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preferentially O O
and O O
flow O B_MEASURE/B_SPORT[ENT]
- O O
independently O O
dilates O B_DISEASE_ADJECTIVE[DISEASE]
large O I_DISEASE_ADJECTIVE[DISEASE]
coronary O I_DISEASE_ADJECTIVE[DISEASE]
arteries O I_DISEASE_ADJECTIVE[DISEASE]
, O O
cromakalim O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
pinacidil O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dilate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
both O O
large O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
coronary O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
arteries O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
this O O
effect O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
not O O
dependent O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
upon O O
the O O
simultaneous O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adrenoceptors O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mediated O O
rise O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in O O
myocardial O B_DISEASE/B_MEASURE
metabolic O B_DISEASE/I_MEASURE
demand O B_DISEASE/I_MEASURE
. O O

Finally O O
, O O
two O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
mechanisms O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
at O O
least O O
, O O
direct O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
vasodilation O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
flow O B_DISEASE
dependency O I_DISEASE
, O O
are O O
involved O O
in O O
the O O
cromakalim O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
and O O
pinacidil O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
CxAD O B_DISEASE/B_GENE
. O O

However O O
, O O
there O O
was O O
a O O
significant O B_MEASURE
difference O I_MEASURE
in O O
parameters O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reflecting O O
bone O B_DISEASE/B_GENE
turnover O I_DISEASE/I_GENE
rates O I_DISEASE/I_GENE
between O O
groups O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
( O O
ABSTRACT O B_TIME[MEASURE]/B_ORGANIZATION
TRUNCATED O I_TIME[MEASURE]/I_ORGANIZATION
AT O O
250 O B_LOCATION/B_ENT
WORDS O I_LOCATION/I_ENT
) O O

Scleroderma B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
renal I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
crisis I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
SRC B B_LOCATION
) O O
is O O
a O O
rare O O
complication O O
of O O
systemic B B_DISEASE
sclerosis I I_DISEASE
( O O
SSc B B_LOCATION/B_ORGANIZATION
) O O
but O O
can O O
be O O
severe O O
enough O O
to O O
require O O
temporary O O
or O O
permanent O O
renal O O
replacement O O
therapy O O
. O O

We O O
report O O
a O O
case O O
of O O
methyldopa O O
- O O
induced O O
hemolytic B B_DISEASE
anemia I I_DISEASE
in O O
a O O
15 O O
- O O
year O O
- O O
old O O
boy O O
who O O
presented O O
to O O
the O O
emergency B B_LOCATION/B_PERSON
department I B_LOCATION/I_PERSON
with O O
near O O
- O O
syncope B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Evaluation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
revealed O O
a O O
hemoglobin O B_MEASURE
of O O
three O B_MEASURE
grams O I_MEASURE
, O O
3 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Coombs O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
polyspecific O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anti O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
human O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
globulin O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
monospecific O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IgG O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reagents O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
a O O
warm O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reacting O B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
autoantibody O B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Emergency O B_PERSON
physicians O I_PERSON
treating O O
children O B_PERSON/B_DISEASE
must O O
be O O
aware O B_PERSON
of O O
this O O
syndrome O B_DISEASE
in O O
order O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
diagnose O O
and O O
treat O O
it O O
correctly O O
. O O

We O O
recently O O
reported O O
in O O
young O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
healthy O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subjects O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
inhibitory O O
cerebellar O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
enhanced O O
the O O
sensorimotor O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
plasticity O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
M1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
that O O
was O O
induced O O
by O O
paired O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
associative O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
stimulation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
PAS O B_DISEASE/B_LOCATION
) O O
. O O

This O O
was O O
evident O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O O
when O O
a O O
sensory O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
component O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
involved O O
in O O
the O O
induction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
plasticity O B_DISEASE
, O O
indicating O O
that O O
cerebellar O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensory O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
processing O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
involved O O
in O O
the O O
resurgence O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
of O O
M1 O B_DISEASE/B_ORGANISM_FUNCTION
plasticity O I_DISEASE/I_ORGANISM_FUNCTION
. O O

The O O
drug O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
discontinued O O
due O O
to O O
adverse O B_DISEASE
reactions O I_DISEASE
in O O
8 O B_PERSON/B_TIME[MEASURE]
patients O I_PERSON/I_TIME[MEASURE]
. O O

We O O
conclude O O
that O O
, O O
despite O O
a O O
relatively O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
incidence O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
adverse O B_DISEASE
reactions O I_DISEASE
, O O
danazol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
proven O O
to O O
be O O
remarkably O O
safe O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
over O O
the O O
long O B_TIME[MEASURE]/B_LOCATION
- O O
term O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
this O O
group O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
patients O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Urodynamic O B_TIME[MEASURE]/B_LOCATION
parameters O I_TIME[MEASURE]/I_LOCATION
, O O
bladder O B_MEASURE/B_LOCATION
pressure O I_MEASURE/I_LOCATION
- O O
volume O B_MEASURE/B_LOCATION
curve O I_MEASURE/I_LOCATION
, O O
maximum O B_MEASURE/B_LOCATION
voiding O I_MEASURE/I_LOCATION
pressure O I_MEASURE/I_LOCATION
( O O
MVP O B_PERSON/B_DISEASE
) O O
, O O
and O O
maximum O B_MEASURE/B_LOCATION
cystometric O I_MEASURE/I_LOCATION
capacity O I_MEASURE/I_LOCATION
( O O
MCC O B_DISEASE/B_GENE
) O O
, O O
were O O
recorded O O
. O O

The O O
incidence O B_MEASURE
of O O
bladder O B_DISEASE
instability O I_DISEASE
during O O
urine O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
storage O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
period O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
significantly O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
intervention O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
X O B_OTHER/B_PROTEIN[GENE]
( O O
2 O B_NUMBER[MEASURE]
) O O
= O O
7 O B_MEASURE
. O O
619 O B_MEASURE
, O O
P O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
007 O B_MEASURE
) O O
and O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O O
X O B_OTHER/B_PROTEIN[GENE]
( O O
2 O B_NUMBER[MEASURE]
) O O
= O O
13 O B_MEASURE
. O O
755 O B_MEASURE
, O O
P O B_PROTEIN[GENE]/B_LOCATION
= O O
0 O B_MEASURE
. O O
000 O B_MEASURE
) O O
. O O

MCC O B_DISEASE/B_MEASURE
in O O
the O O
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
the O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
intervention O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0 O B_MEASURE
. O O
01 O B_MEASURE
) O O
. O O

Perfusion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
bladder O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
with O O
P2X3 O B_GENE
and O O
NK1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antagonists O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ameliorated O O
the O O
bladder O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Bortezomib O O
( O O
bort O O
) O O
- O O
dexamethasone O O
( O O
dex O O
) O O
is O O
an O O
effective O O
therapy O O
for O O
relapsed O O
/ O O
refractory O O
( O O
R O O
/ O O
R O O
) O O
multiple B B_DISEASE
myeloma I I_DISEASE
( O O
MM B B_TIME[MEASURE]/B_LOCATION
) O O
. O O

On O O
an O O
intention O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
to O O
- O O
treat O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
basis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
55 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
of O O
the O O
patients O B_PERSON
achieved O O
at O O
least O O
partial O B_DISEASE/B_LOCATION
response O I_DISEASE/I_LOCATION
, O O
including O O
19 O B_DISEASE/B_LOCATION
% O I_DISEASE/I_LOCATION
CR O I_DISEASE/I_LOCATION
and O O
35 O B_PERSON
% O I_PERSON
achieved O O
at O O
least O O
very O O
good O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
partial O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
response O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

With O O
a O O
median O B_MEASURE
follow O O
up O O
of O O
22 O B_TIME[MEASURE]/B_DISEASE
months O B_TIME[MEASURE]/I_DISEASE
, O O
median O B_MEASURE/B_PERSON
time O I_MEASURE/I_PERSON
to O O
progression O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
progression O B_DISEASE_ADJECTIVE[DISEASE]
- O O
free O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
survival O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
PFS O B_LOCATION
) O O
and O O
overall O B_DISEASE_ADJECTIVE[DISEASE]
survival O I_DISEASE_ADJECTIVE[DISEASE]
( O O
OS O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
were O O
8 O B_MEASURE
. O O
9 O B_MEASURE
, O O
8 O B_MEASURE
. O O
7 O B_MEASURE
, O O
and O O
22 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
, O O
respectively O O
. O O

Prolonged O B_DISEASE
PFS O B_LOCATION/B_DISEASE
and O O
OS O B_TIME[MEASURE]/B_DISEASE
were O O
observed O O
in O O
patients O B_PERSON
achieving O O
CR O B_DISEASE
and O O
receiving O O
bort O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
dex O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a O O
single O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
line O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O O
prior O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
investigated O O
behavioral O B_DISEASE/B_GENE
phenotypes O B_DISEASE/I_GENE
and O O
AChE O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
male O B_PERSON/B_BIO
mice O I_PERSON/I_BIO
following O O
BPA O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
exposure O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
during O O
puberty O B_ORGANISM_FUNCTION/B_PERSON
. O O

On O O
PND71 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
, O O
a O O
behavioral O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
performed O O
using O O
the O O
elevated O O
plus O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
maze O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
EPM O B_DISEASE/B_PROTEIN[GENE]
) O O
and O O
the O O
light O B_COLOR
/ O O
dark O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
test O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
. O O

AChE O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activity O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
significantly O O
decreased O O
in O O
the O O
hippocampus O B_BODY_PART_OR_ORGAN_COMPONENT
of O O
mice O B_BIO/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
BPA O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O O
to O O
control O O
mice O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
whereas O O
no O O
difference O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
found O O
in O O
the O O
prefrontal O B_BODY_PART_OR_ORGAN_COMPONENT
cortex O I_BODY_PART_OR_ORGAN_COMPONENT
, O O
hypothalamus O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
cerebellum O B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Pretreatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
S O B_OTHER/B_LOCATION
. O O
virgaurea O B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extract O I_BACTERIUM[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
5 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weeks O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O O
a O O
dose O B_MEASURE/B_LOCATION
of O O
250 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
followed O O
by O O
isoproterenol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significantly O O
prevented O O
the O O
observed O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alterations O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Median O B_TIME[MEASURE]/B_PERSON
time O I_TIME[MEASURE]/I_PERSON
to O O
CR O B_DISEASE
when O O
RD O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
given O O
as O O
2nd O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
or O O
> O O
2 O B_SEQUENCE[MEASURE]
( O O
nd O B_SEQUENCE[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
- O O
line O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
4 O B_NUMBER[MEASURE]
and O O
11 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
, O O
respectively O O
. O O

Improvement O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
humoral O B_DISEASE
immunity O I_DISEASE
occurred O O
in O O
60 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
of O O
responders O B_PERSON/B_BIO
( O O
p O B_MEASURE/B_PROTEIN[GENE]
< O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
and O O
in O O
the O O
majority O B_PERSON/B_MEASURE
of O O
patients O B_PERSON/B_BIO
who O O
achieved O O
stable O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disease O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Median O B_TIME[MEASURE]/B_PERSON
time O I_TIME[MEASURE]/I_PERSON
to O O
treatment O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
discontinuation O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
16 O B_MEASURE
. O O
8 O B_TIME[MEASURE]
months O I_TIME[MEASURE]
. O O

Extra O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
medullary O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
relapses O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occurred O O
in O O
3 O B_MEASURE
. O O
8 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
patients O B_PERSON/B_LOCATION
. O O

The O O
cytogenetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
action O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
ifosfamide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
mesna O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
their O O
combination O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
on O O
peripheral O B_DISEASE
rabbit O I_DISEASE
lymphocytes O I_DISEASE
: O O
an O O
in O O
vivo O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
/ O O
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytogenetic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
side O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
IFO O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
raises O O
the O O
requirement O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
the O O
co O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
sodium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
sulfanylethanesulfonate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
Mesna O B_DISEASE
) O O
aiming O O
to O O
avoid O O
or O O
minimize O O
this O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Mesna O B_PERSON/B_COLOR
' O O
s O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
action O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
in O O
conjunction O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
IFO O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reduces O O
the O O
frequency O B_MEASURE
of O O
SCEs O B_DISEASE
, O O
in O O
comparison O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O O
the O O
SCEs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
recordings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
obtained O O
when O O
IFO O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O O
administered O O
alone O O
. O O

Busulfan O O
is O O
known O O
to O O
be O O
neurotoxic B B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
animals O O
and O O
humans O O
, O O
but O O
its O O
acute O O
neurotoxicity B B_DISEASE
remains O O
poorly O O
characterized O O
in O O
children O O
. O O

Since O O
plasma O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
pharmacokinetic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O O
a O O
faster O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
busulfan O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
clearance O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
children O B_PERSON/B_BIO
than O O
in O O
adults O B_PERSON/B_BIO
, O O
this O O
new O B_MEASURE
dose O I_MEASURE
may O O
approximate O O
more O O
closely O O
the O O
adult O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
systemic O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
exposure O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
obtained O O
after O O
the O O
usual O B_MEASURE
16 O I_MEASURE
- O O
mg O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
kg O B_TIME[MEASURE]
total O I_TIME[MEASURE]
dose O I_TIME[MEASURE]
, O O
with O O
potential O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inferences O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
terms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
anticancer O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
myeloablative O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
effects O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Additionally O O
, O O
oral O B_DISEASE/B_PERSON
galactose O I_DISEASE/I_PERSON
administration O I_DISEASE/I_PERSON
led O O
to O O
the O O
appearance O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
galactose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
the O O
blood O B_BODY_PART_OR_ORGAN_COMPONENT
. O O

We O O
undertook O O
a O O
descriptive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Yellow O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Card O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
records O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
407 O B_DISEASE
HIV O I_DISEASE
- O O
positive O B_PERSON/B_DISEASE
persons O I_PERSON/I_DISEASE
taking O O
tenofovir O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disoproxil O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fumarate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
TDF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
as O O
part O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
their O O
antiretroviral O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
regimen O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
submitted O O
to O O
the O O
Medicines O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
Healthcare O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Products O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Regulatory O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Agency O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
MHRA O B_DISEASE/B_ORGANIZATION
) O O
with O O
suspected O O
kidney O B_DISEASE_ADJECTIVE[DISEASE]
adverse O I_DISEASE_ADJECTIVE[DISEASE]
effects O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Cessation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
TDF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
associated O O
with O O
complete O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
restoration O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
kidney O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
up O O
half O B_MEASURE
of O O
the O O
patients O B_PERSON
in O O
this O O
report O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Thiopentone O B_DISEASE/B_PERSON
was O O
independently O O
associated O O
with O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
its O O
relative O B_MEASURE/B_DISEASE
risk O I_MEASURE/I_DISEASE
. O O

However O O
, O O
METH O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
significantly O O
increased O O
the O O
immobility O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
time O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
tail O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
suspension O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
test O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
at O O
3 O B_MEASURE
and O O
49 O B_TIME[MEASURE]/B_LOCATION
days O I_TIME[MEASURE]/I_LOCATION
post O I_TIME[MEASURE]/I_LOCATION
- O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Many O B_PERSON
systemic O I_PERSON
antimicrobials O I_PERSON
have O O
been O O
implicated O O
to O O
cause O O
ocular O B_DISEASE
adverse O I_DISEASE
effects O I_DISEASE
. O O

This O O
is O O
especially O O
relevant O B_DISEASE_ADJECTIVE[DISEASE]
in O O
multidrug O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
therapy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
where O O
more O B_MEASURE/B_PERSON
than O O
one O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
cause O O
a O O
similar O B_DISEASE
ocular O I_DISEASE
adverse O I_DISEASE
effect O I_DISEASE
. O O

Discontinuation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
linezolid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
resulted O O
in O O
marked O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
improvement O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
vision O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Our O O
report O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
emphasizes O O
the O O
need O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
monitoring O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
visual O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
patients O B_PERSON/B_LOCATION
on O O
long O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
term O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
linezolid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Resuscitation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
continued O O
for O O
30 O B_TIME[MEASURE]/B_LOCATION
min O I_TIME[MEASURE]/I_LOCATION
or O O
until O O
there O O
was O O
a O O
return O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
spontaneous O B_DISEASE/B_MEASURE
circulation O I_DISEASE/I_MEASURE
( O O
ROSC O B_DISEASE/B_PROTEIN[GENE]
) O O
accompanied O O
by O O
a O O
mean O B_MEASURE/B_LOCATION
arterial O I_MEASURE/I_LOCATION
pressure O I_MEASURE/I_LOCATION
at O O
or O O
superior O B_PERSON/B_MEASURE
to O O
the O O
baseline O B_MEASURE/B_LOCATION
pressure O B_MEASURE/I_LOCATION
and O O
normal O B_DISEASE_ADJECTIVE[DISEASE]
sinus O I_DISEASE_ADJECTIVE[DISEASE]
rhythm O I_DISEASE_ADJECTIVE[DISEASE]
for O O
a O O
period O B_MEASURE/B_LOCATION
of O O
30 O B_TIME[MEASURE]
min O I_TIME[MEASURE]
. O O

Mortality O B_DISEASE
was O O
not O O
significantly O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
three O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
treatment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
but O O
was O O
significantly O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
all O O
the O O
treatment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
compared O O
with O O
control O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

The O O
number O B_MEASURE
of O O
ECG O B_DISEASE/B_MEASURE
abnormalities O I_DISEASE/I_MEASURE
was O O
zero O B_MEASURE
in O O
the O O
Intralipid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
14 O B_MEASURE
and O O
17 O B_MEASURE
, O O
respectively O O
, O O
in O O
the O O
epinephrine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
epinephrine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O O
lipid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
groups O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
P O B_MEASURE/B_PROTEIN[GENE]
< O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

Epinephrine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
alone O O
or O O
in O O
combination O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
with O O
lipid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
associated O O
with O O
an O O
increased O O
number O B_MEASURE/B_LOCATION
of O O
ECG O B_DISEASE
abnormalities O I_DISEASE
compared O O
with O O
lipid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
emulsion O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
. O O

Takotsubo B B_DISEASE/B_GENE
syndrome I I_DISEASE/I_GENE
( O O
TS B B_LOCATION
) O O
, O O
also O O
known O O
as O O
broken B B_LOCATION
heart I I_LOCATION
syndrome I I_LOCATION
, O O
is O O
characterized O O
by O O
left O O
ventricle O O
apical O O
ballooning O O
with O O
elevated O O
cardiac O O
biomarkers O O
and O O
electrocardiographic O O
changes O O
suggestive O O
of O O
an O O
acute B B_DISEASE/B_LOCATION
coronary I I_DISEASE/I_LOCATION
syndrome I I_DISEASE/I_LOCATION
( O O
ie O O
, O O
ST O O
- O O
segment O O
elevation O O
, O O
T O O
wave O O
inversions O O
, O O
and O O
pathologic O O
Q O O
waves O O
) O O
. O O

RATIONALE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
Ecstasy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
3 O B_NUMBER[MEASURE]
, O O
4 O B_NUMBER[MEASURE]
- O O
methylenedioxymethamphetamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
MDMA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
is O O
a O O
worldwide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recreational O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
abuse O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
A O O
sample O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
997 O B_PERSON/B_MEASURE
participants O I_PERSON/I_MEASURE
( O O
52 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
male O I_MEASURE/I_PERSON
) O O
was O O
recruited O O
to O O
four O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control O I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups O I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
non O B_DISEASE_ADJECTIVE[DISEASE]
- O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
( O O
ND O B_LOCATION
) O O
, O O
alcohol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O O
nicotine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
AN O B_LOCATION/B_ORGANIZATION
) O O
, O O
cannabis O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
alcohol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O O
nicotine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CAN O B_LOCATION/B_EDU[ORGANIZATION]
) O O
, O O
non O B_DISEASE
- O O
ecstasy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
polydrug O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
PD O B_LOCATION
) O O
) O O
, O O
and O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
ecstasy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
polydrug O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
groups O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
( O O
present O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
MDMA O B_LOCATION
) O O
and O O
past O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
users O B_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
( O O
EX O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
MDMA O B_LOCATION/B_PERSON
) O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
While O O
the O O
CAN O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
PD O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
groups O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
tended O O
to O O
record O O
greater O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
deficits O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
than O O
the O O
non O B_DISEASE/B_LOCATION
- O O
drug O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
controls O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
the O O
MDMA O B_LOCATION
and O O
EX O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
MDMA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
groups O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
recorded O O
greater O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
deficits O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
than O O
all O O
the O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
groups O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O O
ten O B_NUMBER[MEASURE]
of O O
the O O
13 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
psychometric O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measures O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Strikingly O O
, O O
despite O O
prolonged O O
abstinence O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O O
mean O B_MEASURE/B_LOCATION
, O O
4 O B_MEASURE
. O O
98 O B_MEASURE
; O O
range O B_MEASURE
, O O
4 O B_NUMBER[MEASURE]
- O O
9 O B_TIME[MEASURE]
years O I_TIME[MEASURE]
) O O
, O O
past O O
ecstasy O B_PERSON/B_ORGANIZATION
users O I_PERSON/I_ORGANIZATION
showed O O
few O B_DISEASE_ADJECTIVE[DISEASE]
signs O I_DISEASE_ADJECTIVE[DISEASE]
of O O
recovery O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

HOMER1 O B_GENE
is O O
a O O
protein O B_GENE/B_BACTERIUM[BIO]
with O O
pivotal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
glutamate O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transmission O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
has O O
been O O
related O O
to O O
the O O
pathogenesis O B_DISEASE_ADJECTIVE[DISEASE]
of O O
these O O
complications O B_DISEASE
. O O

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
investigates O O
whether O O
polymorphisms O B_GENE
in O O
the O O
HOMER1 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
associated O O
with O O
the O O
occurrence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
the O O
chronic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complications O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
levodopa O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Our O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O O
that O O
HOMER1 O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rs4704559 O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
G O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
allele O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
a O O
protective O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role O I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
development O B_DISEASE_ADJECTIVE[DISEASE]
of O O
levodopa O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adverse O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Crocin O B_BIO/B_GENE
improves O O
lipid O B_DISEASE_ADJECTIVE[DISEASE]
dysregulation O I_DISEASE_ADJECTIVE[DISEASE]
in O O
subacute O B_DISEASE/B_BIO
diazinon O I_DISEASE/I_BIO
exposure O I_DISEASE/I_BIO
through O O
ERK1 O B_GENE
/ O O
2 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathway O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
rat O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
liver O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
aim O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
to O O
evaluate O O
changes O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
regulation O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
lipid O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
metabolism O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
ERK O B_GENE
and O O
LDLr O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
liver O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
of O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposed O O
to O O
subacute O O
diazinon O B_DISEASE/B_BIO
. O O

Furthermore O O
ameliorating O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effect O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
crocin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
on O O
diazinon O B_DISEASE/B_BIO
induced O O
disturbed O B_DISEASE/B_GENE
cholesterol O I_DISEASE/I_GENE
homeostasis O I_DISEASE/I_GENE
was O O
studied O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
24 O B_PERSON
Rats O I_PERSON
were O O
divided O O
into O O
4 O B_MEASURE/B_ORGANIZATION
groups O B_MEASURE/I_ORGANIZATION
and O O
received O O
following O O
treatments O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
4 O B_DISEASE/B_LOCATION
weeks O I_DISEASE/I_LOCATION
; O O
Corn O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
oil O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
control O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
diazinon O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O O
15mg O B_MEASURE
/ O O
kg O B_MEASURE/B_PERSON
per O O
day O B_TIME[MEASURE]
, O O
orally O O
) O O
and O O
crocin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O O
12 O B_MEASURE
. O O
5 O B_MEASURE
and O O
25mg O B_MEASURE
/ O O
kg O B_MEASURE
per O O
day O B_TIME[MEASURE]
, O O
intraperitoneally O O
) O O
in O O
combination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
with O O
diazinon O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O O
15 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
) O O
. O O

Moreover O O
mRNA O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
LDLr O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
ERK1 O B_GENE
/ O O
2 O B_NUMBER[MEASURE]
as O O
well O O
as O O
protein O B_MEASURE/B_LOCATION
levels O I_MEASURE/I_LOCATION
of O O
total O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O O
activated O O
forms O B_DISEASE/B_GENE
of O O
ERK1 O B_GENE
/ O O
2 O B_NUMBER[MEASURE]
in O O
rat O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
liver O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
evaluated O O
by O O
Western O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blotting O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
quantitative O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
real O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
time O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymerase O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chain O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Overall O B_MEASURE/B_LOCATION
response O B_MEASURE/I_LOCATION
rate O B_MEASURE/I_LOCATION
( O O
ORR O B_DISEASE/B_PROTEIN[GENE]
) O O
to O O
GEM O B_LOCATION/B_ORGANIZATION
- O O
P O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
entire O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cohort O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O O
80 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
( O O
complete O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
response O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
CR O B_LOCATION/B_MEASURE
) O O
37 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
partial O B_DISEASE/B_LOCATION
response O I_DISEASE/I_LOCATION
44 O I_DISEASE/I_LOCATION
% O I_DISEASE/I_LOCATION
) O O
with O O
14 O B_MEASURE
/ O O
15 O B_MEASURE
CR O I_MEASURE
confirmed O O
as O O
a O O
metabolic O B_DISEASE/B_LOCATION
CR O I_DISEASE/I_LOCATION
on O O
PET O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
ORR O B_DISEASE/B_MEASURE
of O O
85 O B_PERSON/B_MEASURE
% O B_PERSON/I_MEASURE
in O O
the O O
20 O B_SEQUENCE[MEASURE]/B_LOCATION
second O I_SEQUENCE[MEASURE]/I_LOCATION
- O O
line O B_TIME[MEASURE]/B_LOCATION
patients O I_TIME[MEASURE]/I_LOCATION
. O O

Following O O
GEM O B_LOCATION/B_ORGANIZATION
- O O
P O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
5 O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]/B_LOCATION
progression O I_TIME[MEASURE]/I_LOCATION
- O O
free O B_DISEASE/B_MEASURE
survival O I_DISEASE/I_MEASURE
was O O
46 O B_MEASURE
% O I_MEASURE
( O O
95 O B_MEASURE
% O I_MEASURE
confidence O I_MEASURE
interval O I_MEASURE
( O O
CI O B_LOCATION/B_MEASURE
) O O
, O O
30 O B_MEASURE
- O O
62 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
and O O
5 O B_NUMBER[MEASURE]
- O O
year O B_TIME[MEASURE]
overall O I_TIME[MEASURE]
survival O I_TIME[MEASURE]
was O O
59 O B_MEASURE
% O I_MEASURE
( O O
95 O B_MEASURE/B_LOCATION
% O B_MEASURE/I_LOCATION
CI O B_MEASURE/I_LOCATION
, O O
43 O B_MEASURE
- O O
74 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
. O O

While O O
some O O
recent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
suggest O O
acute O B_DISEASE_ADJECTIVE[DISEASE]
changes O I_DISEASE_ADJECTIVE[DISEASE]
in O O
neuroendocrine O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
less O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
known O O
about O O
long O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
term O B_MEASURE/B_LOCATION
changes O B_MEASURE/I_LOCATION
in O O
HPA O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functionality O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
recreational O B_PERSON/B_BIO
users O B_PERSON/I_BIO
. O O

OBJECTIVES O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
The O O
current O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SEQUENCE[MEASURE]
to O O
explore O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
of O O
ecstasy O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
polydrug O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
use O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
on O O
psychological O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
distress O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
basal O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functioning O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
HPA O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
axis O I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
through O O
assessing O O
the O O
secretion O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
cortisol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
across O O
the O O
diurnal O B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
period O I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

On O O
day O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
all O O
participants O B_PERSON
exhibited O O
a O O
typical O B_DISEASE/B_MEASURE
cortisol O I_DISEASE/I_MEASURE
profile O I_DISEASE/I_MEASURE
, O O
though O O
light O B_PERSON/B_ORGANIZATION
users O I_PERSON/I_ORGANIZATION
had O O
significantly O O
elevated O O
levels O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pre O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
bed O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

On O O
day O B_TIME[MEASURE]/B_PERSON
2 O I_TIME[MEASURE]/I_PERSON
, O O
heavy O B_PERSON/B_ORGANIZATION
users O I_PERSON/I_ORGANIZATION
demonstrated O O
elevated O B_DISEASE_ADJECTIVE[DISEASE]
levels O I_DISEASE_ADJECTIVE[DISEASE]
upon O O
awakening O O
and O O
all O O
ecstasy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
polydrug O B_PERSON/B_ORGANIZATION
users O I_PERSON/I_ORGANIZATION
demonstrated O O
elevated O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
pre O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
- O O
bed O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
levels O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
compared O O
to O O
non O B_DISEASE
- O O
users O B_PERSON
. O O

Significant O B_DISEASE_ADJECTIVE[DISEASE]
between O O
group O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
differences O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
also O O
observed O O
in O O
afternoon O B_MEASURE/B_PERSON
cortisol O B_MEASURE/I_PERSON
levels O B_MEASURE/I_PERSON
and O O
in O O
overall O B_DISEASE
cortisol O I_DISEASE
secretion O I_DISEASE
across O O
the O O
day O B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Dysregulated O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
diurnal O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
cortisol O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
may O O
be O O
indicative O B_DISEASE/B_PERSON
of O O
inappropriate O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anticipation O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
forthcoming O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
demands O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
hypersecretion O B_TIME[MEASURE]/B_LOCATION
may O O
lead O O
to O O
the O O
increased O O
psychological O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
physical O B_DISEASE_ADJECTIVE[DISEASE]
morbidity O I_DISEASE_ADJECTIVE[DISEASE]
associated O O
with O O
heavy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
recreational O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
use O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
of O O
ecstasy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Initial O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
EEG O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
showed O O
epileptiform O B_DISEASE_ADJECTIVE[DISEASE]
discharges O I_DISEASE_ADJECTIVE[DISEASE]
in O O
three O B_NUMBER[MEASURE]/B_PERSON
patients O B_NUMBER[MEASURE]/I_PERSON
; O O
run O O
of O O
triphasic O B_DISEASE/B_MEASURE
waves O I_DISEASE/I_MEASURE
in O O
one O B_PERSON/B_NUMBER[MEASURE]
patient O I_PERSON/I_NUMBER[MEASURE]
and O O
moderate O B_DISEASE_ADJECTIVE[DISEASE]
degree O I_DISEASE_ADJECTIVE[DISEASE]
diffuse O I_DISEASE_ADJECTIVE[DISEASE]
generalized O O
slowing O B_DISEASE
. O O

CIN O B_DISEASE/B_LOCATION
was O O
defined O O
as O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
serum O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
creatinine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Cr O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
of O O
0 O B_MEASURE
. O O
5 O B_MEASURE
mg O I_MEASURE
/ O O
dl O B_TIME[MEASURE]/B_PROTEIN[GENE]
or O O
more O B_MEASURE/B_LOCATION
, O O
or O O
elevation O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
Cr O B_LOCATION/B_MEASURE
to O O
25 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
over O O
baseline O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O O

Relationships O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
CIN O B_DISEASE
and O O
possible O B_DISEASE/B_ORGANIZATION
risk O I_DISEASE/I_ORGANIZATION
factors O I_DISEASE/I_ORGANIZATION
were O O
investigated O O
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O O
CIN O B_DISEASE/B_GENE
was O O
detected O O
in O O
18 O B_MEASURE
/ O O
90 O B_MEASURE
( O O
20 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
patients O B_PERSON
. O O

CIN O B_DISEASE
developed O O
in O O
25 O B_MEASURE
. O O
5 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
patients O I_MEASURE/I_PERSON
who O O
underwent O O
chemotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
in O O
11 O B_PERSON
% O I_PERSON
patients O I_PERSON
who O O
did O O
not O O
( O O
P O B_OTHER/B_MEASURE
= O O
0 O B_MEASURE
. O O
1 O B_MEASURE
) O O
. O O

CIN O B_DISEASE
more O O
frequently O O
developed O O
in O O
patients O B_PERSON
who O O
had O O
undergone O O
CT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
within O O
45 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
after O O
the O O
last O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
chemotherapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O O
P O B_OTHER/B_LOCATION
= O O
0 O B_MEASURE
. O O
005 O B_MEASURE
) O O
; O O
it O O
was O O
also O O
an O O
independent O B_DISEASE_ADJECTIVE[DISEASE]
risk O I_DISEASE_ADJECTIVE[DISEASE]
factor O I_DISEASE_ADJECTIVE[DISEASE]
( O O
P O B_OTHER/B_LOCATION
= O O
0 O B_MEASURE
. O O
017 O B_MEASURE
) O O
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
The O O
incidence O B_MEASURE/B_DISEASE
of O O
CIN O B_DISEASE/B_LOCATION
after O O
CT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
hospitalised O B_PERSON/B_LOCATION
oncological O B_PERSON/I_LOCATION
patients O B_PERSON/I_LOCATION
was O O
20 O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

. O O
CIN O B_DISEASE
occurs O O
more O O
often O O
when O O
CT O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
is O O
performed O O
< O O
45 O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
after O O
chemotherapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

After O O
4 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
the O O
sodium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
increased O O
to O O
128 O B_MEASURE/B_PERSON
mmol O I_MEASURE/I_PERSON
/ O O
L O B_OTHER/B_TIME[MEASURE]
and O O
fluid O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
restriction O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
was O O
relaxed O O
. O O

Pre O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
operative O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
intra O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
operative O B_PERSON/B_ORGANIZATION
, O O
and O O
post O B_DISEASE
- O O
operative O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
data O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
collected O O
. O O

Hemodynamic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
histamine O B_DISEASE
release O I_DISEASE
by O O
bolus O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injection O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
0 O B_MEASURE
. O O
35 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
of O O
d O B_PROTEIN[GENE]/B_DISEASE
- O O
tubocurarine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
studied O O
in O O
24 O B_SPECIES[BIO]/B_TIME[MEASURE]
patients O I_SPECIES[BIO]/I_TIME[MEASURE]
. O O

Histamine O B_DISEASE
release O I_DISEASE
occurred O O
in O O
most O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
patients O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
, O O
the O O
highest O B_TIME[MEASURE]
level O I_TIME[MEASURE]
2 O I_TIME[MEASURE]
minutes O I_TIME[MEASURE]
after O O
d O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
tubocurarine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dosing O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Prior O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dosing O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
antagonists O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
partially O O
prevented O O
the O O
fall O B_DISEASE_ADJECTIVE[DISEASE]
in O O
systemic O B_DISEASE/B_GENE
vascular O B_DISEASE/I_GENE
resistance O B_DISEASE/I_GENE
. O O

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
demonstrate O O
that O O
the O O
hemodynamic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
associated O O
with O O
d O B_PROTEIN[GENE]/B_DISEASE
- O O
tubocurarine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dosing O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
only O O
partially O O
explained O O
by O O
histamine O B_DISEASE
release O I_DISEASE
. O O

Cholecystokinin O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
octapeptide O B_NUMBER[MEASURE]
( O O
CCK O B_LOCATION/B_ORGANIZATION
- O O
8 O B_NUMBER[MEASURE]
) O O
, O O
which O O
is O O
a O O
typical O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
brain O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
- O O
gut O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
peptide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
exerts O O
a O O
wide O B_MEASURE/B_LOCATION
range O I_MEASURE/I_LOCATION
of O O
biological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activities O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
central O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nervous O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Here O O
, O O
we O O
investigated O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
CCK O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
8 O B_NUMBER[MEASURE]
on O O
long O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
term O B_DISEASE_ADJECTIVE[DISEASE]
potentiation O I_DISEASE_ADJECTIVE[DISEASE]
( O O
LTP O B_DISEASE
) O O
in O O
the O O
lateral O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
perforant O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
path O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( O O
LPP O B_LOCATION/B_PROTEIN[GENE]
) O O
- O O
granule O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
synapse O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
of O O
rat O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
dentate O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
gyrus O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
DG O B_PROTEIN[GENE]/B_LOCATION
) O O
in O O
acute O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
saline O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
morphine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
treated O O
rats O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

Population O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
spikes O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
PS O B_LOCATION/B_PROTEIN[GENE]
) O O
, O O
which O O
were O O
evoked O O
by O O
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
LPP O B_DISEASE/B_PROTEIN[GENE]
, O O
were O O
recorded O O
in O O
the O O
DG O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
region O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Acute O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
morphine O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
30mg O B_MEASURE/B_LOCATION
/ O O
kg O B_MEASURE
, O O
s O O
. O O
c O B_DISEASE/B_LOCATION
. O O
) O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
significantly O O
attenuated O O
hippocampal O B_LOCATION/B_DISEASE
LTP O I_LOCATION/I_DISEASE
and O O
CCK O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
8 O B_NUMBER[MEASURE]
( O O
1ug O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O O
i O O
. O O
c O O
. O O
v O O
. O O
) O O
restored O O
the O O
amplitude O B_MEASURE
of O O
PS O B_DISEASE
that O O
was O O
attenuated O O
by O O
morphine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
injection O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Furthermore O O
, O O
microinjection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
CCK O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
8 O B_NUMBER[MEASURE]
( O O
0 O B_MEASURE/B_LOCATION
. O O
1 O B_MEASURE
and O O
1ug O B_MEASURE/B_LOCATION
, O O
i O O
. O O
c O O
. O O
v O O
. O O
) O O
also O O
significantly O O
augmented O O
hippocampal O B_DISEASE/B_GENE
LTP O I_DISEASE/I_GENE
in O O
saline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
treated O O
( O O
1ml O B_MEASURE
/ O O
kg O B_MEASURE
, O O
s O O
. O O
c O B_DISEASE/B_PROTEIN[GENE]
. O O
) O O
rats O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
aim O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
to O O
investigate O O
and O O
compare O O
the O O
protective O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
isotonic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
sodium O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
chloride O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
with O O
sodium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
bicarbonate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
infusion O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
isotonic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sodium O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
chloride O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
infusion O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O O
diltiazem O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
calcium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
channel O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blocker O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
in O O
preventing O O
CIN O B_DISEASE
. O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
There O O
was O O
no O O
significant O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
difference O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
isotonic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloride O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
sodium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bicarbonate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
isotonic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sodium O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
chloride O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O O
diltiazem O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
application O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
prevention O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
CIN O B_DISEASE
. O O

This O O
supports O O
ongoing O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
concerns O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
about O O
intensive O B_DISEASE
MTX O I_DISEASE
exposure O I_DISEASE
as O O
a O O
major O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
contributor O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O O
CNS O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
late O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Testing O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
autoantibodies O B_DISEASE
was O O
also O O
negative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Lindane O O
( O O
gamma O O
- O O
hexachlorocyclohexane O O
) O O
is O O
an O O
organochlorine O O
insecticide O O
with O O
known O O
neurotoxic B B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O O
. O O

Its O O
mechanism O B_LOCATION
of O O
action O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
is O O
not O O
well O O
understood O O
although O O
it O O
has O O
been O O
proposed O O
that O O
lindane O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acts O O
as O O
a O O
non O B_DISEASE
- O O
competitive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antagonist O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
at O O
the O O
gamma O B_PROTEIN[GENE]
- O O
aminobutyric O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
GABA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
- O O
A O B_PROTEIN[GENE]/B_LOCATION
receptor O I_PROTEIN[GENE]/I_LOCATION
. O O

Following O O
successful O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
completion O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
VCUG O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
a O O
60 O B_MEASURE
- O O
min O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
recovery O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
period O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O O
the O O
patient O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
' O O
s O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
level O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
consciousness O B_DISEASE
and O O
vital O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
signs O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
returned O O
to O O
presedation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Upon O O
leaving O O
the O O
sedation O B_LOCATION
area O I_LOCATION
, O O
the O O
patient O B_PERSON/B_LOCATION
collapsed O O
, O O
with O O
no O O
apparent O B_DISEASE
inciting O I_DISEASE
event O I_DISEASE
. O O

The O O
patient O B_PERSON
quickly O O
regained O O
consciousness O B_DISEASE/B_MEASURE
and O O
no O O
injury O B_DISEASE
occurred O O
. O O

Systolic O B_MEASURE/B_DISEASE
blood O I_MEASURE/I_DISEASE
pressure O I_MEASURE/I_DISEASE
( O O
SBP O B_DISEASE/B_PROTEIN[GENE]
) O O
was O O
measured O O
using O O
tail O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
- O O
cuff O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
significantly O O
increased O O
SBP O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
plasma O B_DISEASE/B_PROTEIN[GENE]
H2O2 O B_DISEASE/I_PROTEIN[GENE]
level O B_DISEASE/I_PROTEIN[GENE]
and O O
decreased O O
thymus O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
body O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
weights O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Sleep O B_DISEASE
plays O O
an O O
important O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
role O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
consolidation O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
integration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
memory O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
process O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
called O O
overnight O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
memory O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
consolidation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
extend O O
past O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
by O O
examining O O
overnight O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
memory O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
consolidation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
among O O
regular O B_DISEASE/B_PERSON
ecstasy O I_DISEASE/I_PERSON
users O I_DISEASE/I_PERSON
( O O
n O B_MEASURE/B_LOCATION
= O O
12 O B_MEASURE
) O O
and O O
drug O B_PERSON
naive O I_PERSON
healthy O I_PERSON
controls O I_PERSON
( O O
n O B_OTHER/B_MEASURE
= O O
26 O B_MEASURE
) O O
. O O

On O O
the O O
contrary O B_MEASURE/B_BIO
, O O
though O O
not O O
clinically O O
apparent O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
pethidine O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potentially O O
causes O O
inhibitory O B_DISEASE_ADJECTIVE[DISEASE]
impacts O I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
CNS O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
impairs O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
cerebellar O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
oculomotor O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
function O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
short O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
term O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

This O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
rapidly O O
absorbed O O
from O O
the O O
gastrointestinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tract O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
most O B_DISEASE/B_MEASURE
of O O
it O O
is O O
excreted O O
from O O
the O O
kidney O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O O

All O O
- O O
trans O O
retinoic O O
acid O O
( O O
ATRA O O
) O O
, O O
a O O
component O O
of O O
standard O O
therapy O O
for O O
acute B B_DISEASE
promyelocytic I I_DISEASE
leukemia I I_DISEASE
( O O
APL B B_LOCATION/B_ORGANIZATION
) O O
, O O
is O O
associated O O
with O O
potentially O O
serious O O
but O O
treatable O O
adverse O O
effects O O
involving O O
numerous O O
organ O O
systems O O
, O O
including O O
rare O O
skeletal O O
muscle O O
involvement O O
. O O

She O O
tolerated O O
therapy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
well O O
, O O
entered O O
a O O
complete O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
remission O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
recovered O O
her O O
renal O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
week O B_TIME[MEASURE]
after O O
this O O
second O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
cycle O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
she O O
noted O O
numbness O B_DISEASE
in O O
her O O
lower O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
extremities O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
magnetic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resonance O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imaging O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
MRI O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
of O O
her O O
spine O B_BODY_PART_OR_ORGAN_COMPONENT
demonstrated O O
changes O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
C2 O B_PROTEIN[GENE]
to O O
C6 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consistent O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
subacute O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
combined O O
degeneration O B_DISEASE
. O O

Nelarabine O B_DISEASE/B_PERSON
was O O
felt O O
to O O
be O O
the O O
cause O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
her O O
symptoms O B_DISEASE
. O O

After O O
withdraw O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
valproate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
patients O B_DISEASE
' O I_DISEASE
symptoms O I_DISEASE
resolved O O
within O O
24 O B_MEASURE
h O O
. O O

Despite O O
immediate O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
intravenous O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
antimicrobial O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
he O O
succumbed O O
23 O B_MEASURE/B_LOCATION
h O O
after O O
the O O
onset O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Significant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increases O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
peak O B_BODY_PART_OR_ORGAN_COMPONENT
myocardial O I_BODY_PART_OR_ORGAN_COMPONENT
contrast O I_BODY_PART_OR_ORGAN_COMPONENT
enhancement O I_BODY_PART_OR_ORGAN_COMPONENT
and O O
serological O B_DISEASE
cardiac O I_DISEASE
troponin O I_DISEASE
I O I_DISEASE
( O O
cTnI O B_LOCATION/B_PROTEIN[GENE]
) O O
emerged O O
after O O
eight O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
doses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
importantly O O
preceding O O
the O O
LVEF O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
decline O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O O
< O O
50 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
. O O

Myocardial O B_DISEASE
contrast O I_DISEASE
enhancement O I_DISEASE
and O O
elevations O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
cTnI O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
occurred O O
later O O
. O O

If O O
untreated O O
, O O
these O O
patients O O
can O O
develop O O
a O O
secondary O O
glaucoma B B_DISEASE
that O O
resembles O O
primary B B_DISEASE/B_GENE
open I I_DISEASE/I_GENE
- I I_DISEASE/I_GENE
angle I I_DISEASE/I_GENE
glaucoma I I_DISEASE/I_GENE
( O O
POAG B B_LOCATION
) O O
. O O

Similar O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
patients O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
withdrawal O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduced O O
elevated O O
IOP O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
ER O B_DISEASE
stress O I_DISEASE
in O O
this O O
animal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

On O O
the O O
test O B_SEQUENCE[MEASURE]
day O I_SEQUENCE[MEASURE]
( O O
day O B_TIME[MEASURE]
10 O I_TIME[MEASURE]
) O O
, O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
subjected O O
to O O
the O O
thermal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
sensitivity O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
test O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
the O O
acetic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
writhing O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
both O O
agents O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
associated O O
with O O
significant O B_DISEASE
hemodynamic O I_DISEASE
side O I_DISEASE
effects O I_DISEASE
. O O

The O O
primary O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
objective O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
to O O
compare O O
the O O
prevalence O B_MEASURE
of O O
severe O B_DISEASE
hemodynamic O I_DISEASE
effects O I_DISEASE
in O O
neurocritical O B_PERSON
care O I_PERSON
patients O I_PERSON
receiving O O
dexmedetomidine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
propofol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

No O O
difference O B_MEASURE
in O O
the O O
primary O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
composite O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcome O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
both O O
the O O
unmatched O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
30 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
vs O I_MEASURE/I_LOCATION
30 O I_MEASURE/I_LOCATION
% O I_MEASURE/I_LOCATION
, O O
p O O
= O O
0 O B_MEASURE
. O O
94 O B_MEASURE
) O O
or O O
matched O O
cohorts O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
28 O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
% O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
vs O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
34 O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
% O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
p O O
= O O
0 O B_MEASURE
. O O
35 O B_MEASURE
) O O
could O O
be O O
found O O
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
hydroxytyrosol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
improve O O
the O O
mitochondrial O B_DISEASE
electron O I_DISEASE
transport O I_DISEASE
chain O I_DISEASE
. O O

Haemodynamic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
improvement O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
along O O
with O O
complete O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
recovery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
mental O B_DISEASE
status O I_DISEASE
, O O
occurred O O
after O O
48 O B_MEASURE
h O O
. O O

A O O
thyroid O B_SEQUENCE[MEASURE]/B_PERSON
ultrasound O I_SEQUENCE[MEASURE]/I_PERSON
showed O O
diffuse O B_DISEASE
heterogeneity O I_DISEASE
. O O

PURPOSE O O
: O O
The O O
case O O
of O O
an O O
oncology O O
patient O O
who O O
developed O O
heparin O O
- O O
induced O O
thrombocytopenia B B_DISEASE
with O O
thrombosis B B_DISEASE
( O O
HITT B B_LOCATION/B_ORGANIZATION
) O O
and O O
was O O
treated O O
with O O
argatroban O O
plus O O
catheter O O
- O O
directed O O
thrombolysis B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
CDT O O
) O O
with O O
alteplase O O
is O O
presented O O
. O O

A O O
second O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
percutaneous O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mechanical O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
thrombectomy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
performed O O
six O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
later O O
and O O
resulted O O
in O O
partial O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
revascularization O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
SVC O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
central O B_DISEASE/B_LOCATION
veins O I_DISEASE/I_LOCATION
. O O

Postthrombectomy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
continuous O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
CDT O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
with O O
alteplase O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
commenced O O
while O O
argatroban O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
withheld O O
, O O
and O O
complete O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
patency O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
SVC O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
central O B_DISEASE/B_LOCATION
veins O I_DISEASE/I_LOCATION
was O O
achieved O O
after O O
three O B_TIME[MEASURE]/B_ENT
days O I_TIME[MEASURE]/I_ENT
of O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Statistical O O
analysis O O
was O O
carried O O
out O O
using O O
Kruskal O O
- O O
Wallis O O
test O O
for O O
hyper B B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
locomotion O O
, O O
and O O
one O O
- O O
way O O
ANOVA O O
for O O
climbing O O
and O O
catalepsy B B_SPORT[ENT]/B_LOCATION
tests O O
. O O

Field O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
potential O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
duration O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
FPD O B_DISEASE/B_LOCATION
) O O
in O O
human O B_PERSON/B_SPECIES[BIO]
- O O
induced O B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
pluripotent O I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
stem O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
- O O
derived O O
cardiomyocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
( O O
hiPS O B_BIO/B_LOCATION
- O O
CMs O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
, O O
which O O
can O O
express O O
QT O B_DISEASE
interval O I_DISEASE
in O O
an O O
electrocardiogram O B_BODY_PART_OR_ORGAN_COMPONENT/B_TIME[MEASURE]
, O O
is O O
reported O O
to O O
be O O
a O O
useful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
tool O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
predict O O
K O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
+ O B_PROTEIN[GENE]/B_DISEASE
) O O
channel O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
Ca O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
2 O B_MEASURE/B_PROTEIN[GENE]
+ O I_MEASURE/I_PROTEIN[GENE]
) O O
channel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocker O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
QT O B_DISEASE
interval O I_DISEASE
. O O

Also O O
, O O
the O O
multichannel O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blockers O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Amiodarone O I_MEASURE
, O O
Paroxetine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Terfenadine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Citalopram O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prolonged O O
FPDc O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
concentration O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
dependent O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
manner O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

hiPS O B_DISEASE/B_PROTEIN[GENE]
- O O
CMs O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
MEA O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
FPDc O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O O
predict O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
candidates O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
QT O B_DISEASE/B_GENE
interval O I_DISEASE/I_GENE
. O O

This O O
study O O
also O O
shows O O
that O O
this O O
assay O O
can O O
help O O
detect O O
EAD O O
for O O
drugs O O
with O O
TdP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
potential O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
AND O O
RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
: O O
Two O B_NUMBER[MEASURE]
- O O
week O B_TIME[MEASURE]
- O O
old O B_MEASURE/B_LOCATION
MHC O I_MEASURE/I_LOCATION
- O O
CB7 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mice O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
which O O
express O O
dominant O O
- O O
interfering O O
p53 O B_GENE
in O O
cardiomyocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
) O O
and O O
their O O
non O B_DISEASE/B_GENE
- O O
transgenic O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
NON O B_GENE/B_DISEASE
- O O
TXG O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
littermates O B_PERSON/B_ORGANIZATION
received O O
weekly O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DOX O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injections O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
5 O B_TIME[MEASURE]/B_DISEASE
weeks O B_TIME[MEASURE]/I_DISEASE
( O O
25 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
cumulative O I_MEASURE
dose O I_MEASURE
) O O
. O O

One O B_TIME[MEASURE]/B_LOCATION
week O I_TIME[MEASURE]/I_LOCATION
after O O
the O O
last O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
DOX O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O O
acute O B_MEASURE
stage O I_MEASURE
) O O
, O O
MHC O B_PROTEIN[GENE]/B_DISEASE
- O O
CB7 O B_MEASURE/B_PROTEIN[GENE]
mice O I_MEASURE/I_PROTEIN[GENE]
exhibited O O
improved O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
cardiac O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
function O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
lower O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cardiomyocyte O B_DISEASE/B_GENE
apoptosis O I_DISEASE/I_GENE
when O O
compared O O
with O O
the O O
NON O B_GENE/B_DISEASE
- O O
TXG O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
mice O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Surprisingly O O
, O O
by O O
13 O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
following O O
the O O
last O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
DOX O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O O
late O B_TIME[MEASURE]
stage O I_TIME[MEASURE]
) O O
, O O
MHC O B_PROTEIN[GENE]/B_DISEASE
- O O
CB7 O B_MEASURE/B_GENE
exhibited O O
a O O
progressive O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decrease O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
cardiac O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
higher O B_DISEASE_ADJECTIVE[DISEASE]
rates O I_DISEASE_ADJECTIVE[DISEASE]
of O O
cardiomyocyte O B_DISEASE/B_GENE
apoptosis O I_DISEASE/I_GENE
when O O
compared O O
with O O
NON O B_GENE/B_DISEASE
- O O
TXG O B_LOCATION/B_ORGANIZATION
mice O I_LOCATION/I_ORGANIZATION
. O O

p53 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibition O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blocked O O
transient O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DOX O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
STAT3 O B_DISEASE/B_GENE
activation O I_DISEASE/I_GENE
in O O
MHC O B_PROTEIN[GENE]/B_DISEASE
- O O
CB7 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mice O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
was O O
associated O O
with O O
enhanced O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induction O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
DNA O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
repair O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Ku70 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
Ku80 O B_GENE
. O O

Mice O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
cardiomyocyte O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
- O O
restricted O O
deletion O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
STAT3 O B_GENE
exhibited O O
worse O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiac O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
higher O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cardiomyocyte O B_DISEASE/B_GENE
apoptosis O B_DISEASE/I_GENE
, O O
and O O
a O O
greater O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
induction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
Ku70 O B_GENE
and O O
Ku80 O B_GENE
in O O
response O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
DOX O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
during O O
the O O
acute O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stage O B_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O O
compared O O
with O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
animals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

CONCLUSION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
support O O
a O O
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
wherein O O
a O O
p53 O B_GENE
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cardioprotective O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pathway O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
mediated O O
via O O
STAT3 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activation O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
mitigates O O
DOX O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
myocardial O B_DISEASE/B_GENE
stress O I_DISEASE/I_GENE
during O O
drug O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
delivery O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Metronidazole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O O
produce O O
neurological O B_DISEASE
complications O I_DISEASE
although O O
it O O
is O O
not O O
a O O
common O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scenario O I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Magnetic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
resonance O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
imaging O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
MRI O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
brain O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
showed O O
abnormal O B_DISEASE
signal O I_DISEASE
intensity O I_DISEASE
involving O O
both O O
dentate O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nuclei O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
cerebellum O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
splenium O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
of O O
corpus O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
callosum O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

To O O
confirm O O
the O O
pro O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
apoptotic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
we O O
performed O O
flow O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cytometric O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
detection O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
cardiac O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
histology O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
transmission O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
electron O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
microscopy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
terminal O B_GENE
deoxynucleotidyl O I_GENE
transferase O I_GENE
- O O
mediated O O
dUTP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
biotin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
nick O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
end O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
labeling O I_TIME[MEASURE]
assay O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

The O O
expression O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Ca O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
2 O B_MEASURE/B_PROTEIN[GENE]
+ O I_MEASURE/I_PROTEIN[GENE]
) O O
handling O O
proteins O B_GENE/B_DISEASE
demonstrated O O
that O O
aconitine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
promoted O O
Ca O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
2 O B_MEASURE/B_PROTEIN[GENE]
+ O I_MEASURE/I_PROTEIN[GENE]
) O O
overload O B_DISEASE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
through O O
the O O
expression O B_DISEASE_ADJECTIVE[DISEASE]
regulation O I_DISEASE_ADJECTIVE[DISEASE]
of O O
Ca O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
2 O B_MEASURE/B_PROTEIN[GENE]
+ O I_MEASURE/I_PROTEIN[GENE]
) O O
handling O O
proteins O B_GENE/B_DISEASE
. O O

The O O
expression O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
apoptosis O B_DISEASE/B_GENE
- O O
related O O
proteins O B_GENE/B_DISEASE
revealed O O
that O O
pro O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
apoptotic O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
upregulated O O
, O O
and O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
apoptotic O B_GENE/B_DISEASE
protein O I_GENE/I_DISEASE
BCL O I_GENE/I_DISEASE
- O O
2 O B_MEASURE/B_PROTEIN[GENE]
expression O I_MEASURE/I_PROTEIN[GENE]
was O O
downregulated O O
. O O

Furthermore O O
, O O
increased O O
phosphorylation O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_MEASURE
of O O
MAPK O B_GENE
family O I_GENE
members O I_GENE
, O O
especially O O
the O O
P O B_GENE
- O O
P38 O B_GENE
/ O O
P38 O B_GENE
ratio O I_GENE
was O O
found O O
in O O
cardiac O B_DISEASE
tissues O I_DISEASE
. O O

Male O B_PERSON/B_ORGANIZATION
Wistar O I_PERSON/I_ORGANIZATION
rats O I_PERSON/I_ORGANIZATION
were O O
randomly O O
assigned O O
to O O
one O B_NUMBER[MEASURE]/B_LOCATION
of O O
5 O B_NUMBER[MEASURE]/B_PERSON
groups O I_NUMBER[MEASURE]/I_PERSON
( O O
n O B_OTHER/B_MEASURE
= O O
6 O B_MEASURE
) O O
: O O
normal O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
groups O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
were O O
injected O O
isoproterenol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
after O O
chronic O B_DISEASE/B_MEASURE
pre O I_DISEASE/I_MEASURE
- O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
0 O B_MEASURE
, O O
25 O B_MEASURE
, O O
50 O B_MEASURE
, O O
or O O
100mg O B_MEASURE
/ O O
kg O B_MEASURE
of O O
metformin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
twice O O
daily O O
for O O
14 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
literature O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
related O O
to O O
antithyroid O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
side O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
mechanisms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
their O O
occurrence O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
are O O
reviewed O O
and O O
the O O
efficacy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
complications O B_DISEASE
of O O
thyroidectomy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
radioiodine O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
compared O O
to O O
those O O
of O O
antithyroid O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
drugs O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Tetrabenazine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O O
be O O
administered O O
very O O
carefully O O
in O O
combination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
with O O
other O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
neuroleptic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
particularly O O
in O O
patients O B_PERSON/B_LOCATION
with O O
a O O
worsening O O
general O B_DISEASE
condition O I_DISEASE
. O O

The O O
heart O B_DISEASE
rate O I_DISEASE
ameliorated O O
first O O
with O O
a O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
dose O B_MEASURE/B_LOCATION
of O O
metoprolol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
: O O
STZ O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
administration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
and O O
castration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
markedly O O
decreased O O
both O O
STL1 O B_GENE/B_DISEASE
( O O
the O O
short O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
memory O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
) O O
and O O
STL2 O B_GENE
( O O
the O O
long O B_DISEASE/B_MEASURE
memory O I_DISEASE/I_MEASURE
) O O
in O O
passive O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
avoidance O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tests O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
GABA O B_DISEASE/B_GENE
content O B_DISEASE/I_GENE
of O O
mice O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
hippocampus O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
treated O O
with O O
GFC75 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plus O O
P400 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
showed O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]
of O O
46 O B_MEASURE
. O O
90 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
when O O
compared O O
with O O
seized O O
mice O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Hippocampus O B_BIO/B_PERSON
mice O I_BIO/I_PERSON
treated O O
with O O
GFC75 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plus O O
P400 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
showed O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
AChE O B_DISEASE/B_MEASURE
activity O I_DISEASE/I_MEASURE
( O O
63 O B_MEASURE
. O O
30 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
when O O
compared O O
with O O
seized O O
mice O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
our O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
GFC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
may O O
influence O O
in O O
epileptogenesis O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
promote O O
anticonvulsant O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
actions O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
pilocarpine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
by O O
modulating O O
the O O
GABA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
glutamate O O
contents O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
of O O
AChE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activity O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
seized O O
mice O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
hippocampus O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

This O O
compound O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
useful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
produce O O
neuronal O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protection O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
it O O
can O O
be O O
considered O O
as O O
an O O
anticonvulsant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agent O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
increases O O
mortality O B_DISEASE
, O O
hospital O B_MEASURE/B_PERSON
length O I_MEASURE/I_PERSON
of O O
stay O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
, O O
and O O
costs O B_DISEASE
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O O
This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
carried O O
out O O
as O O
a O O
prospective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
non O B_DISEASE
- O O
interventional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
observational O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Consolidation O O
therapy O O
for O O
patients O O
with O O
multiple B B_DISEASE
myeloma I I_DISEASE
( O O
MM B B_TIME[MEASURE]/B_LOCATION
) O O
has O O
been O O
widely O O
adopted O O
to O O
improve O O
treatment O O
response O O
following O O
autologous O O
stem O O
cell O O
transplantation O O
. O O

The O O
VTD O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regimen O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
safe O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
effective O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O O
a O O
consolidation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
in O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
MM O B_DISEASE/B_LOCATION
in O O
Japanese O B_PERSON/B_LOCATION
population O I_PERSON/I_LOCATION
. O O

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aimed O O
to O O
identify O O
the O O
molecular O B_DISEASE_ADJECTIVE[DISEASE]
pathways O I_DISEASE_ADJECTIVE[DISEASE]
and O O
putative O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
biomarkers O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
CsA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
to O O
- O O
SRL O B_DISEASE
conversion O I_DISEASE
in O O
a O O
rat O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

Four O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
animal O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
( O O
n O B_OTHER/B_MEASURE
= O O
6 O B_MEASURE
) O O
were O O
tested O O
during O O
9 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
weeks O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
: O O
control O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
CsA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
SRL O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
conversion O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CsA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
3 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weeks O B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
followed O O
by O O
SRL O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
6 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
weeks O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
) O O
. O O

PKC O B_GENE/B_LOCATION
- O O
alpha O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
null O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
mice O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
( O O
PKCa O B_LOCATION/B_PERSON
KO O I_LOCATION/I_PERSON
) O O
and O O
strain O B_DISEASE/B_BIO
- O O
matched O O
wild O B_BIO/B_GENE
type O I_BIO/I_GENE
( O O
WT O B_PROTEIN[GENE]/B_LOCATION
) O O
controls O B_PERSON/B_BIO
were O O
treated O O
with O O
lithium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O O
0 O B_NUMBER[MEASURE]/B_LOCATION
, O O
3 O B_NUMBER[MEASURE]
or O O
5 O B_MEASURE/B_ENT
days O I_MEASURE/I_ENT
. O O

Is O O
Dysguesia B B_LOCATION/B_PERSON
Going O O
to O O
be O O
a O O
Rare O O
or O O
a O O
Common O O
Side O O
- O O
effect O O
of O O
Amlodipine O O
? O O

Clarithromycin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
the O O
most O O
documented O B_DISEASE_ADJECTIVE[DISEASE]
cytochrome O I_DISEASE_ADJECTIVE[DISEASE]
P450 O I_DISEASE_ADJECTIVE[DISEASE]
3A4 O I_DISEASE_ADJECTIVE[DISEASE]
( O O
CYP3A4 O B_GENE
) O O
inhibitor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
cause O O
an O O
adverse O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interaction O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
simvastatin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Here O O
, O O
we O O
report O O
a O O
case O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
prolonged O B_DISEASE
neuromuscular O I_DISEASE
block O I_DISEASE
after O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
suxamethonium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
leading O O
to O O
the O O
discovery O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O O
a O O
novel O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
BCHE O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
variant O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
c O B_DISEASE/B_GENE
. O O
695T O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
> O O
A O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
p O B_PROTEIN[GENE]/B_LOCATION
. O O
Val204Asp O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Inhibition O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
kinetic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
molecular O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dynamics O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
undertaken O O
to O O
understand O O
how O O
this O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
disrupts O O
the O O
catalytic O B_LOCATION/B_ENZYME[GENE]
triad O B_LOCATION/I_ENZYME[GENE]
and O O
determines O O
a O O
" O O
silent O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
" O O
phenotype O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Low O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
patient O B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
plasma O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
butyrylcholinesterase O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
butyrylthiocholine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
BTC O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
benzoylcholine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
values O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
dibucaine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
fluoride O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
numbers O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fit O O
with O O
heterozygous O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
atypical O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
silent O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genotype O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Molecular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
dynamic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
MD O B_DISEASE/B_PROTEIN[GENE]
) O O
simulations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
that O O
the O O
overall O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
effect O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
mutation O B_DISEASE/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
p O B_DISEASE/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
. O O
Val204Asp O B_MEASURE/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
is O O
disruption O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
hydrogen O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
bonding O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
between O O
Gln223 O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Glu441 O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
leading O O
Ser198 O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
and O O
His438 O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
move O O
away O O
from O O
each O O
other O B_NUMBER[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
subsequent O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disruption O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
catalytic O B_LOCATION/B_MEASURE
triad O I_LOCATION/I_MEASURE
functionality O I_LOCATION/I_MEASURE
regardless O O
of O O
the O O
type O B_MEASURE/B_DISEASE
of O O
substrate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

MD O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
showed O O
that O O
the O O
enzyme O B_MEASURE
volume O I_MEASURE
is O O
increased O O
, O O
suggesting O O
a O O
pre O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
denaturation O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
state O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
The O O
sensory O B_MEASURE
action O I_MEASURE
potential O I_MEASURE
amplitude O I_MEASURE
of O O
the O O
right O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
lateral O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
antebrachial O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
cutaneous O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
nerve O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
( O O
LACN O B_DISEASE/B_PROTEIN[GENE]
) O O
( O O
6 O B_MEASURE
. O O
2 O B_MEASURE
uV O I_MEASURE
) O O
was O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
that O O
of O O
the O O
left O B_BODY_PART_OR_ORGAN_COMPONENT
( O O
13 O B_MEASURE
. O O
1 O B_MEASURE/B_PERSON
uV O I_MEASURE/I_PERSON
) O O
. O O

She O O
was O O
diagnosed O O
with O O
right O B_DISEASE/B_LOCATION
LACNP O I_DISEASE/I_LOCATION
( O O
mainly O O
axonal O B_DISEASE_ADJECTIVE[DISEASE]
involvement O I_DISEASE_ADJECTIVE[DISEASE]
) O O
on O O
the O O
basis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
clinical O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
manifestation O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
electrodiagnostic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
findings O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Her O O
symptoms O B_DISEASE
improved O O
through O O
physical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
but O O
persisted O O
to O O
some O O
degree O B_TIME[MEASURE]/B_LOCATION
. O O

An O O
electrodiagnostic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
including O O
a O O
nerve O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
conduction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
LACN O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O O
was O O
helpful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O O
diagnose O O
right O B_DISEASE
LACNP O I_DISEASE
and O O
to O O
find O O
the O O
passage O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O O
the O O
LACN O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
on O O
the O O
lateral O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
epicondyle O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Oxidative O B_DISEASE
stress O I_DISEASE
was O O
determined O O
by O O
measuring O O
the O O
oxidation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
lipids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
proteins O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
diminution O B_DISEASE_ADJECTIVE[DISEASE]
in O O
renal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Nrf2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
levels O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Maleate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
cell O B_DISEASE_ADJECTIVE[DISEASE]
damage O I_DISEASE_ADJECTIVE[DISEASE]
and O O
reactive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxygen O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
species O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ROS O B_GENE
) O O
production O B_ENT/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
LLC O B_DISEASE/B_PROTEIN[GENE]
- O O
PK1 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
cells O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
in O O
culture O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
protection O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
associated O O
to O O
the O O
prevention O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
oxidative O B_DISEASE_ADJECTIVE[DISEASE]
stress O I_DISEASE_ADJECTIVE[DISEASE]
and O O
preservation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
mitochondrial O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oxygen O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consumption O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
activity O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
respiratory O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
complex O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
I O O
, O O
and O O
the O O
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
protection O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
was O O
associated O O
to O O
the O O
prevention O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
ROS O B_DISEASE/B_GENE
production O I_DISEASE/I_GENE
. O O

Renal O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
angiotensin O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
AT2R O B_GENE/B_LOCATION
) O O
gene O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
adult O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
offspring O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
was O O
reduced O O
by O O
PCE O B_DISEASE
, O O
whereas O O
the O O
renal O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
angiotensin O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1a O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
AT1aR O B_PROTEIN[GENE]/B_LOCATION
) O O
/ O O
AT2R O B_GENE
expression O I_GENE
ratio O I_GENE
was O O
increased O O
. O O

The O O
fetal O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
kidneys O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
the O O
PCE O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
displayed O O
an O O
enlarged O O
Bowman O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
' O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
s O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
space O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
a O O
shrunken O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glomerular O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tuft O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
accompanied O O
by O O
a O O
reduced O O
cortex O B_MEASURE/B_DISEASE
width O I_MEASURE/I_DISEASE
and O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
nephrogenic O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
zone O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
cortical O B_MEASURE/B_LOCATION
zone O B_MEASURE/I_LOCATION
ratio O B_MEASURE/I_LOCATION
. O O

Observation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
electronic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscope O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
revealed O O
structural O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
damage O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
podocytes O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
; O O
the O O
reduced O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
expression O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
level O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
podocyte O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
marker O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
nephrin O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
podocin O B_GENE/B_BACTERIUM[BIO]
, O O
was O O
also O O
detected O O
by O O
q O O
- O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Ionizing O O
radiation O O
is O O
capable O O
of O O
inducing O O
the O O
requisite O O
CML B B_DISEASE
- O O
associated O O
t O O
( O O
9 O O
: O O
22 O O
) O O
translocation O O
( O O
Philadelphia B B_LOCATION/B_ORGANIZATION
chromosome I I_LOCATION/I_ORGANIZATION
) O O
in O O
appropriate O O
cells O O
in O O
vitro O O
but O O
, O O
thus O O
far O O
, O O
chemicals O O
have O O
not O O
shown O O
this O O
capacity O O
. O O

We O O
have O O
proposed O O
that O O
1 O B_NUMBER[MEASURE]
, O O
3 O B_NUMBER[MEASURE]
- O O
butadiene O B_DISEASE/B_PROTEIN[GENE]
metabolites O B_DISEASE/I_PROTEIN[GENE]
be O O
so O O
tested O O
as O O
a O O
reality O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
check O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
on O O
the O O
epidemiological O B_LOCATION/B_PERSON
reports O I_LOCATION/I_PERSON
. O O

In O O
order O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
conduct O O
reliable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
testing O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
this O O
regard O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
it O O
is O O
essential O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
a O O
positive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
induction O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
be O O
available O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
described O O
here O O
demonstrate O O
that O O
this O O
agent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
does O O
in O O
fact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
induce O O
pathogenic O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
t O O
( O O
9 O B_MEASURE
: O O
22 O B_MEASURE
) O O
translocations O B_DISEASE/B_GENE
in O O
a O O
human O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
myeloid O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
cell O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
line O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
but O O
does O O
so O O
at O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
frequencies O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

However O O
, O O
trends O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
both O O
lifetime O B_TIME[MEASURE]
and O O
intensity O B_MEASURE/B_DISEASE
- O O
weighted O O
lifetime O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
metolachor O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
statistically O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
with O O
an O O
unexposed O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reference O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
group O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Mechanisms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Underlying O O
Latent O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Disease O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Risk O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Associated O O
with O O
Early O B_MEASURE/B_LOCATION
- O O
Life O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
Arsenic O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
Exposure O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
: O O
Current O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Research O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Trends O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O O
Scientific O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Gaps O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

An O O
80 O O
year O O
old O O
diabetic B B_PERSON/B_LOCATION
male O O
with O O
evidence O O
of O O
peripheral B B_DISEASE
and I I_DISEASE
autonomic I I_DISEASE
neuropathy I I_DISEASE
was O O
admitted O O
with O O
chest B B_DISEASE
pain I I_DISEASE
. O O

The O O
feasibility O O
of O O
using O O
labetalol O O
, O O
an O O
alpha O O
- O O
and O O
beta O O
- O O
adrenergic O O
blocking O O
agent O O
, O O
as O O
a O O
hypotensive B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agent O O
in O O
combination O O
with O O
inhalation O O
anaesthetics O O
( O O
halothane O O
, O O
enflurane O O
or O O
isoflurane O O
) O O
was O O
studied O O
in O O
23 O O
adult O O
patients O O
undergoing O O
middle O O
- O O
ear O O
surgery O O
. O O

The O O
mean O B_DISEASE/B_GENE
arterial O I_DISEASE/I_GENE
pressure O I_DISEASE/I_GENE
was O O
decreased O O
from O O
86 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
5 O B_MEASURE
( O O
s O B_DISEASE/B_MEASURE
. O O
e O O
. O O
mean O B_MEASURE
) O O
mmHg O B_MEASURE/B_LOCATION
to O O
52 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
1 O B_MEASURE
mmHg O I_MEASURE
( O O
11 O B_MEASURE
. O O
5 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_NUMBER[MEASURE]
. O O
7 O B_MEASURE
to O O
6 O B_MEASURE
. O O
9 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
1 O B_MEASURE
kPa O I_MEASURE
) O O
for O O
98 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
10 O B_TIME[MEASURE]/B_PERSON
min O I_TIME[MEASURE]/I_PERSON
in O O
the O O
halothane O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
H O B_OTHER/B_PROTEIN[GENE]
) O O
group O B_ORGANIZATION/B_LOCATION
, O O
from O O
79 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
5 O B_MEASURE
to O O
53 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
1 O B_MEASURE
mmHg O I_MEASURE
( O O
10 O B_MEASURE
. O O
5 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_NUMBER[MEASURE]
. O O
7 O B_MEASURE
to O O
7 O B_MEASURE
. O O
1 O B_MEASURE/B_LOCATION
+ O I_MEASURE/I_LOCATION
/ O O
- O O
0 O B_MEASURE
. O O
1 O B_MEASURE
kPa O I_MEASURE
) O O
for O O
129 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
11 O B_TIME[MEASURE]/B_PERSON
min O I_TIME[MEASURE]/I_PERSON
in O O
the O O
enflurane O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
E O B_OTHER/B_PROTEIN[GENE]
) O O
group O B_ORGANIZATION/B_LOCATION
, O O
and O O
from O O
80 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
4 O B_MEASURE
to O O
49 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
1 O B_MEASURE
mmHg O I_MEASURE
( O O
10 O B_MEASURE
. O O
7 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_NUMBER[MEASURE]
. O O
5 O B_MEASURE
to O O
6 O B_MEASURE
. O O
5 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
1 O B_MEASURE
kPa O I_MEASURE
) O O
for O O
135 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
15 O B_TIME[MEASURE]/B_PERSON
min O I_TIME[MEASURE]/I_PERSON
in O O
the O O
isoflurane O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O O
I O B_OTHER/B_MEASURE
) O O
group O B_ORGANIZATION/B_MEASURE
. O O

The O O
initial O B_MEASURE
dose O I_MEASURE
of O O
labetalol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
lowering O O
blood O B_DISEASE/B_GENE
pressure O I_DISEASE/I_GENE
was O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
0 O B_MEASURE/B_LOCATION
. O O
52 O B_MEASURE
- O O
0 O B_MEASURE
. O O
59 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
, O O
in O O
all O O
the O O
groups O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O O

Pharmacology O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
ACC O B_DISEASE/B_PROTEIN[GENE]
- O O
9653 O B_NUMBER[MEASURE]
( O O
phenytoin O B_MEASURE
prodrug O I_MEASURE
) O O
. O O

The O O
ED50 O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doses O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
16 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
for O O
i O O
. O O
v O B_PROTEIN[GENE]/B_LOCATION
. O O
ACC O B_DISEASE/B_PROTEIN[GENE]
- O O
9653 O B_NUMBER[MEASURE]/B_LOCATION
and O O
8 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
for O O
i O O
. O O
v O B_PROTEIN[GENE]/B_LOCATION
. O O
phenytoin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
sodium O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Importantly O O
, O O
the O O
local O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
irritation O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
ACC O B_ORGANIZATION/B_LOCATION
- O O
9653 O B_NUMBER[MEASURE]
was O O
markedly O O
less O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O O
phenytoin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sodium O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
following O O
i O O
. O O
m O B_DISEASE/B_LOCATION
. O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O
( O O
ABSTRACT O B_MEASURE/B_ORGANIZATION
TRUNCATED O I_MEASURE/I_ORGANIZATION
AT O O
250 O B_LOCATION/B_ENT
WORDS O I_LOCATION/I_ENT
) O O

The O O
purpose O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
the O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O O
to O O
investigate O O
whether O O
tachyphylaxis O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occurs O O
during O O
prolonged O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
high O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inhaled O O
salbutamol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
had O O
no O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
baseline O B_DISEASE
values O I_DISEASE
. O O

There O O
were O O
dose O B_MEASURE
- O O
dependent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increases O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
FEV1 O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
FEF25 O B_LOCATION
- O O
75 O B_MEASURE
( O O
p O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
0 O B_MEASURE/B_LOCATION
. O O
001 O B_MEASURE
) O O
, O O
and O O
pretreatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
with O O
HDS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
did O O
not O O
displace O O
the O O
DRC O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
to O O
the O O
right O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

There O O
were O O
also O O
differences O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
HDS O B_LOCATION/B_ORGANIZATION
and O O
LDS O B_DISEASE/B_PROTEIN[GENE]
for O O
HR O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
p O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
and O O
Glu O B_LOCATION/B_PROTEIN[GENE]
( O O
p O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
responses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

In O O
a O O
patient O B_PERSON
receiving O I_PERSON
phenytoin O I_PERSON
who O O
presents O O
a O O
viral O B_DISEASE
- O O
like O B_DISEASE
illness O I_DISEASE
, O O
early O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
recognition O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
discontinuation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
mandatory O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
lethal O B_DISEASE/B_PERSON
pertussis O I_DISEASE/I_PERSON
vaccine O I_DISEASE/I_PERSON
reaction O I_DISEASE/I_PERSON
with O O
histamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
H1 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antagonists O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

By O O
means O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
intra O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
arterial O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
ambulatory O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
monitoring O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
the O O
haemodynamic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
followed O O
for O O
18 O B_MEASURE
h O O
after O O
the O O
infusions O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
stopped O O
. O O

The O O
various O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
drug O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatments O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
produced O O
improvements O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
some O O
, O O
but O O
not O O
all O O
, O O
measurements O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
renal O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Adverse O B_DISEASE
ocular O I_DISEASE
reactions O I_DISEASE
possibly O O
associated O O
with O O
isotretinoin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Reported O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
decreased O B_DISEASE
dark O I_DISEASE
adaptation O I_DISEASE
are O O
under O O
investigation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
compared O O
the O O
potential O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
receptor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocker O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
B O B_MEASURE
24 O I_MEASURE
/ O O
76 O B_MEASURE
i O O
. O O
e O B_DISEASE/B_PROTEIN[GENE]
. O O
1 O B_MEASURE
- O O
( O O
2 O B_NUMBER[MEASURE]/B_LOCATION
, O O
4 O B_NUMBER[MEASURE]
- O O
dichlorophenoxy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
- O O
3 O B_MEASURE/B_LOCATION
[ O O
2 O B_MEASURE/B_PROTEIN[GENE]
- O O
3 O B_NUMBER[MEASURE]/B_LOCATION
, O O
4 O B_NUMBER[MEASURE]
- O O
dimethoxyphenyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
ethanolamino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O O
- O O
prop O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
an O O
- O O
2 O B_MEASURE
- O O
ol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
is O O
characterized O O
by O O
beta O B_PROTEIN[GENE]/B_DISEASE
1 O I_PROTEIN[GENE]/I_DISEASE
- O O
adrenoceptor O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocking O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
beta O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
adrenoceptor O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulating O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
properties O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
with O O
propranolol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
the O O
patients O B_PERSON/B_DISEASE
, O O
but O O
not O O
the O O
healthy O B_PERSON/B_BIO
subjects O I_PERSON/I_BIO
, O O
these O O
symptoms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O O
significantly O O
correlated O O
with O O
plasma O B_DISEASE/B_GENE
caffeine O I_DISEASE/I_GENE
levels O I_DISEASE/I_GENE
. O O

Caffeine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
did O O
not O O
alter O O
plasma O B_DISEASE
MHPG O I_DISEASE
levels O I_DISEASE
in O O
either O O
the O O
healthy O B_PERSON/B_BIO
subjects O I_PERSON/I_BIO
or O O
patients O B_PERSON/B_BIO
. O O

Caffeine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
increased O O
plasma O B_DISEASE/B_GENE
cortisol O I_DISEASE/I_GENE
levels O I_DISEASE/I_GENE
equally O O
in O O
the O O
patient O B_PERSON/B_DISEASE
and O O
healthy O B_PERSON/B_BIO
groups O I_PERSON/I_BIO
. O O

( O O
6 O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subjects O B_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
whereas O O
11 O B_NUMBER[MEASURE]/B_PERSON
received O O
theophylline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
300 O B_MEASURE
mg O O
b O B_DISEASE/B_PROTEIN[GENE]
. O O
i O O
. O O
d O B_TIME[MEASURE]/B_DISEASE
. O O

Morning O B_DISEASE
dipping O I_DISEASE
, O O
assessed O O
by O O
the O O
fall O B_DISEASE/B_MEASURE
in O O
peak O B_MEASURE/B_PROTEIN[GENE]
flow O B_MEASURE/I_PROTEIN[GENE]
overnight O O
, O O
was O O
significantly O O
reduced O O
in O O
the O O
periods O B_TIME[MEASURE]/B_LOCATION
when O O
either O O
active O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
drug O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O O
taken O O
, O O
whereas O O
no O O
difference O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
was O O
noticed O O
during O O
the O O
placebo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
administration O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extend O O
previous O B_LOCATION/B_MEASURE
findings O I_LOCATION/I_MEASURE
implicating O O
a O O
cholinergic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
opioid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
interaction O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
memory O B_DISEASE
processes O I_DISEASE
. O O

This O O
damages O O
the O O
cellular O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
barrier O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
against O O
the O O
hypertonic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
urine O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
morphological O B_DISEASE_ADJECTIVE[DISEASE]
changes O I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
endothelial O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
become O O
more O O
pronounced O O
in O O
the O O
later O B_TIME[MEASURE]/B_LOCATION
stages O I_TIME[MEASURE]/I_LOCATION
of O O
the O O
experiment O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
involvement O B_DISEASE/B_MEASURE
of O O
blood O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
vessels O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
regardless O O
of O O
their O O
diameter O B_MEASURE/B_LOCATION
and O O
the O O
location O B_MEASURE
- O O
dependent O B_MEASURE/B_LOCATION
extent O I_MEASURE/I_LOCATION
of O O
the O O
damage O B_DISEASE
indicate O O
a O O
direct O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
type O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
damage O B_DISEASE
which O O
is O O
preceded O O
by O O
a O O
mediator O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
permeability O B_DISEASE/B_MEASURE
, O O
the O O
morphological O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
correlate O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
which O O
is O O
the O O
formation O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
of O O
gaps O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
interendothelial O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
cell O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
connections O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
on O O
the O O
venules O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
changes O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
effectively O O
prevented O O
by O O
mesna O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
only O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sign O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
possible O B_DISEASE
involvement O I_DISEASE
is O O
the O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
the O O
number O B_MEASURE/B_LOCATION
of O O
specific O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
granules O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
a O O
presumed O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
lysosomal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
the O O
superficial O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
cells O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O O

Pretreatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
sodium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
salicylate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
ED50 O B_MEASURE
103 O I_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
( O O
60 O B_MEASURE
- O O
174 O B_MEASURE
) O O
, O O
and O O
phenylbutazone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
59 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
( O O
50 O B_MEASURE
- O O
70 O B_MEASURE
) O O
converted O O
the O O
non O B_DISEASE/B_MEASURE
- O O
convulsant O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
dose O I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
pilocarpine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
200 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
, O O
to O O
a O O
convulsant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
one O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Two O B_PERSON
liver O I_PERSON
biopsy O I_PERSON
specimens O I_PERSON
and O O
the O O
hepatectomy O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
specimen O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
were O O
remarkable O B_DISEASE_ADJECTIVE[DISEASE]
for O O
almost O O
complete O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disappearance O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
interlobular O B_DISEASE
bile O I_DISEASE
ducts O I_DISEASE
. O O

Therefore O O
, O O
it O O
is O O
suggested O O
that O O
the O O
administration O O
of O O
PS O O
enhances O O
the O O
toxicity B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
AMNS O O
on O O
the O O
glomerulus O O
and O O
readily O O
produces O O
progressive O O
FSGS B B_DISEASE
in O O
rats O O
resulting O O
in O O
the O O
end B B_DISEASE
- I I_DISEASE
stage I I_DISEASE
renal I I_DISEASE
disease I I_DISEASE
. O O

It O O
is O O
concluded O O
that O O
advanced O O
pregnancy O O
has O O
a O O
negligible O O
effect O O
on O O
the O O
neurotoxic B B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O O
to O O
theophylline O O
in O O
rats O O
. O O

The O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
microinjection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
clonidine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
1 O B_NUMBER[MEASURE]
- O O
10 O B_MEASURE
micrograms O I_MEASURE
in O O
1 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
microliter O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O O
into O O
a O O
region O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
adjacent O O
to O O
the O O
ventrolateral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
surface O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
medulla O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oblongata O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
on O O
cardiovascular O B_DISEASE/B_ORGANISM_FUNCTION
function O I_DISEASE/I_ORGANISM_FUNCTION
were O O
assessed O O
in O O
urethane O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- O O
anesthetized O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

When O O
their O O
adverse O B_DISEASE
reactions O I_DISEASE
subsided O O
, O O
seven O B_NUMBER[MEASURE]
of O O
these O O
15 O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
were O O
rechallenged O O
with O O
inhaled O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beclomethasone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
study O O
reaffirms O O
the O O
principle O O
that O O
drug O O
toxicity B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlates O O
with O O
dose O O
per O O
body O O
surface O O
area O O
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
are O O
discussed O O
in O O
the O O
light O B_COLOR/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
various O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
non O B_DISEASE/B_MEASURE
- O O
uniform O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
from O O
the O O
literature O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Patients O O
were O O
divided O O
into O O
three O O
groups O O
; O O
19 O O
patients O O
without O O
myocardial B B_DISEASE/B_LOCATION
infarction I I_DISEASE/I_LOCATION
( O O
non O O
- O O
MI B B_DISEASE/B_LOCATION
group O O
) O O
, O O
14 O O
with O O
anterior B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
infarction I I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
ANT B B_LOCATION
- I I_LOCATION
MI I I_LOCATION
) O O
and O O
eight O O
with O O
inferior B B_DISEASE
infarction I I_DISEASE
( O O
INF B B_LOCATION/B_ORGANIZATION
- I I_LOCATION/I_ORGANIZATION
MI I I_LOCATION/I_ORGANIZATION
) O O
. O O

After O O
dipyridamole O O
, O O
ischemic B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
ST O O
- O O
segment O O
depression B B_DISEASE_ADJECTIVE[DISEASE]
( O O
0 O O
. O O
05 O O
mV O O
or O O
more O O
) O O
was O O
observed O O
in O O
84 O O
% O O
of O O
the O O
non O O
- O O
MI B B_DISEASE/B_LOCATION
group O O
, O O
29 O O
% O O
of O O
the O O
ANT B B_LOCATION
- I I_LOCATION
MI I I_LOCATION
group O O
, O O
63 O O
% O O
of O O
the O O
INF B B_LOCATION/B_ORGANIZATION
- I I_LOCATION/I_ORGANIZATION
MI I I_LOCATION/I_ORGANIZATION
group O O
and O O
61 O O
% O O
of O O
the O O
total O O
population O O
. O O

The O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
pressure O B_DISEASE/B_PROTEIN[GENE]
rate O B_DISEASE/I_PROTEIN[GENE]
product O B_DISEASE/I_PROTEIN[GENE]
after O O
dipyridamole O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
was O O
significantly O O
less O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
that O O
during O O
the O O
treadmill O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exercise O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Neuroradiologic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
investigations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
including O O
magnetic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resonance O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imaging O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scans O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
both O O
patients O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
showed O O
no O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
intracranial O B_DISEASE
abnormality O I_DISEASE
. O O

With O O
100 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
micrograms O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
denopamine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
almost O O
complete O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
restoration O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
cardiac O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
performance O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
attained O O
, O O
associated O O
with O O
a O O
slight O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
heart O B_DISEASE/B_GENE
rate O I_DISEASE/I_GENE
. O O

Improvement O B_DISEASE_ADJECTIVE[DISEASE]
of O O
abnormal O B_DISEASE
EEG O I_DISEASE
was O O
noticed O O
in O O
76 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
of O O
diffuse O B_DISEASE_ADJECTIVE[DISEASE]
paroxysms O I_DISEASE_ADJECTIVE[DISEASE]
and O O
in O O
67 O B_PERSON/B_MEASURE
% O B_PERSON/I_MEASURE
of O O
focal O B_DISEASE_ADJECTIVE[DISEASE]
paroxysms O I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
postmarketing O O
surveillance O O
study O O
was O O
conducted O O
to O O
determine O O
the O O
safety O O
and O O
efficacy O O
of O O
a O O
fixed O O
- O O
ratio O O
combination O O
containing O O
10 O O
mg O O
of O O
timolol O O
maleate O O
and O O
25 O O
mg O O
of O O
hydrochlorothiazide O O
, O O
administered O O
twice O O
daily O O
for O O
one O O
month O O
to O O
hypertensive B B_NUMBER[MEASURE]
patients O O
. O O

Mean O B_DISEASE/B_GENE
systolic O I_DISEASE/I_GENE
blood O I_DISEASE/I_GENE
pressure O I_DISEASE/I_GENE
decreased O O
25 O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mmHg O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
mean O O
diastolic O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
blood O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
pressure O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
declined O O
15 O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mmHg O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
after O O
one O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
month O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
timolol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
hydrochlorothiazide O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
( O O
P O B_MEASURE/B_PERSON
less O I_MEASURE/I_PERSON
than O O
0 O B_MEASURE
. O O
01 O B_MEASURE
, O O
both O O
comparisons O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O O
. O O

Age O B_TIME[MEASURE]/B_PERSON
, O O
race O B_SPORT[ENT]/B_PERSON
, O O
and O O
sex O B_PERSON/B_MEASURE
appeared O O
to O O
have O O
no O O
influence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
blood O B_DISEASE/B_MEASURE
pressure O I_DISEASE/I_MEASURE
. O O

Treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
590 O B_MEASURE
patients O I_MEASURE
was O O
discontinued O O
because O O
of O O
adverse O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
events O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Aspirin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
reduced O O
PGE2 O B_DISEASE/B_GENE
synthesis O B_DISEASE/I_GENE
in O O
all O O
regions O B_LOCATION/B_BIO
, O O
but O O
outer O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
medullary O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
PGE2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
remained O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
jj O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
18 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
3 O B_MEASURE
) O O
than O O
jJ O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
rats O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
( O O
9 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
2 O B_MEASURE
) O O
( O O
p O B_MEASURE
less O I_MEASURE
than O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

PGF2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
also O O
significantly O O
higher O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
the O O
outer O B_BODY_PART_OR_ORGAN_COMPONENT
medulla O I_BODY_PART_OR_ORGAN_COMPONENT
of O O
jj O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
rats O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
and O O
without O O
aspirin O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
p O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
0 O B_MEASURE
. O O
05 O B_MEASURE
) O O
. O O

Under O O
barbiturate O B_DISEASE
anesthesia O I_DISEASE
, O O
virtually O O
all O O
of O O
the O O
myocardial O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contractile O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indices O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
depressed O O
significantly O O
in O O
barium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
exposed O O
rats O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relative O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
corresponding O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
fed O O
rats O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Subjects O B_PERSON
received O O
propranolol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
either O O
by O O
mouth O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
48 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hours O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
before O O
PPA O B_DISEASE
or O O
as O O
a O O
rapid O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
intravenous O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infusion O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O O
PPA O B_DISEASE
. O O

PPA O B_MEASURE/B_DISEASE
, O O
75 O B_MEASURE
mg O O
alone O O
, O O
increased O O
blood O B_DISEASE/B_GENE
pressure O B_DISEASE/I_GENE
( O O
31 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
14 O B_MEASURE
mm O I_MEASURE
Hg O I_MEASURE
systolic O I_MEASURE
, O O
20 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
5 O B_MEASURE
mm O I_MEASURE
Hg O I_MEASURE
diastolic O I_MEASURE
) O O
, O O
and O O
propranolol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pretreatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonized O O
this O O
increase O B_DISEASE
( O O
12 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
10 O B_MEASURE
mm O I_MEASURE
Hg O I_MEASURE
systolic O I_MEASURE
, O O
10 O B_MEASURE
+ O O
/ O O
- O O
7 O B_MEASURE
mm O I_MEASURE
Hg O I_MEASURE
diastolic O I_MEASURE
) O O
. O O

Intravenous O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
propranolol O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
after O O
PPA O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
also O O
decreased O O
blood O B_DISEASE/B_GENE
pressure O I_DISEASE/I_GENE
. O O

Systemic O B_DISEASE/B_PROTEIN[GENE]
vascular O B_DISEASE/I_PROTEIN[GENE]
resistance O B_DISEASE/I_PROTEIN[GENE]
was O O
increased O O
by O O
PPA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
28 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
from O O
1710 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
200 O B_MEASURE
to O O
2190 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
700 O B_MEASURE/B_PERSON
dyne O I_MEASURE/I_PERSON
X O I_MEASURE/I_PERSON
sec O I_MEASURE/I_PERSON
/ O O
cm5 O B_MEASURE
) O O
and O O
was O O
further O O
increased O O
by O O
propranolol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
22 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
% O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
to O O
2660 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
1200 O B_TIME[MEASURE]
dyne O I_TIME[MEASURE]
X O I_TIME[MEASURE]
sec O I_TIME[MEASURE]
/ O O
cm5 O B_MEASURE
) O O
. O O

We O O
conclude O O
that O O
PPA O B_DISEASE/B_GENE
increases O O
blood O B_DISEASE/B_PROTEIN[GENE]
pressure O B_DISEASE/I_PROTEIN[GENE]
by O O
increasing O O
systemic O B_DISEASE/B_GENE
vascular O B_DISEASE/I_GENE
resistance O B_DISEASE/I_GENE
and O O
cardiac O B_MEASURE/B_DISEASE
output O B_MEASURE/I_DISEASE
, O O
and O O
that O O
propranolol O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonizes O I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
this O O
increase O B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
reversing O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
PPA O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
cardiac O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
output O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Cluster O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O O
a O O
random O B_MEASURE/B_LOCATION
distribution O I_MEASURE/I_LOCATION
of O O
lesions O B_DISEASE
in O O
the O O
PAN O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
glomeruli O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O O
concordance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O O
the O O
random O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
localization O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
mesangial O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
areas O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
with O O
dysfunction O B_DISEASE
in O O
this O O
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

The O O
role O O
of O O
p O O
- O O
aminophenol O O
in O O
acetaminophen O O
- O O
induced O O
nephrotoxicity B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
effect O O
of O O
bis O O
( O O
p O O
- O O
nitrophenyl O O
) O O
phosphate O O
on O O
acetaminophen O O
and O O
p O O
- O O
aminophenol O O
nephrotoxicity B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
and O O
metabolism O O
in O O
Fischer O O
344 O O
rats O O
. O O

Therefore O O
, O O
the O O
effect O O
of O O
bis O O
( O O
p O O
- O O
nitrophenyl O O
) O O
phosphate O O
( O O
BNPP O O
) O O
, O O
an O O
acylamidase O O
inhibitor O O
, O O
on O O
APAP O O
and O O
PAP O O
nephrotoxicity B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
and O O
metabolism O O
was O O
determined O O
. O O

BNPP O B_DISEASE/B_GENE
did O O
not O O
alter O O
the O O
excretion O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
APAP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
or O O
any O O
of O O
its O O
non O O
- O O
deacetylated O O
metabolites O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nor O O
did O O
BNPP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
alter O O
excretion O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
PAP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O O
its O O
metabolites O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
PAP O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
doses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
150 O B_MEASURE
and O O
300 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_TIME[MEASURE]
. O O

It O O
is O O
suggested O O
that O O
post O B_DISEASE/B_MEASURE
- O O
operative O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
intravenous O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
morphine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
should O O
not O O
exceed O O
20 O B_MEASURE
micrograms O I_MEASURE
/ O O
kg O B_MEASURE
/ O O
ml O B_MEASURE/B_PERSON
in O O
neonates O B_PERSON/B_BIO
. O O

In O O
sodium O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
repleted O O
animals O B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indomethacin O I_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O O
not O O
change O O
systolic O B_MEASURE
blood O I_MEASURE
pressure O I_MEASURE
( O O
BP O B_PROTEIN[GENE]/B_DISEASE
) O O
although O O
plasma O B_DISEASE/B_GENE
renin O B_DISEASE/I_GENE
activity O B_DISEASE/I_GENE
was O O
decreased O O
. O O

In O O
rhesus O B_SPECIES[BIO]
monkeys O I_SPECIES[BIO]
, O O
intravenous O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
challenge O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
0 O B_MEASURE/B_LOCATION
. O O
6 O B_MEASURE
x O O
10 O B_NUMBER[MEASURE]
( O O
10 O B_MEASURE
) O O
to O O
2 O B_MEASURE
. O O
2 O B_MEASURE
x O O
10 O B_MEASURE
( O O
10 O B_MEASURE
) O O
Pseudomonas O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
aeruginosa O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
organisms O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
caused O O
acute O B_DISEASE
illness O I_DISEASE
of O O
4 O B_NUMBER[MEASURE]/B_LOCATION
to O O
5 O B_TIME[MEASURE]
days O I_TIME[MEASURE]
' O I_TIME[MEASURE]
duration O I_TIME[MEASURE]
with O O
spontaneous O B_DISEASE
recovery O I_DISEASE
in O O
13 O B_NUMBER[MEASURE]/B_PERSON
of O O
15 O B_MEASURE/B_PERSON
monkeys O B_MEASURE/I_PERSON
; O O
blood O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cultures O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
became O O
negative O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
3 O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
17 O B_SEQUENCE[MEASURE]/B_ENT
days O I_SEQUENCE[MEASURE]/I_ENT
after O O
challenge O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

In O O
the O O
propranolol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
insulin O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
there O O
was O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
fall O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
heart O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
rate O B_MEASURE/B_ENT
in O O
most O B_PERSON/B_BIO
subjects O I_PERSON/I_BIO
and O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
diastolic O B_MEASURE/B_DISEASE
pressure O B_MEASURE/I_DISEASE
. O O

Hypertension B B_DISEASE/B_PERSON
in O O
diabetics B B_PERSON/B_BIO
prone O O
to O O
hypoglycaemia B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
attacks O O
should O O
not O O
be O O
treated O O
with O O
beta O O
- O O
blockers O O
because O O
these O O
drugs O O
may O O
cause O O
a O O
sharp O O
rise O O
in O O
blood O O
- O O
pressure O O
in O O
such O O
patients O O
. O O

Five O B_PERSON
patients O I_PERSON
with O O
serial O B_DISEASE
pregnancies O I_DISEASE
with O O
and O O
without O O
propranolol O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
also O O
examined O O
. O O

An O O
attempt O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
made O O
to O O
differentiate O O
drug O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
- O O
related O O
complications O B_DISEASE
from O O
maternal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
disease O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
- O O
related O O
complications O B_DISEASE
. O O

An O O
interaction O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
between O O
FZP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
pentylenetetrazol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PTZ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
was O O
shown O O
by O O
pretreating O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
FZP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
before O O
PTZ O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
challenge O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
propanolol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administered O O
intravenously O O
( O O
1 O B_MEASURE
- O O
5 O B_TIME[MEASURE]
mg O I_TIME[MEASURE]
) O O
produced O O
increases O B_DISEASE_ADJECTIVE[DISEASE]
in O O
supine O B_BODY_PART_OR_ORGAN_COMPONENT/B_TIME[MEASURE]
and O O
upright O B_DISEASE/B_GENE
blood O I_DISEASE/I_GENE
pressure O I_DISEASE/I_GENE
in O O
4 O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
5 O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
individuals O I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
with O O
rises O B_DISEASE
ranging O O
from O O
11 O B_MEASURE
/ O O
6 O B_MEASURE
to O O
22 O B_MEASURE
/ O O
11 O B_MEASURE
mmHg O I_MEASURE
. O O

Chronic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
oral O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
administration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
propranolol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
40 O B_MEASURE
- O O
160 O B_MEASURE
mg O I_MEASURE
/ O O
day O B_TIME[MEASURE]
) O O
also O O
elevated O O
the O O
blood O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pressures O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
individuals O B_PERSON/B_BIO
with O O
increases O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
the O O
order O B_MEASURE/B_PERSON
of O O
20 O B_MEASURE
- O O
35 O B_MEASURE
/ O O
15 O B_MEASURE
- O O
25 O B_MEASURE
mmg O I_MEASURE
being O O
observed O O
. O O

Hemodynamic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurements O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
1 O B_NUMBER[MEASURE]
of O O
the O O
patients O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrated O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
total O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peripheral O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resistance O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
essentially O O
no O O
change O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
cardiac O B_MEASURE/B_DISEASE
output O B_MEASURE/I_DISEASE
following O O
propranolol O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

An O O
investigation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
undertaken O O
to O O
determine O O
the O O
dosage O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
etomidate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
required O O
to O O
maintain O O
sleep O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
adults O B_PERSON/B_LOCATION
undergoing O O
surgery O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
under O O
regional O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
local O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
anesthesia O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Premedication O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
diazepam O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
atropine O B_MEASURE
0 O I_MEASURE
. O O
5 O B_MEASURE
mg O I_MEASURE
was O O
given O O
, O O
and O O
sleep O B_DISEASE
was O O
induced O O
and O O
maintained O O
by O O
intermittent O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
intravenous O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injections O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
etomidate O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
1 O B_MEASURE
/ O O
mg O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
kg O B_TIME[MEASURE]
, O O
given O O
whenever O O
the O O
patient O B_PERSON
would O O
open O O
his O O
eyes O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
on O O
request O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
mean O B_MEASURE
overall O I_MEASURE
dose O I_MEASURE
of O O
etomidate O B_MEASURE
17 O I_MEASURE
. O O
4 O B_MEASURE
microgram O I_MEASURE
/ O O
kg O B_MEASURE
/ O O
min O B_PERSON/B_TIME[MEASURE]
. O O
was O O
required O O
to O O
maintain O O
sleep O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
but O O
great O B_DISEASE
individual O I_DISEASE
variation O I_DISEASE
occurred O O
, O O
with O O
older O B_PERSON
patients O I_PERSON
requiring O O
less O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
drug O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
. O O

In O O
several O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
patients O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
uncontrollable O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
muscle O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
movements O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
persisted O O
for O O
many O B_TIME[MEASURE]/B_ENT
minutes O I_TIME[MEASURE]/I_ENT
after O O
complete O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
recovery O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
consciousness O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O O
that O O
hormonal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
replacement O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
safely O O
prescribed O O
if O O
the O O
following O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
criteria O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O O
satisfied O O
: O O
1 O B_SEQUENCE[MEASURE]
) O O
preliminary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
patients O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
a O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
metabolic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
cytologic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
mammographic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
perspective O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
; O O
2 O B_NUMBER[MEASURE]
) O O
cyclic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
schedule O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
with O O
a O O
progestative O B_MEASURE/B_LOCATION
phase O I_MEASURE/I_LOCATION
of O O
10 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
days O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
; O O
and O O
3 O B_NUMBER[MEASURE]
) O O
periodic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
complete O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
follow O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
up O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
with O O
accurate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thermographic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
breast O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tissues O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
analogues O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CCK O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
8 O B_NUMBER[MEASURE]
- O O
SE O B_LOCATION
and O O
CCK O B_LOCATION/B_GENE
- O O
8 O B_SEQUENCE[MEASURE]
- O O
NS O B_LOCATION
( O O
dose O B_MEASURE/B_LOCATION
range O I_MEASURE/I_LOCATION
0 O I_MEASURE/I_LOCATION
. O O
2 O B_MEASURE
- O O
6 O B_MEASURE
. O O
4 O B_MEASURE/B_PERSON
mumol O I_MEASURE/I_PERSON
/ O O
kg O B_MEASURE
) O O
and O O
caerulein O B_MEASURE/B_LOCATION
dose O I_MEASURE/I_LOCATION
range O I_MEASURE/I_LOCATION
0 O I_MEASURE/I_LOCATION
. O O
1 O B_MEASURE
- O O
0 O B_MEASURE
. O O
8 O B_MEASURE/B_PERSON
mumol O I_MEASURE/I_PERSON
/ O O
kg O B_MEASURE
) O O
showed O O
bell O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
shaped O O
dose O B_MEASURE/B_LOCATION
- O O
effect O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
curves O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
with O O
the O O
greatest O B_MEASURE
maximum O I_MEASURE
inhibition O I_MEASURE
for O O
CCK O B_LOCATION/B_GENE
- O O
8 O B_NUMBER[MEASURE]
- O O
NS O B_LOCATION
. O O

Experiments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
analogues O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
derivatives O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
CCK O B_LOCATION/B_GENE
- O O
5 O B_NUMBER[MEASURE]
- O O
8 O B_TIME[MEASURE]/B_LOCATION
demonstrated O O
that O O
the O O
effectiveness O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
beta O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
alanyl O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derivatives O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
CCK O B_LOCATION/B_GENE
- O O
5 O B_NUMBER[MEASURE]
- O O
8 O B_TIME[MEASURE]/B_LOCATION
were O O
enhanced O O
and O O
that O O
they O O
were O O
equipotent O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
CCK O B_LOCATION/B_PROTEIN[GENE]
- O O
8 O B_MEASURE
- O O
SE O B_DISEASE/B_MEASURE
. O O

Administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
DDAVP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
which O O
has O O
antidiuretic O B_DISEASE_ADJECTIVE[DISEASE]
action O I_DISEASE_ADJECTIVE[DISEASE]
but O O
minimal O B_TIME[MEASURE]/B_LOCATION
vasopressor O I_TIME[MEASURE]/I_LOCATION
effect O I_TIME[MEASURE]/I_LOCATION
failed O O
to O O
increase O O
blood O B_DISEASE/B_GENE
pressure O B_DISEASE/I_GENE
to O O
the O O
levels O B_MEASURE/B_GENE
observed O O
after O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
AVP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

The O O
electrocardiogram O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
showed O O
alternation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
long O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
short O B_DISEASE_ADJECTIVE[DISEASE]
P O I_DISEASE_ADJECTIVE[DISEASE]
- O O
P O B_MEASURE
intervals O I_MEASURE
and O O
occasional O B_DISEASE/B_MEASURE
pauses O I_DISEASE/I_MEASURE
. O O

These O O
pauses O B_DISEASE/B_TIME[MEASURE]
were O O
always O O
preceded O O
by O O
the O O
short O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
P O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
P O B_MEASURE
intervals O I_MEASURE
and O O
were O O
usually O O
followed O O
by O O
one O B_NUMBER[MEASURE]/B_PERSON
or O O
two O B_NUMBER[MEASURE]
P O I_NUMBER[MEASURE]
- O O
P O B_TIME[MEASURE]/B_LOCATION
intervals O I_TIME[MEASURE]/I_LOCATION
of O O
0 O B_MEASURE
. O O
92 O B_MEASURE
- O O
0 O B_NUMBER[MEASURE]
. O O
95 O B_MEASURE
s O I_MEASURE
representing O O
the O O
basic O B_TIME[MEASURE]/B_PERSON
sinus O I_TIME[MEASURE]/I_PERSON
cycle O I_TIME[MEASURE]/I_PERSON
. O O

The O O
duration O B_MEASURE/B_LOCATION
of O O
the O O
pauses O B_DISEASE/B_TIME[MEASURE]
were O O
equal O B_MEASURE
or O O
almost O O
equal O B_MEASURE
to O O
one O B_NUMBER[MEASURE]
short O I_NUMBER[MEASURE]
plus O O
one O B_NUMBER[MEASURE]/B_LOCATION
long O I_NUMBER[MEASURE]/I_LOCATION
P O I_NUMBER[MEASURE]/I_LOCATION
- O O
P O B_MEASURE/B_LOCATION
interval O I_MEASURE/I_LOCATION
or O O
to O O
twice O O
the O O
basic O B_MEASURE
sinus O I_MEASURE
cycle O I_MEASURE
. O O

In O O
one O O
recording O O
a O O
short O O
period O O
of O O
regular O O
sinus O O
rhythm O O
with O O
intermittent O O
2 O O
/ O O
1 O O
S B B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
block I I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
observed O O
. O O

This O O
short O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
period O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
sinus O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rhythm O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
interrupted O O
by O O
sudden O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
prolongation O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
P O B_OTHER/B_LOCATION
- O O
P O B_MEASURE/B_LOCATION
interval O I_MEASURE/I_LOCATION
starting O O
the O O
alternative O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
rhythm O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

S O B_DISEASE/B_PROTEIN[GENE]
- O O
A O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conduction O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O O
two O B_LOCATION
pathways O I_LOCATION
, O O
the O O
first O B_SEQUENCE[MEASURE]/B_LOCATION
with O O
2 O B_NUMBER[MEASURE]
/ O O
1 O B_MEASURE
block O O
the O O
second O B_SEQUENCE[MEASURE]/B_PERSON
having O O
0 O B_MEASURE/B_LOCATION
. O O
12 O B_MEASURE
- O O
0 O B_MEASURE
. O O
14 O B_MEASURE
s O I_MEASURE
longer O I_MEASURE
conduction O I_MEASURE
time O I_MEASURE
and O O
with O O
occasional O B_TIME[MEASURE]
2 O I_TIME[MEASURE]
/ O O
1 O B_MEASURE/B_LOCATION
block O I_MEASURE/I_LOCATION
was O O
proposed O O
for O O
the O O
explanation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
alternating O O
P O B_OTHER/B_LOCATION
- O O
P O B_MEASURE
interval O I_MEASURE
and O O
other O B_DISEASE/B_PROTEIN[GENE]
electrocardiographic O B_DISEASE/I_PROTEIN[GENE]
features O B_DISEASE/I_PROTEIN[GENE]
seen O O
. O O

Atropine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
1 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
given O O
intravenously O O
resulted O O
in O O
shortening O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
all O O
P O B_PROTEIN[GENE]/B_LOCATION
- O O
P O B_MEASURE
intervals O I_MEASURE
without O O
changing O O
the O O
rhythm O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
then O O
progressive O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
fall O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
global O B_DISEASE
LV O I_DISEASE
function O I_DISEASE
was O O
observed O O
at O O
a O O
cumulative O B_MEASURE/B_LOCATION
doxorubicin O I_MEASURE/I_LOCATION
dose O I_MEASURE/I_LOCATION
of O O
4 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
. O O

Myocardial O B_DISEASE/B_PROTEIN[GENE]
O2 O B_DISEASE/I_PROTEIN[GENE]
consumption O B_DISEASE/I_PROTEIN[GENE]
and O O
O2 O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
availability O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
directly O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
on O O
the O O
coronary O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
perfusion O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

Careful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
invasive O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
monitoring O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
blood O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pressure O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
blood O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gases O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
of O O
the O O
ECG O B_DISEASE/B_PROTEIN[GENE]
ST O B_DISEASE/I_PROTEIN[GENE]
- O O
T O B_NUMBER[MEASURE]/B_LOCATION
segment O I_NUMBER[MEASURE]/I_LOCATION
is O O
mandatory O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
reduction O O
of O O
amphetamine O O
hyperactivity B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
induced O O
by O O
DSP4 O O
was O O
blocked O O
by O O
pretreatment O O
with O O
the O O
noradrenaline O O
- O O
uptake O O
blocking O O
agent O O
, O O
desipramine O O
, O O
which O O
prevents O O
the O O
neurotoxic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
action O O
of O O
DSP4 O O
. O O

Acute O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
toxic O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
dosage O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
dependent O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
behavioral O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
effects O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
caffeine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
compared O O
in O O
adult O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
males O B_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
seven O B_LOCATION/B_PERSON
inbred O I_LOCATION/I_PERSON
mouse O I_LOCATION/I_PERSON
strains O I_LOCATION/I_PERSON
( O O
A O B_OTHER/B_LOCATION
/ O O
J O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O O
BALB O B_SPECIES[BIO]/B_PROTEIN[GENE]
/ O O
cJ O B_DISEASE/B_LOCATION
, O O
CBA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
/ O O
J O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
C3H O B_SPECIES[BIO]/B_LOCATION
/ O O
HeJ O B_LOCATION/B_DISEASE
, O O
C57BL O B_BIO/B_PROTEIN[GENE]
/ O O
6J O B_MEASURE
, O O
DBA O B_PROTEIN[GENE]/B_DISEASE
/ O O
2J O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
SWR O B_DISEASE/B_PROTEIN[GENE]
/ O O
J O B_OTHER/B_PROTEIN[GENE]
) O O
. O O

C57BL O B_MEASURE/B_BIO
/ O O
6J O B_MEASURE
, O O
chosen O O
as O O
a O O
" O O
prototypic O B_MEASURE/B_GENE
" O O
mouse O B_SPECIES[BIO]/B_MEASURE
strain O I_SPECIES[BIO]/I_MEASURE
, O O
was O O
used O O
to O O
determine O O
behavioral O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
a O O
broad O B_MEASURE/B_LOCATION
range O I_MEASURE/I_LOCATION
( O O
5 O B_MEASURE
- O O
500 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
) O O
of O O
caffeine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doses O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Animals O O
surviving O O
for O O
20 O O
min O O
were O O
immediately O O
stressed O O
by O O
a O O
swim O O
test O O
in O O
25 O O
degrees O O
C O O
water O O
, O O
and O O
death O O
- O O
producing O O
tonic B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
seizures I B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
were O O
scored O O
for O O
2 O O
min O O
. O O

There O O
were O O
no O O
drug O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
- O O
related O O
deaths O B_DISEASE
. O O

In O O
vitro O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
perfusion O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
bepridil O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
life O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
support O B_LOCATION/B_PERSON
medium O I_LOCATION/I_PERSON
for O O
isolated O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
sino O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
- O O
atrial O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissue O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
from O O
rabbit O B_SPECIES[BIO]
heart O I_SPECIES[BIO]
, O O
caused O O
a O O
reduction O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
action O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
potential O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O O
AP O B_DISEASE/B_PROTEIN[GENE]
) O O
spike O B_MEASURE
frequency O I_MEASURE
( O O
recorded O O
by O O
KCl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
microelectrodes O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
) O O
starting O O
at O O
doses O B_MEASURE/B_LOCATION
of O O
5 O B_MEASURE
X O I_MEASURE
10 O I_MEASURE
( O O
- O O
6 O B_MEASURE
) O O
M O B_OTHER/B_MEASURE
. O O

This O O
effect O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O O
dose O B_MEASURE
- O O
dependent O B_DISEASE_ADJECTIVE[DISEASE]
up O O
to O O
concentrations O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
5 O B_MEASURE
X O I_MEASURE
10 O I_MEASURE
( O O
- O O
5 O B_MEASURE
) O O
M O B_OTHER/B_MEASURE
, O O
whereupon O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
blockade O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
sinus O B_DISEASE/B_GENE
activity O B_DISEASE/I_GENE
set O O
in O O
. O O

Bepridil O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
at O O
a O O
dose O B_MEASURE/B_LOCATION
of O O
5 O B_MEASURE
X O O
10 O B_NUMBER[MEASURE]
( O O
- O O
6 O B_MEASURE
) O O
M O B_OTHER/B_MEASURE
, O O
induced O O
a O O
concomitant O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reduction O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
AP O B_MEASURE/B_DISEASE
amplitude O I_MEASURE/I_DISEASE
( O O
falling O O
from O O
71 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
8 O B_MEASURE
mV O I_MEASURE
to O O
47 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
6 O B_MEASURE
mV O I_MEASURE
) O O
, O O
maximum O B_MEASURE
systolic O I_MEASURE
depolarization O I_MEASURE
velocity O I_MEASURE
( O O
phase O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
which O O
fell O O
from O O
1 O B_MEASURE
. O O
85 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
35 O B_MEASURE
V O I_MEASURE
/ O O
s O O
to O O
0 O B_MEASURE
. O O
84 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
28 O B_MEASURE
V O I_MEASURE
/ O O
s O B_MEASURE/B_DISEASE
, O O
together O O
with O O
maximum O B_MEASURE/B_LOCATION
diastolic O I_MEASURE/I_LOCATION
depolarization O I_MEASURE/I_LOCATION
velocity O I_MEASURE/I_LOCATION
( O O
phase O B_LOCATION/B_PROTEIN[GENE]
4 O I_LOCATION/I_PROTEIN[GENE]
) O O
which O O
fell O O
from O O
38 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
3 O B_MEASURE/B_LOCATION
mV O I_MEASURE/I_LOCATION
/ O O
s O O
to O O
24 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
5 O B_TIME[MEASURE]/B_PERSON
mV O I_TIME[MEASURE]/I_PERSON
/ O O
s O B_MEASURE/B_DISEASE
. O O

It O O
is O O
concluded O O
that O O
bepridil O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduces O O
heart O B_DISEASE
rate O I_DISEASE
by O O
acting O O
directly O O
on O O
the O O
sinus O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
node O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O O

5 O O
patients O O
with O O
acute B B_DISEASE
renal I I_DISEASE
failure I I_DISEASE
( O O
3 O O
with O O
thrombopenia B B_DISEASE
and O O
hemolysis B B_NUMBER[MEASURE]/B_PERSON
) O O
induced O O
by O O
the O O
reintroduction O O
of O O
rifampicin O O
are O O
described O O
. O O

No O O
correlation O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
found O O
between O O
the O O
severity O B_MEASURE
of O O
clinical O B_DISEASE
manifestations O I_DISEASE
and O O
the O O
total O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
taken O O
by O O
the O O
patients O B_PERSON
. O O

In O O
all O O
but O O
1 O B_NUMBER[MEASURE]/B_PERSON
patient O I_NUMBER[MEASURE]/I_PERSON
, O O
antirifampicin O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
antibodies O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
detected O O
. O O

ATP O B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
10 O B_MEASURE/B_ENT
dogs O I_MEASURE/I_ENT
) O O
or O O
SNP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
10 O B_MEASURE/B_ENT
dogs O I_MEASURE/I_ENT
) O O
was O O
administered O O
to O O
reduce O O
mean O B_DISEASE
arterial O I_DISEASE
pressure O I_DISEASE
by O O
30 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
to O O
70 O B_PERSON/B_MEASURE
% O B_PERSON/I_MEASURE
of O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Hexabrix O O
and O O
Vasurix O O
polyvidone O O
are O O
considered O O
the O O
best O O
contrast O O
media O O
for O O
hysterosalpingography O O
and O O
perhaps O O
because O O
of O O
its O O
low O O
toxicity B B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Hexabrix O O
should O O
be O O
preferred O O
. O O

The O O
hypothesis O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
intense O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vasoconstriction O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
would O O
increase O O
the O O
number O B_MEASURE
of O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
vacuoles O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
has O O
been O O
tested O O
. O O

By O O
7 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
the O O
vessel O B_DISEASE/B_MEASURE
was O O
almost O O
restored O O
to O O
normal O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Triple O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
over O O
1 O B_NUMBER[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
day O I_NUMBER[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induced O O
more O B_DISEASE
severe O I_DISEASE
changes O I_DISEASE
in O O
the O O
media O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

These O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
smooth O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
muscle O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
susceptible O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
damage O B_DISEASE
in O O
the O O
course O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
their O O
specific O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

One O B_PERSON
case O I_PERSON
had O O
only O O
a O O
unilateral O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

He O O
was O O
found O O
to O O
have O O
atypical O B_DISEASE/B_GENE
plasma O I_DISEASE/I_GENE
cholinesterase O I_DISEASE/I_GENE
with O O
a O O
dibucaine O B_MEASURE/B_PERSON
number O I_MEASURE/I_PERSON
of O O
12 O B_NUMBER[MEASURE]
, O O
indicating O O
homozygocity O B_DISEASE
. O O

A O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
etomidate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O O
outpatient O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cystoscopy O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
embarked O O
upon O O
. O O

The O O
trial O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
discontinued O O
after O O
20 O B_TIME[MEASURE]
cases O I_TIME[MEASURE]
because O O
of O O
an O O
unacceptable O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
incidence O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
side O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
risk O B_DISEASE/B_MEASURE
for O O
those O O
prescribed O O
cephalexin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
somewhat O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
2 O B_MEASURE
. O O
0 O B_MEASURE
/ O O
100 O B_MEASURE
, O O
000 O B_MEASURE/B_LOCATION
) O O
. O O

We O O
conclude O O
that O O
the O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
the O O
serious O B_DISEASE_ADJECTIVE[DISEASE]
diseases O I_DISEASE_ADJECTIVE[DISEASE]
studied O O
is O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
for O O
the O O
three O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
compares O O
reasonably O O
with O O
the O O
risk O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
many O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
other O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
antibiotics O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Therapeutic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O O
noted O O
at O O
all O O
dose O B_MEASURE/B_LOCATION
levels O B_MEASURE/I_LOCATION
, O O
with O O
objective O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
17 O B_NUMBER[MEASURE]
( O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
complete O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
15 O B_DISEASE_ADJECTIVE[DISEASE]
partial O I_DISEASE_ADJECTIVE[DISEASE]
regressions O I_DISEASE_ADJECTIVE[DISEASE]
) O O
of O O
41 O B_NUMBER[MEASURE]
previously O O
untreated O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Toxicities B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
compared O O
with O O
a O O
cohort O O
of O O
patients O O
in O O
a O O
phase O O
I O O
trial O O
of O O
paclitaxel O O
alone O O
at O O
identical O O
dose O O
levels O O
. O O

The O O
200 O B_MEASURE
- O O
micrograms O B_MEASURE
dose O I_MEASURE
was O O
able O B_DISEASE_ADJECTIVE[DISEASE]
to O O
totally O O
abolish O O
the O O
deleterious O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
renal O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
effects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
indomethacin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
whereas O O
the O O
800 O B_MEASURE
- O O
micrograms O B_MEASURE
dose O I_MEASURE
resulted O O
in O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
worsening O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
renal O B_DISEASE
hemodynamics O I_DISEASE
and O O
sodium O B_DISEASE
retention O I_DISEASE
. O O

Concern O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
has O O
been O O
raised O O
with O O
regard O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
safety O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
lorazepam O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
this O O
age O B_MEASURE/B_LOCATION
group O B_MEASURE/I_LOCATION
, O O
especially O O
in O O
very O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
birth O B_TIME[MEASURE]/B_PERSON
- O O
weight O B_MEASURE/B_BIO
( O O
VLBW O B_DISEASE
; O O
< O O
1 O B_MEASURE
, O O
500 O B_MEASURE
g O I_MEASURE
) O O
infants O B_PERSON/B_BIO
. O O

In O O
four O B_PERSON/B_MEASURE
patients O I_PERSON/I_MEASURE
, O O
cardiac O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pacing O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
used O O
, O O
resulting O O
in O O
a O O
temporary O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
captured O O
rhythm O B_DISEASE/B_MEASURE
and O O
restoration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
their O O
cardiac O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
output O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

In O O
one O B_PERSON/B_MEASURE
patient O B_PERSON/I_MEASURE
, O O
cardiac O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pacing O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
not O O
used O O
, O O
because O O
he O O
converted O O
to O O
normal O B_DISEASE
sinus O I_DISEASE
rhythm O I_DISEASE
by O O
electrical O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
defibrillation O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
within O O
three O B_TIME[MEASURE]/B_ENT
minutes O I_TIME[MEASURE]/I_ENT
of O O
initiating O O
CPR O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Safety O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analyses O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
included O O
incidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
adverse O B_DISEASE
experiences O I_DISEASE
and O O
laboratory O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
parameter O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

As O O
granisetron O B_MEASURE/B_DISEASE
dose O I_MEASURE/I_DISEASE
increased O O
, O O
appetite O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
return O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increased O O
( O O
P O B_OTHER/B_PROTEIN[GENE]
= O O
. O O
040 O B_MEASURE
) O O
. O O

We O O
describe O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
such O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
cases O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
discuss O O
the O O
various O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
might O O
cause O O
such O O
an O O
interaction O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

CONCLUSIONS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
: O O
Caution O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
recommended O O
in O O
combining O O
clonidine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
verapamil O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
even O O
in O O
patients O B_PERSON
who O O
do O O
not O O
have O O
sinus O B_BODY_PART_OR_ORGAN_COMPONENT/B_PROTEIN[GENE]
or O O
AV O B_DISEASE
node O I_DISEASE
dysfunction O I_DISEASE
. O O

The O O
two O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
drugs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
may O O
act O O
synergistically O O
on O O
both O O
the O O
AV O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
node O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
peripheral O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
circulation O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

5th O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
communication O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
: O O
anticonvulsant O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

For O O
sumatriptan O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
tightness O B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
chest O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
caused O O
by O O
an O O
unknown O B_DISEASE
mechanism O I_DISEASE
has O O
been O O
reported O O
in O O
3 O B_NUMBER[MEASURE]/B_LOCATION
- O O
5 O B_SEQUENCE[MEASURE]/B_LOCATION
% O I_SEQUENCE[MEASURE]/I_LOCATION
of O O
users O B_PERSON/B_BIO
. O O

She O O
recovered O O
without O O
complications O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Superoxide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dismutase O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
SOD O B_GENE
) O O
or O O
dimethylthiourea O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
DMTU O B_LOCATION/B_ORGANIZATION
) O O
significantly O O
lessened O O
the O O
GM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
decrement O B_DISEASE_ADJECTIVE[DISEASE]
in O O
CIn O B_DISEASE/B_GENE
. O O

The O O
SOD O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
glomerular O B_MEASURE/B_DISEASE
filtration O B_MEASURE/I_DISEASE
rate O B_MEASURE/I_DISEASE
was O O
associated O O
with O O
a O O
marked O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
improvement O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
RBF O B_DISEASE/B_GENE
, O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
urinary O B_DISEASE/B_GENE
cGMP O I_DISEASE/I_GENE
excretion O I_DISEASE/I_GENE
, O O
and O O
a O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
renal O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
renin O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
endothelin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
1 O B_TIME[MEASURE]/B_LOCATION
content O I_TIME[MEASURE]/I_LOCATION
. O O

An O O
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
cephalothin O B_DISEASE/B_GENE
IgG O B_DISEASE/I_GENE
antibody O B_DISEASE/I_GENE
was O O
detected O O
in O O
the O O
patient O B_PERSON/B_BIO
' O O
s O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serum O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
in O O
the O O
eluates O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
from O O
her O O
erythrocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
. O O

CCB O B_DISEASE/B_GENE
was O O
measured O O
before O O
and O O
after O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
either O O
vehicle O B_PRODUCT[OBJECT]/B_LOCATION
, O O
AVP O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
ANP O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
or O O
both O O
peptides O O
together O O
. O O

ANP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
did O O
not O O
cause O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
changes O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
MAP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
both O O
strains O B_BIO
as O O
compared O O
to O O
vehicle O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O O
but O O
it O O
abolished O O
AVP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
MAP O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
WKY O B_LOCATION/B_ORGANIZATION
and O O
SHR O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
SHR O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O O
not O O
in O O
WKY O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
ANP O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
AVP O B_LOCATION/B_GENE
and O O
ANP O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O O
AVP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
decreased O O
CCB O B_DISEASE/B_PROTEIN[GENE]
during O O
Phe O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
induced O O
MAP O B_DISEASE
elevation O I_DISEASE
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
centrally O O
applied O O
AVP O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
ANP O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exert O O
differential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
blood O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pressure O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
baroreflex O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
heart O B_DISEASE
rate O I_DISEASE
in O O
WKY O B_PROTEIN[GENE]
and O O
SHR O B_LOCATION/B_ORGANIZATION
and O O
suggest O O
interaction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
these O O
two O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptides O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
blood O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
pressure O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
regulation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
at O O
the O O
level O B_MEASURE/B_LOCATION
of O O
central O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
nervous O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
system O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Pediatric O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
heart O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
transplantation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
without O O
chronic O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
maintenance O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
steroids O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

In O O
patients O B_PERSON
less O I_PERSON
than O O
7 O B_TIME[MEASURE]/B_ENT
years O I_TIME[MEASURE]/I_ENT
of O O
age O B_TIME[MEASURE]/B_PERSON
, O O
rejection O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
monitored O O
noninvasively O O
. O O

In O O
the O O
first O B_TIME[MEASURE]/B_LOCATION
postoperative O B_TIME[MEASURE]/I_LOCATION
month O B_TIME[MEASURE]/I_LOCATION
, O O
89 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
of O O
patients O B_PERSON
were O O
treated O O
for O O
rejection O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Cytomegalovirus B B_PERSON
infections I I_PERSON
were O O
treated O O
successfully O O
with O O
ganciclovir O O
in O O
11 O O
patients O O
. O O

No O O
impairment O B_DISEASE_ADJECTIVE[DISEASE]
of O O
growth O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
observed O O
in O O
children O B_PERSON/B_BIO
who O O
underwent O O
transplantation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
compared O O
with O O
a O O
control O B_PERSON/B_BIO
population O I_PERSON/I_BIO
. O O

The O O
correlation O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
high O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
serum O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
tricyclic O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
antidepressant O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
concentrations O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
central O B_DISEASE
nervous O I_DISEASE
system O I_DISEASE
side O I_DISEASE
effects O I_DISEASE
has O O
been O O
well O O
established O O
. O O

Sequential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biological O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assays O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_MEASURE
, O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
2 O B_NUMBER[MEASURE]
, O O
TNF O B_LOCATION
and O O
PAF O B_GENE
were O O
performed O O
during O O
Ara O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
C O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infusion O I_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
ten O B_NUMBER[MEASURE]/B_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
, O O
including O O
the O O
four O B_NUMBER[MEASURE]/B_PERSON
who O O
developed O O
the O O
syndrome O B_DISEASE
. O O

Left O O
atrial O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
left O O
ventricular O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
papillary O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
muscle O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contractile O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
isoproterenol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
reduced O O
compared O O
to O O
controls O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O O
groups O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
treated O O
with O O
clentiazem O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
, O O
but O O
combined O O
with O O
epinephrine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
clentiazem O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
restored O O
left O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
atrial O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
responses O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
enhanced O O
left O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ventricular O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
papillary O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
responses O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
isoproterenol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

On O O
the O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hand O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clentiazem O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O O
not O O
prevent O O
epinephrine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
induced O O
down O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
regulation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
alpha O B_PROTEIN[GENE]
and O O
beta O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
adrenoceptors O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Interestingly O O
, O O
clentiazem O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
infused O O
alone O O
, O O
resulted O O
in O O
decreased O O
adrenergic O B_DISEASE/B_MEASURE
receptor O I_DISEASE/I_MEASURE
densities O I_DISEASE/I_MEASURE
in O O
the O O
left O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ventricle O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

It O O
is O O
not O O
known O O
why O O
this O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
occurred O O
in O O
some O O
individuals O B_PERSON/B_BIO
but O O
not O O
in O O
others O B_PERSON/B_BIO
, O O
but O O
our O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
indicate O O
a O O
correlation O B_MEASURE/B_LOCATION
between O O
aldosterone O B_DISEASE
production O I_DISEASE
and O O
this O O
renal O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effect O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
L O B_PROTEIN[GENE]/B_MEASURE
- O O
dopa O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Recently O O
we O O
developed O O
a O O
new O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O O
measure O O
ECG O B_DISEASE
values O I_DISEASE
in O O
freely O O
moving O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
telemetry O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Epinephrine O B_DISEASE
dysrhythmogenicity O I_DISEASE
is O O
not O O
enhanced O O
by O O
subtoxic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
bupivacaine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
dogs O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
the O O
bupivacaine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O O
epinephrine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
caused O O
fewer O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prodysrhythmic O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
without O O
bupivacaine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

There O O
is O O
no O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
systemic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subtoxic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bupivacaine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhances O O
the O O
dysrhythmogenicity O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
subsequent O B_DISEASE/B_PROTEIN[GENE]
epinephrine O B_DISEASE/I_PROTEIN[GENE]
. O O

This O O
patient O O
could O O
have O O
been O O
diagnosed O O
as O O
having O O
either O O
neuroleptic B B_DISEASE
malignant I I_DISEASE
syndrome I I_DISEASE
( O O
NMS B B_LOCATION
) O O
or O O
serotonin B B_DISEASE
syndrome I I_DISEASE
( O O
SS B B_LOCATION
) O O
. O O

The O O
major O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
determinant O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
the O O
symptoms O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
have O O
been O O
dopamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
serotonin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
imbalance O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
central O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nervous O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
NMS B B_DISEASE/B_GENE
- O O
like O O
encephalopathy B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
develops O O
in O O
association O O
with O O
the O O
use O O
of O O
antidepressants O O
indicates O O
that O O
NMS B B_LOCATION
and O O
SS B B_DISEASE
are O O
spectrum O O
disorders O O
induced O O
by O O
drugs O O
with O O
both O O
antidopaminergic O O
and O O
serotonergic O O
effects O O
. O O

The O O
same O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DES O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O O
no O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
8 O B_MEASURE
. O O
9 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
5 O B_MEASURE
mg O I_MEASURE
for O O
treated O O
females O B_PERSON/B_BIO
versus O O
8 O B_MEASURE
. O O
7 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
1 O B_MEASURE
. O O
1 O B_MEASURE
for O O
untreated O B_PERSON/B_BIO
females O I_PERSON/I_BIO
) O O
or O O
morphological O B_DISEASE/B_ORGANISM_FUNCTION
changes O I_DISEASE/I_ORGANISM_FUNCTION
in O O
Brown O B_PERSON/B_LOCATION
Norway O I_PERSON/I_LOCATION
( O O
BN O B_MEASURE/B_DISEASE
) O O
rat O B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
pituitaries O I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

An O O
F1 O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hybrid O B_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
F344 O B_LOCATION/B_PERSON
and O O
BN O B_MEASURE/B_DISEASE
exhibited O O
significant O B_DISEASE/B_MEASURE
pituitary O I_DISEASE/I_MEASURE
growth O I_DISEASE/I_MEASURE
after O O
10 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weeks O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
DES O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
with O O
an O O
average O B_MEASURE
mass O I_MEASURE
of O O
26 O B_MEASURE
. O O
3 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
7 O B_MEASURE
mg O I_MEASURE
compared O O
with O O
8 O B_MEASURE
. O O
6 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
9 O B_MEASURE
mg O I_MEASURE
for O O
untreated O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
rats O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Expression O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
both O O
growth O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
morphological O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
changes O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
is O O
due O O
to O O
multiple O B_DISEASE/B_GENE
genes O I_DISEASE/I_GENE
. O O

Fos O B_GENE
- O O
IR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
spinal O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cord O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
was O O
not O O
changed O O
in O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receiving O O
chronic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CYP O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
n O B_PROTEIN[GENE]/B_LOCATION
= O O
15 O B_MEASURE
, O O
75 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_TIME[MEASURE]
, O O
i O O
. O O
p O B_MEASURE/B_LOCATION
. O O
, O O
every O O
3rd O B_TIME[MEASURE]/B_PERSON
day O I_TIME[MEASURE]/I_PERSON
for O O
2 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weeks O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
. O O

In O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
animals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O O
in O O
animals O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treated O O
acutely O O
with O O
CYP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
only O O
small O B_MEASURE/B_LOCATION
numbers O I_MEASURE/I_LOCATION
of O O
NOS O B_GENE/B_DISEASE
- O O
IR O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PROTEIN[GENE]
( O O
0 O B_MEASURE/B_LOCATION
. O O
5 O B_MEASURE
- O O
0 O B_MEASURE
. O O
7 O B_MEASURE
cell O I_MEASURE
profiles O I_MEASURE
/ O O
sections O B_LOCATION/B_MEASURE
) O O
were O O
detected O O
in O O
the O O
L6 O B_PROTEIN[GENE]
- O O
S1 O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
dorsal O B_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
root O B_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
ganglia O B_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
( O O
DRG O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
) O O
. O O

Chronic O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CYP O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significantly O O
( O O
P O B_MEASURE/B_LOCATION
< O I_MEASURE/I_LOCATION
or O O
= O O
. O O
002 O B_MEASURE
) O O
increased O O
bladder O B_MEASURE/B_DISEASE
weight O B_MEASURE/I_DISEASE
by O O
60 O B_NUMBER[MEASURE]/B_LOCATION
% O I_NUMBER[MEASURE]/I_LOCATION
and O O
increased O O
( O O
7 O B_NUMBER[MEASURE]
- O O
to O O
11 O B_NUMBER[MEASURE]
- O O
fold O B_TIME[MEASURE]
) O O
the O O
numbers O B_MEASURE
of O O
NOS O B_GENE/B_DISEASE
- O O
immunoreactive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
IR O B_PROTEIN[GENE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
afferent O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
neurons O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
L6 O B_PROTEIN[GENE]
- O O
S1 O B_DISEASE/B_PROTEIN[GENE]
DRG O B_DISEASE/I_PROTEIN[GENE]
. O O

Bladder O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
afferent O I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
L6 O B_PROTEIN[GENE]
- O O
S1 O B_DISEASE/B_LOCATION
DRG O B_DISEASE/I_LOCATION
labeled O O
by O O
Fluorogold O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
40 O B_PROTEIN[GENE]
microliters O I_PROTEIN[GENE]
) O O
injected O O
into O O
the O O
bladder O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
wall O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
did O O
not O O
exhibit O O
NOS O B_LOCATION
- O O
IR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
animals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
; O O
however O O
, O O
following O O
chronic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
CYP O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
administration O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
significant O B_MEASURE/B_PERSON
percentage O I_MEASURE/I_PERSON
of O O
bladder O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
afferent O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
neurons O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
were O O
NOS O B_GENE/B_DISEASE
- O O
IR O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
L6 O B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
19 O B_MEASURE
. O O
8 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
4 O B_MEASURE
. O O
6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
and O O
S1 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
25 O B_MEASURE
. O O
3 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
2 O B_MEASURE
. O O
9 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
neuronal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
visceral O B_DISEASE/B_SPECIES[BIO]
sensory O B_DISEASE/I_SPECIES[BIO]
pathways O B_DISEASE/I_SPECIES[BIO]
can O O
be O O
upregulated O O
by O O
chemical O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
irritation O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
afferent O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
receptors O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
urinary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tract O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
/ O O
or O O
that O O
pathological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
changes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
urinary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tract O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
can O O
initiate O O
chemical O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signals O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
alter O O
the O O
chemical O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
visceral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
afferent O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
neurons O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Both O O
CD O B_LOCATION
- O O
832 O B_MEASURE
and O O
diltiazem O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
not O O
nifedipine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
significantly O O
reduced O O
the O O
increase O B_DISEASE_ADJECTIVE[DISEASE]
in O O
heart O B_DISEASE/B_PROTEIN[GENE]
rate O B_DISEASE/I_PROTEIN[GENE]
induced O O
by O O
ISO O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
infusion O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Co O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
nefiracetam O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
apomorphine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
training O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
or O O
10h O B_TIME[MEASURE]/B_LOCATION
thereafter O O
produced O O
no O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
anti O I_DISEASE_ADJECTIVE[DISEASE]
- O O
amnesic O B_DISEASE
effect O I_DISEASE
. O O

It O O
is O O
suggested O O
that O O
nefiracetam O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
augments O O
molecular O B_DISEASE/B_GENE
processes O I_DISEASE/I_GENE
in O O
the O O
early O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stages O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
events O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
ultimately O O
lead O O
to O O
consolidation O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
memory O B_DISEASE
. O O

No O O
statistically O O
significant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
differences O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
observed O O
between O O
the O O
two O B_NUMBER[MEASURE]/B_PERSON
isoproterenol O I_NUMBER[MEASURE]/I_PERSON
treated O O
groups O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
severity O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
the O O
induced O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lesions O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
changes O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
heart O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
weight O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
or O O
heart O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
weight O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
to O O
body O B_MEASURE/B_PERSON
weight O I_MEASURE/I_PERSON
ratios O I_MEASURE/I_PERSON
. O O

In O O
a O O
placebo O B_LOCATION/B_PERSON
- O O
controlled O O
, O O
single O B_NUMBER[MEASURE]/B_LOCATION
- O O
blind O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
we O O
aimed O O
to O O
clarify O O
if O O
both O O
peptides O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
act O O
by O O
altering O O
central O B_DISEASE
chemosensitivity O I_DISEASE
. O O

We O O
performed O O
a O O
single O B_PERSON/B_MEASURE
- O O
blind O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
placebo O B_LOCATION/B_PERSON
- O O
controlled O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
assess O O
its O O
effectiveness O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
safety O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
Chinese O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hepatitis O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
surface O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antigen O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
HBsAg O B_DISEASE/B_GENE
) O O
carriers O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Although O O
25 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
mg O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
lamivudine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
slightly O O
less O O
effective O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O O
100 O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
P O B_MEASURE/B_PROTEIN[GENE]
= O B_MEASURE/I_PROTEIN[GENE]
. O O
011 O B_MEASURE
) O O
and O O
300 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
P O B_LOCATION/B_PERSON
= O I_LOCATION/I_PERSON
. O O
005 O B_MEASURE
) O O
, O O
it O O
still O O
induced O O
94 O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
% O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
suppression O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
HBV O B_DISEASE/B_GENE
DNA O I_DISEASE/I_GENE
after O O
the O O
fourth O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
week O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

In O O
conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
a O O
4 O B_NUMBER[MEASURE]
- O O
week O B_MEASURE/B_LOCATION
course O I_MEASURE/I_LOCATION
of O O
lamivudine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
safe O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
effective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
suppression O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
HBV O B_DISEASE/B_GENE
DNA O I_DISEASE/I_GENE
in O O
Chinese O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
HBsAg O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
carriers O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
long O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
term O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
lamivudine O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
administration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
should O O
be O O
performed O O
to O O
determine O O
if O O
prolonged O O
suppression O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
HBV O B_DISEASE/B_GENE
DNA O I_DISEASE/I_GENE
can O O
be O O
achieved O O
. O O

BACKGROUND O O
: O O
Four O O
studies O O
published O O
since O O
December O O
, O O
1995 O O
, O O
reported O O
that O O
the O O
incidence O O
of O O
venous B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
thromboembolism I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
VTE B B_LOCATION/B_ORGANIZATION
) O O
was O O
higher O O
in O O
women O O
who O O
used O O
oral O O
contraceptives O O
( O O
OCs O O
) O O
containing O O
the O O
third O O
- O O
generation O O
progestagens O O
gestodene O O
or O O
desogestrel O O
than O O
in O O
users O O
of O O
OCs O O
containing O O
second O O
- O O
generation O O
progestagens O O
. O O

We O O
used O O
a O O
multiple O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
logistic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
regression O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
that O O
included O O
body O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
mass O B_MEASURE/B_LOCATION
index O I_MEASURE/I_LOCATION
, O O
number O B_MEASURE/B_LOCATION
of O O
cycles O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
change O O
in O O
type O B_MEASURE/B_DISEASE
of O O
OC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
prescribed O O
within O O
3 O B_TIME[MEASURE]/B_LOCATION
months O I_TIME[MEASURE]/I_LOCATION
of O O
the O O
event O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
previous O B_DISEASE/B_PERSON
pregnancy O I_DISEASE/I_PERSON
, O O
and O O
concurrent O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disease O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

FINDINGS O O
: O O
85 O O
women O O
met O O
the O O
inclusion O O
criteria O O
for O O
VTE B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
two O O
of O O
whom O O
were O O
users O O
of O O
progestagen O O
- O O
only O O
OCs O O
. O O

INTERPRETATION O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
The O O
previously O O
reported O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
odds O B_DISEASE
ratio O I_DISEASE
associated O O
with O O
third O B_SEQUENCE[MEASURE]
- O O
generation O B_PERSON
OCs O I_PERSON
when O O
compared O O
with O O
second O B_SEQUENCE[MEASURE]
- O O
generation O B_PERSON/B_TIME[MEASURE]
products O B_PERSON/I_TIME[MEASURE]
is O O
likely O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
have O O
been O O
the O O
result O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
residual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
confounding O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
age O B_TIME[MEASURE]/B_PERSON
. O O

The O O
tuberoinfundibular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dopaminergic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TIDA O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
system O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O O
known O O
to O O
inhibit O O
prolactin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
PRL O B_PROTEIN[GENE]/B_LOCATION
) O O
secretion O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

However O O
, O O
this O O
responsiveness O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
lost O O
in O O
aging O O
rats O B_BIO/B_PERSON
with O O
chronically O O
high O B_DISEASE
serum O I_DISEASE
PRL O I_DISEASE
levels O I_DISEASE
. O O

The O O
age O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
related O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]
in O O
hypothalamic O B_GENE
dopamine O I_GENE
function O I_GENE
may O O
be O O
associated O O
with O O
increases O B_DISEASE_ADJECTIVE[DISEASE]
in O O
PRL O B_DISEASE
secretion O I_DISEASE
. O O

Fetal O B_DISEASE_ADJECTIVE[DISEASE]
risks O I_DISEASE_ADJECTIVE[DISEASE]
due O I_DISEASE_ADJECTIVE[DISEASE]
to O O
warfarin O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
during O O
pregnancy O B_DISEASE/B_ORGANISM_FUNCTION
. O O

Two O B_PERSON/B_BIO
mothers O I_PERSON/I_BIO
with O O
heart O B_DISEASE
valve O I_DISEASE
prosthesis O I_DISEASE
were O O
treated O O
with O O
warfarin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
pregnancy O B_DISEASE/B_PERSON
. O O

In O O
view O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
risks O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
both O O
mother O B_PERSON/B_BIO
and O O
fetus O B_PERSON
in O O
women O B_PERSON
with O O
prosthetic O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cardiac O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
valves O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
it O O
is O O
recommended O O
that O O
therapeutic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
abortion O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
be O O
advised O O
as O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alternative O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Based O O
on O O
the O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
behaviour O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
CSSEP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
NMP O B_DISEASE
, O O
it O O
was O O
concluded O O
that O O
the O O
pharmacological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
process O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
underlying O O
this O O
phenomenon O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
localised O O
in O O
the O O
periphery O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

By O O
means O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
simultaneous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
recording O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
interrelated O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
peripheral O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
central O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
electrophysiologic O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
correlates O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
nociception O B_DISEASE
, O O
it O O
was O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
separate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
central O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
peripheral O B_LOCATION
effects O I_LOCATION
of O O
an O O
NSAID O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Dehydrated B B_PERSON
rats O O
regularly O O
develop O O
acute B B_DISEASE
renal I I_DISEASE
failure I I_DISEASE
following O O
single O O
injection O O
of O O
aminoglycoside O O
antibiotics O O
combined O O
with O O
dextran O O
or O O
of O O
antibiotics O O
only O O
. O O

The O O
reduction O O
effect O O
of O O
D O O
- O O
glucarates O O
against O O
nephrotoxicity B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
basic O O
antibiotics O O
was O O
discussed O O
. O O

CNA O B_PERSON
patients O I_PERSON
had O O
higher O B_DISEASE_ADJECTIVE[DISEASE]
heart O I_DISEASE_ADJECTIVE[DISEASE]
rates O I_DISEASE_ADJECTIVE[DISEASE]
during O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
which O O
may O O
reflect O O
severity O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
illness O B_DISEASE
. O O

The O O
incidence O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
intubation O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
conclude O O
that O O
CNA O B_LOCATION/B_ORGANIZATION
and O O
INA O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
demonstrated O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profiles O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
regard O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
safety O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
morbidity O B_DISEASE
, O O
and O O
mortality O B_DISEASE
. O O

The O O
ten O B_NUMBER[MEASURE]
previously O O
reported O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
unusual O B_DISEASE
complication O I_DISEASE
are O O
reviewed O O
. O O

The O O
following O O
factors O O
appear O O
to O O
predispose O O
to O O
the O O
development O O
of O O
this O O
complication O O
: O O
abnormal O O
cerebrospinal O O
dynamics O O
related O O
to O O
the O O
presence O O
of O O
central B B_DISEASE
nervous I I_DISEASE
system I I_DISEASE
leukemia I I_DISEASE
, O O
and O O
epidural O O
cerebrospinal O O
leakage O O
; O O
elevated O O
cerebrospinal O O
fluid O O
methothexate O O
concentration O O
related O O
to O O
abnormal O O
cerebrospinal O O
fluid O O
dynamics O O
and O O
to O O
inappropriately O O
high O O
methotrexate O O
doses O O
based O O
on O O
body O O
surface O O
area O O
calculations O O
in O O
older O O
children O O
and O O
adults O O
; O O
the O O
presence O O
of O O
neurotoxic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preservatives O O
in O O
commercially O O
available O O
methotrexate O O
preparations O O
and O O
diluents O O
; O O
and O O
the O O
use O O
of O O
methotrexate O O
diluents O O
of O O
unphysiologic O O
pH O O
, O O
ionic O O
content O O
and O O
osmolarity O O
. O O

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
done O O
to O O
assess O O
the O O
influence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
high O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intracoronary O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cocaine O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
LV O B_BODY_PART_OR_ORGAN_COMPONENT
systolic O I_BODY_PART_OR_ORGAN_COMPONENT
and O O
diastolic O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
function O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
humans O B_PERSON/B_SPECIES[BIO]
. O O

With O O
cocaine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
drug O B_MEASURE/B_DISEASE
concentration O I_MEASURE/I_DISEASE
in O O
blood O B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
obtained O O
from O O
the O O
coronary O B_DISEASE/B_PERSON
sinus O I_DISEASE/I_PERSON
was O O
3 O B_MEASURE
. O O
0 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
4 O B_MEASURE
( O O
mean O B_MEASURE
+ O O
/ O O
- O O
SD O B_MEASURE/B_DISEASE
) O O
mg O B_LOCATION/B_MEASURE
/ O O
L O B_OTHER/B_MEASURE
, O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
magnitude O B_MEASURE/B_LOCATION
to O O
the O O
blood O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cocaine O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
concentration O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
reported O O
in O O
abusers O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
dying O O
of O O
cocaine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
intoxication O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Cocaine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induced O O
no O O
significant O B_MEASURE
change O I_MEASURE
in O O
heart O B_DISEASE/B_PROTEIN[GENE]
rate O B_DISEASE/I_PROTEIN[GENE]
, O O
LV O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
dP O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
dt O B_PROTEIN[GENE]/B_DISEASE
( O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
negative O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
or O O
LV O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
diastolic O B_MEASURE/B_LOCATION
volume O I_MEASURE/I_LOCATION
, O O
but O O
it O O
caused O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
systolic O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
and O O
mean O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
arterial O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
pressures O I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
LV O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
diastolic O B_MEASURE/B_LOCATION
pressure O I_MEASURE/I_LOCATION
, O O
and O O
LV O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end O I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
systolic O B_MEASURE
volume O I_MEASURE
, O O
as O O
well O O
as O O
a O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
LV O B_MEASURE/B_DISEASE
ejection O I_MEASURE/I_DISEASE
fraction O I_MEASURE/I_DISEASE
. O O

MATERIALS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
AND O O
METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Carbetocin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
was O O
given O O
as O O
an O O
intramuscular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
injection O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
immediately O O
after O O
the O O
birth O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
infant O B_PERSON/B_BIO
in O O
45 O B_PERSON
healthy O I_PERSON
women O I_PERSON
with O O
normal O B_DISEASE/B_ORGANISM_FUNCTION
singleton O I_DISEASE/I_ORGANISM_FUNCTION
pregnancies O I_DISEASE/I_ORGANISM_FUNCTION
who O O
delivered O O
vaginally O O
at O O
term O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
. O O

Dosage O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
groups O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
15 O B_MEASURE
, O O
30 O B_MEASURE
, O O
50 O B_MEASURE
, O O
75 O B_MEASURE
, O O
100 O B_MEASURE
, O O
125 O B_MEASURE
, O O
150 O B_MEASURE
, O O
175 O B_MEASURE
or O O
200 O B_MEASURE/B_LOCATION
microg O I_MEASURE/I_LOCATION
carbetocin O I_MEASURE/I_LOCATION
were O O
assigned O O
to O O
blocks O B_LOCATION/B_ORGANIZATION
of O O
three O B_NUMBER[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
women O I_NUMBER[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
according O O
to O O
the O O
continual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reassessment O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
method O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
CRM O B_DISEASE/B_LOCATION
) O O
. O O

All O O
retained O O
placentae O B_DISEASE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
found O O
in O O
the O O
group O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
200 O B_NUMBER[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
microg O I_NUMBER[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
calculi O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
are O O
not O O
opaque O B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
secondary O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
signs O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
obstruction O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
may O O
be O O
absent O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O O
minimal O B_DISEASE_ADJECTIVE[DISEASE]
and O O
should O O
be O O
sought O O
carefully O O
. O O

Recently O O
, O O
vasopressor O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
responses O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O O
are O O
distinct O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
from O O
the O O
cranial O B_DISEASE/B_MEASURE
circulation O I_DISEASE/I_MEASURE
have O O
been O O
demonstrated O O
to O O
occur O O
in O O
the O O
systemic O B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
pulmonary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
and O O
coronary O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
circulations O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

No O O
other O B_DISEASE
complications O I_DISEASE
were O O
seen O O
. O O

On O O
the O O
other O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
hand O I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
pressor O B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O I_DISEASE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
i O O
. O O
c O B_DISEASE/B_LOCATION
. O O
carbachol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O B_TIME[MEASURE]
mug O I_TIME[MEASURE]
) O O
was O O
almost O O
completely O O
blocked O O
by O O
i O O
. O O
c O B_DISEASE/B_LOCATION
. O O
atropine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
3 O B_MEASURE
mug O I_MEASURE
) O O
or O O
hexamethonium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
( O O
500 O B_MEASURE
mug O I_MEASURE
) O O
, O O
and O O
significantly O O
reduced O O
by O O
i O O
. O O
c O B_DISEASE/B_LOCATION
. O O
chlorpromazine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
50 O B_MEASURE
mug O I_MEASURE
) O O
but O O
significantly O O
potentiated O O
by O O
i O O
. O O
c O B_DISEASE/B_LOCATION
. O O
desmethylimipramine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
30 O B_MEASURE
mug O I_MEASURE
) O O
. O O

The O O
pressor O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
response O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O O
i O O
. O O
c O B_DISEASE/B_LOCATION
. O O
carbachol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O B_PROTEIN[GENE]
mug O I_PROTEIN[GENE]
) O O
remained O O
unchanged O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
after O O
sectioning O O
of O O
the O O
bilateral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cervical O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
vagal O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
nerves O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
but O O
disappeared O O
after O O
sectioning O O
of O O
the O O
spinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cord O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O O
C7 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
C8 O B_MEASURE/B_PROTEIN[GENE]
) O O
. O O

From O O
the O O
above O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
result O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
it O O
is O O
suggested O O
that O O
the O O
pressor O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
response O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O O
i O O
. O O
c O B_DISEASE/B_LOCATION
. O O
carbachol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ortral O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
peripheral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
adrenergic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mechanisms O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
that O O
the O O
sympathetic O B_BODY_PART_OR_ORGAN_COMPONENT
trunk O I_BODY_PART_OR_ORGAN_COMPONENT
is O O
the O O
main O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
pathway O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
dopaminergic O B_DISEASE_ADJECTIVE[DISEASE]
blockade O I_DISEASE_ADJECTIVE[DISEASE]
mechanism O I_DISEASE_ADJECTIVE[DISEASE]
generally O O
is O O
accepted O O
as O O
the O O
pathogenesis O B_DISEASE
of O O
this O O
syndrome O B_DISEASE
. O O

However O O
, O O
methylphenidate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
a O O
dopamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agonist O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
via O O
the O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O O
uptake O B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
dopamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
therefore O O
dopaminergic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
systems O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
the O O
brainstem O B_BODY_PART_OR_ORGAN_COMPONENT
( O O
mainly O O
the O O
midbrain O B_BODY_PART_OR_ORGAN_COMPONENT
) O O
and O O
the O O
spinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cord O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O O
unlikely O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
participate O O
in O O
the O O
onset O B_DISEASE_ADJECTIVE[DISEASE]
of O O
this O O
syndrome O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
17alpha O B_MEASURE/B_PERSON
- O O
ethinylestradiol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
EE O B_LOCATION/B_ORGANIZATION
) O O
on O O
the O O
neutral O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
acidic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biosynthetic O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathways O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
bile O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
salt O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O O
BS O B_LOCATION
) O O
synthesis O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O O
evaluated O O
in O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
an O O
intact O B_DISEASE
enterohepatic O I_DISEASE
circulation O I_DISEASE
and O O
in O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
long O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
term O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
bile O B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
diversion O B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
to O O
induce O O
BS O B_DISEASE
synthesis O I_DISEASE
. O O

For O O
this O O
purpose O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
bile O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
salt O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pool O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
composition O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
synthesis O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
individual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
BS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
in O O
vivo O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
hepatic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activities O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
expression O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
cholesterol O B_MEASURE
7alpha O I_MEASURE
- O O
hydroxylase O B_ENZYME[GENE]
( O O
CYP7A O B_GENE/B_LOCATION
) O O
, O O
and O O
sterol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
27 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
hydroxylase O B_ENZYME[GENE]
( O O
CYP27 O B_LOCATION/B_ORGANIZATION
) O O
, O O
as O O
well O O
as O O
of O O
other O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
enzymes O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
involved O O
in O O
BS O B_DISEASE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
synthesis O B_DISEASE/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
, O O
were O O
analyzed O O
in O O
rats O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treated O O
with O O
EE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
5 O B_MEASURE
mg O I_MEASURE
/ O O
kg O B_MEASURE
, O O
3 O B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days O B_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
or O O
its O O
vehicle O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Simultaneous O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
impairment O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
other O B_ENZYME[GENE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enzymes O B_ENZYME[GENE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
BS O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
biosynthetic O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
pathways O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
may O O
contribute O O
to O O
overall O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
EE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O O
BS O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
synthesis O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

The O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
helodermin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
basic O B_MEASURE
35 O I_MEASURE
- O O
amino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
acid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
peptide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
isolated O O
from O O
the O O
venom O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
lizard O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
salivary O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
gland O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
on O O
arterial O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pressure O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
heart O B_DISEASE
rate O I_DISEASE
were O O
examined O O
in O O
the O O
rat O B_SPECIES[BIO]/B_GENE
, O O
focusing O O
on O O
the O O
possibility O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
activation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O O
ATP O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sensitive O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
K O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
+ O O
( O O
K O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ATP O B_PROTEIN[GENE]/B_LOCATION
) O O
) O O
channels O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O O
involved O O
in O O
the O O
responses O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

